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Abstract
The transcription factor Interferon Regulatory Factor-1 (IRF-1) has been demonstrated
to suppress tumour growth through the regulation of many anti-oncogenic genes. Pro- and
anti-apoptotic factors, cell cycle control genes, DNA damage response genes and pro-
metastatic factors are all under the control of IRF-1, which effects both transcriptional
activation and repression. In addition to these cell autonomous tumour suppressor activ-
ities, IRF-1 is also a key regulator of the immune system and, as such, mediates immune
surveillance of tumours. Numerous studies have confirmed that loss or mis-regulation of
IRF-1 is a key factor in several different types of cancer.
Despite strong evidence for the crucial role of IRF-1 in cancer, and frequent assertions
that this protein warrants further investigation as a drug target, very little is known about
its regulation. Furthermore, since recent studies have linked upregulation of IRF-1 to the
development of autoimmune diseases, it is particularly important that drugs be able to
decouple autoimmune and anti-cancer functions of IRF-1 to avoid harmful side effects.
This thesis describes how phosphorylation of IRF-1 in its regulatory C-terminal Mf1
domain modulates transactivatory and tumour suppressor activity. Phosphospecific an-
tibodies were developed as tools to study the C-terminal phosphorylation. Using these,
it was shown that treatment of cells with Interferon-γ (IFN-γ) not only causes accumu-
lation of IRF-1 protein, but also results in phosphorylation of IRF-1 at two sites in the
C-terminal Mf1 domain.
Phosphomimetic mutants demonstrated that these phosphorylations enhanced the trans-
activatory activity of IRF-1 at various promoters, but did not affect repressor activity. Gel
shift assays revealed that dual phosphorylation of IRF-1 (IRF-1 D/D) promoted DNA-
binding and suggested this was through increased interaction with the cofactor/histone
acetylase p300 which induces a conformational change in IRF-1, favouring DNA-binding.
Acetylation by p300 appears to be important although it is not yet clear whether this di-
rectly or indirectly affects IRF-1 activity.
Since the tumour suppressor activity of IRF-1 is of particular interest, the effect of
phosphorylation was examined in clonogenic and invasion assays. IRF-1 D/D more ef-
ficiently suppressed colony formation in both anchorage dependent and independent as-
says, and may improve inhibition of invasion in Transwell assays. Thus, cell treatment
with the therapeutic agent IFN-γ induces phosphorylation of IRF-1, resulting in enhanced
DNA binding of IRF-1 through improved p300 binding. In cells the outcome is more ef-
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Interferon Regulatory Factor-1 (IRF-1) is a transcription factor that acts as a tumour sup-
pressor through the regulation of genes in many anti-oncogenic pathways. Although
much is known about the function of IRF-1, very little is known about its post-translational
regulation. This thesis describes how phosphorylation of IRF-1 regulates its transactiva-
tory activity and presents evidence that phosphorylation enhances IRF-1’s tumour sup-
pressor function.
IRF-1 was first identified as an inducer of the interferon-β (IFN-β) gene [1]. Sub-
sequent investigation revealed that the DNA recognition sequence of IRF-1 is found not
only in the IFN-α and IFN-β promoters, but also in interferon-inducible genes such as
the MHC class I gene [2]. Comparison of the consensus IRF-1 recognition sequence,
the IRF-E, with the IFN stimulated response element (ISRE) indicated that the IRF-E
matched all ISREs studied; thus, IFN-activated genes are also IRF-1 inducible [3].
Subsequently, IRF-1 has been shown to activate or repress genes involved in many
anti-viral, immunomodulatory and anti-oncogenic pathways and has been recognised as
a tumour suppressor. This introduction will outline the role of IRF-1 in tumour sup-
pression, the mechanisms of its induction, the current understanding of its regulation by
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post-translational modification and co-factor interaction.
1.2 IRF-1 in cancer
The role of IRF-1 in cancer was first recognised in 1993 when it was mapped to a chro-
mosomal locus commonly deleted in leukaemia or myelodysplasia [4]. At the same time,
the overexpression of IRF-2 (an antagonist of IRF-1) was shown to transform cells, while
concomitant overexpression of IRF-1 was able to suppress the transformation [5]. This
provided context for previous observations of growth suppression/terminal differentiation
by IRF-1 in myeloid [6] and lymphoid cells [7].
Since then, loss of heterozygosity at the IRF-1 locus has been reported in gastric [8],
oesophageal [9], non-small cell lung [10], pulmonary large cell neuroendocrine [11] and
breast [12] [13] carcinomas.
In addition to deletion of the chromosomal locus, IRF-1 activity can be inhibited in
cancers by point mutation [14], expression of an inhibitor NPM [15] and expression of the
HPV oncoprotein E7 [16]. Aberrant splicing and exon skipping can produce attenuated
or inactive forms of IRF-1 [17] [18] and even dominant negative forms of IRF-1 [19].
1.3 IRF-1 as a tumour suppressor
Since loss or inactivation of IRF-1 is critical to so many different types of cancer, its tu-
mour suppressor capabilities were studied in some detail. As mentioned above, IRF-1 was
shown to reverse the transformation of cells overexpressing IRF-2 [5]. Following this, it
was demonstrated that IRF-1 can suppress the transformation induced by other, unrelated,
oncogenes, namely c-myc and fos-B [20]. In addition, in IRF-1−/− cells, expression of a
single oncogene, for example, c-Ha-ras is sufficient to transform cells, and the transfor-
mation can be reversed by expression of IRF-1 [21]. Normally at least two oncogenes are
required for transformation. Thus, IRF-1 was firmly estabilished as a tumour suppressor.
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Interestingly, however, it was later observed that in mice, loss of IRF-1 alone had
very little impact on the frequency of spontanoeus tumour development. In contrast,
in the background of c-Ha-ras expression or p53 knock-out, IRF-1 deficiency resulted
in increased frequency of tumour development. Furthermore, in p53−/−IRF-1−/− mice,
death due to tumour occured much earlier, multiple tumour frequency increased and the
spectrum of tumours was altered relative to p53−/− mice [22]. Thus, IRF-1 could be
characterised as a tumour susceptibility gene rather than a bona fide tumour suppressor.
Despite this, the activity of IRF-1 in cancer is clearly important: Introduction of dom-
inant negative (dn)IRF-1 into human breast cancer cells (which quite likely exhibit a
background of other oncogenic mutations) functions to enhance proliferation. More-
over, IRF-1 expression varied with the agressiveness of the cell line; “highly invasive
and metastatic” cell lines exhibit lowest IRF-1 expression while “tumourigenic but non-
metastatic” cell lines express intermediate levels of IRF-1 compared to normal cells [23].
1.4 Mechanisms of tumour suppression by IRF-1
IRF-1 has been shown to upregulate or suppress genes involved in several anti-oncogenic
pathways (Fig 1.1). These will be discussed below.
1.4.1 Apoptosis and Autophagy
Apoptosis is the programmed death of a cell in a controlled manner. In the context of
cancer, it enables cells with irreparably damaged DNA to be safely removed before they
become neoplastic. It is also the mechanism by which immune cells trigger death of cells
displaying tumour associated antigens.
Apoptosis can be induced by two pathways: the extrinsic pathway and the intrinsic
pathway (Fig 1.2). This is reviewed in [47]. Briefly, the extrinsic pathway is triggered by
the activation of death receptors by death ligands. This induces the recruitment of various
factors to the receptor and the formation of a death-inducing signalling complex (DISC).
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Figure 1.1: IRF-1 regulates gene expression of proteins involved in all aspects of anti-
oncogenesis including: immune surveillance ([24],[25],[26],[27],[28],[29]); anti-proliferation
([30],[31],[32],[33]); pro-apoptosis ([34],[35],[36],[37],[38],[39],[40],[41],[42]); DNA damage
response ([43],[44]); and anti-metastasis ([45],[46]). Upregulated genes are green, downregulated
genes are red.



























































Figure 1.2: IRF-1 regulates the intrinsic and extrinsic pathways of apoptosis. Proteins upreg-
ulated by IRF-1 are indicated by ∗, proteins downregulated by IRF-1 are indicated by §. The
intrinsic pathway of apoptosis is initiated by intracellular signals such as ROS, DNA damage and
oncogenes. These cause upregulation of Bax, Bak∗ [34] and PUMA∗ [38], which facilitates acti-
vation of Bak. Active Bax and Bak form homodimers and, after insertion into the mitochondrial
membrane, induce release of apoptotic factors SMAC/DIABLO and cytochrome c. The activation
of Bax and Bak is inhibited by Bcl2§ [42] and Bcl-xl. SMAC/DIABLO and also XAF-1∗ [36]
inhibits the inhibitor of apoptosis proteins (IAPs), which inhibit caspases 3,7∗ [34] and 9 while
cytochrome c associates with APAF-1 to form the apoptosome which catalyses cleavage of pro-
caspase-9 to caspase-9. Survivin§ [41], an atypical IAP, is down-regulated by IRF-1. Activated
caspase-9 cleaves pro-caspase-3 to caspase-3 at the start of the execution pathway. At this point
the intrinsic and extrinsic pathways converge. The extrinsic pathway of apoptosis is initiated by
binding of death ligands (Fas ligand∗ [39], TNF-α and TRAIL∗ [37],[46]) to the death receptor.
Binding activates the death receptor and triggers assembly of various factors into the DISC which
catalyses cleavage of pro-caspase-8∗ into active caspase-8. Caspase-8 cleaves pro-caspase-3 to
active caspase-3 at the start of the execution pathway. In some cases, it also converts Bid to t-Bid
and recruits the mitochondrial factors to amplify the apoptotic signal. The execution pathway is a
cascade of caspase cleavages culminating in the activation of the factors responsible for apoptosis.
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Assembly of this complex results in activation of procaspase-8 to caspase-8. Caspase-8
is an initiator caspase which catalyses the activation of effector caspases. The result is
a cascade of cleavage events culminating in apoptosis through both the direct action of
caspases, and the activation of other pro-apoptotic molecules.
The intrinsic pathway is triggered by events within the cell, for example, DNA dam-
age. This results in the activation of the pro-apoptotic factors Bax and Bak, which form
homodimers. PUMA (p53 Upregulated Modulator of Apoptosis) mediates the activation
of Bax. The homodimers insert into the mitochondrial membrane and cause the release
of cytochrome c and second mitochondria activator of caspases (SMAC). Cytochrome
C interacts with apoptotic protease activating factor-1 (APAF-1) and ATP to recruit pro-
caspase-9 and form the apoptosome. Cleavage of pro-caspase-9 to caspase-9 ensues, and
caspase-9 activates caspase-3 from which point apoptosis proceeds in the same way as
for the extrinsic pathway (reviewed in [47]).
Apoptosis can be inhibited by the action of various factors. Bcl2 and Bcl-xl inhibit
the activation of Bak, Bax, and Bid. When the intrinsic pathway is activated, the action
of Bcl2 and Bcl-xl is itself inhibited. Inhibitor of Apoptosis Proteins (IAPs) can inhibit
the activity of caspases 3,7 and 9. Again, pro-apoptotic factors can inhibit these anti-
apoptotic factors. SMAC is released from the mitochondria along with cytochrome c and
inhibits the action of IAPs as do other proteins e.g. XAF1 (XIAP associated factor 1)
[47].
IRF-1 is involved in the regulation of apoptosis at many points in both the intrinsic
and extrinsic pathways. It upregulates proteins which initiate apoptosis such as Fas ligand
[39] and TRAIL [37], [46], both of which can be used by cytotoxic T cells to induce
apoptosis in tumour cells [48], [49] or, in the case of TRAIL, tumour cell auto/paracrine
apoptosis [50]. IRF-1 also upregulates mediators of apoptosis such as caspases-7 and
-8 [34]. Bak [34] is responsible for release of apoptotic factors from mitochondria [47]
and PUMA [38] mediates apoptosis by recruiting Bax to the mitochondrial membrane
[51]. Inhibitors of apoptosis are also modulated by IRF-1: XAF-1 [36] sensitises cells to
apoptosis through antagonism of the inhibition of caspase-3 and -9 by XIAP [52] and is
upregulated by IRF-1. Correspondingly, both Bcl-2 [42], which inhibits Bak activation
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and survivin [41], an IAP which inhibits caspase-8 are downregulated by IRF-1. Survivin
has been found to be the fourth highest upregulated transcriptome in a number of cancers
[53]. The process of apoptosis and the role of IRF-1 is summarised in (Fig 1.2).
The upregulation of MHC Class I molecules by IRF-1 is also of relevance here, as it
sensitises tumour cells to apoptosis induced by T cells [27].
The mechanism by which IRF-1 activates apoptosis appears to be cell type dependent,
for example, TRAIL upregulation is important in bladder cancer cells [37], and paracrine
death of Jurkat T cells [50] whereas in MDA-MB-468 cells, IRF-1 mediates a ligand
independent apoptogenic action [54].
The ability of IRF-1 to induce apoptosis in cells was first noticed by Tanaka et. al.
when investigating the function of IRF-1 as a tumour suppressor. They observed that
IRF-1 WT embryonic fibroblasts undergo apoptosis after the expression of the c-Ha-ras
oncogene, while IRF-1−/− cells do not [21]. The relevance of IRF-1’s proapoptotic activ-
ity in cancer has since been demonstrated both in vitro and in vivo in a number of cancers
[34], [55], [54], [41].
This apoptotic activity has been intensively studied in breast cancer where IRF-1 has
been shown to be responsible for apoptosis in response to treatments such as antioestro-
gens. Antioestrogens are a highly effective treatment for breast cancer. They compete
with oestrogens for oestrogen receptors and, in breast tissue, this results in reduced inci-
dence and burden of cancer but unfortunately, resistance to these compounds is common
[56]. Thus, investigating factors that mediate the antioestrogen response, such as IRF-1,
is important, as they might give insights into how to reverse this resistance.
IRF-1 is induced by antioestrogens, for example, Faslodex, and mediates their apop-
totic action. In Faslodex resistant cells, IRF-1 expression is downregulated and cannot be
induced by antioestrogens. Expression of the IRF-1 inhibitor protein NPM is upregulated
[57]. It is tempting to speculate that interventions that restore IRF-1 signalling in resis-
tant cells might re-establish sensitivity to antioestrogens. Indeed, induction of IRF-1 by
IFN-γ treatment is sufficient to restore antioestrogen sensitivity to apoptosis [58]. This
suggests that combination therapy of IRF-1 activating agents with antioestrogen could be
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effective against resistance.
Recently, a similar phenomenon has been observed in gastric cancers where IRF-1
overexpression sensitises cells to 5-fluorouracil (the most commonly used chemothera-
peutic for this cancer) through enhanced apoptosis [59]. Likewise, in melanoma cells,
IFN- induced IRF-1 results in enhanced apoptotic cell death when combined with the
chemotherapeutic vinblastine [60].
In vivo studies have confirmed the efficacy of IRF-1 upregulation in tumour suppres-
sion. In a mouse xenograft model, adenoviral (Ad)-IRF-1 inhibited tumour growth and
the resected tumours showed a downregulation of the antiapoptotic factor survivin [41].
Overexpression of IRF-1 in MCF7 cells significantly reduced the establishment of tu-
mours when these cells were injected into nude mice. IRF-1 was shown to enhance
apoptosis of these cells in vitro [23]. Ad-IRF-1 moderately suppressed tumour growth
in a murine model of oesophageal adenocarcinoma, and again, in vitro, apoptosis was
enhanced [61].
A particularly interesting aspect of the apoptotic activity of IRF-1 is that it can be
selective for transformed cells. As Tanaka et. al. observed, the expression of c-Ha-
ras was required for IRF-1 to initiate apoptosis [21]. Kirchhoff and Hauser confirmed
this selective effect when they demonstrated that IRF-1 will not induce apoptosis in non-
transformed NIH3T3 cells, but when HER2 and IRF-1 are simultaneously activated in
NIH3T3 cells, apoptosis occurs [62]. Similar selectivity has been observed with leukaemic
vs normal CD4+ cells although in this case, IRF-1 induced TRAIL expression in SK-BR-
3 cells which was secreted and resulted in only leukaemic T cell apoptosis [50]. This
selectivity makes IRF-1 an attractive anti-cancer drug target as it should result in fewer
side effects.
IRF-1 has also been shown to induce autophagic cell death in human hepatocellular
carcinoma cells [63]. This could be another example of its tumour suppressor capabili-
ties, however, autophagy can also protect cells from the environmental stresses of some
antineoplastic drugs [64]. In contrast, in immune cells, IRF-1 seems to negatively reg-
ulate autophagy, and promotes the apoptotic pathway. In this context, it may actually
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contribute to mortality by enhancing apoptosis in response to LPS (lipopolysaccharide,
an endotoxin) thus leading to sepsis-induced immunosuppression [65].
Therefore, although IRF-1 generally activates apoptosis, this can be dependent on the
environment and cell death by autophagy due to IRF-1 activity has been observed [63], as
well as simply cell cycle arrest. In most cases, the activation of apoptosis is advantageous
as it removes potentially/actively tumourigenic cells without providing them a potential
respite from anti-cancer drugs. In the context of the immune system, however, excessive
apoptosis in response to LPS stimulation can lead to sepsis-induced immunodeficiency
[65]. IRF-1 KO mice are resistant to the lethal cytokinase cascade triggered by LPS
injection [66]. Clearly the effects of IRF-1 expression are not all beneficial (see also
its role in autoimmune responses below) and the positive (tumour suppression/immune
function) functions come at the cost of a propensity to septic shock and autoimmune
disorders.
1.4.2 Cell Cycle Arrest
The role of IRF-1 in cell cycle arrest was first addressed by Tanaka et. al. as a follow-
up to their earlier observations that IRF-1 suppresses ras-induced transformation [30],
[21]. They showed that IRF-1 is a mediator of DNA-damage-induced cell cycle arrest
and upregulates the cyclin dependent kinase (Cdk) inhibitor p21 in cooperation with p53
in embryonic fibroblasts (EFs) [30]. Dornan et. al. later showed that this cooperation
was independent of the DNA-binding activity of IRF-1 but involved IRF-1 binding to and
stabilising a DNA-p53-p300 complex. This facilitates acetylation of p53, which results in
p53 being clamped to the p21 promoter DNA thus enhancing p21 expression [67]. IRF-
1 can also, however, upregulate p21 independetly of p53 [30], [68]. p21 arrests the cell
cycle through two mechanisms: It binds and inhibits cyclin-Cdk complexes which oversee
progression through the cell cycle, and inhibits DNA replication through interaction with
Proliferating Cell Nuclear Antigen (PCNA), a subunit of DNA polymerase δ [69]. siRNA
knockdown of p21 blocks cell cycle arrest by IRF-1 in H1299 cells [68].
In addition to upregulation of the cyclin-Cdk inhibitor (CdkI) p21, IRF-1 transcrip-
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tionally regulates components of the Cyclin-Cdk complexes. The actions of Cyclin/Cdk
complexes are essential for progression of cells through the cell cycle. Cyclins D and E,
and Cdks 2 and 4 have been shown to be downregulated in MDA-MB-468 cells by IRF-1
[68], [70], [33]. IRF-1 represses the Cdk2 promoter by interfering with SP1 activation
[32]. A specific element in the C-terminus of IRF-1 has been shown to be required for
repression of the Cdk2 promoter and loss of this region has a significant impact on the
ability of IRF-1 to act as a tumour suppressor [70].
The Cyclin D/Cdk4 complex phosphorylates and inactivates pRb thereby releasing
a check on the cell cycle [71]. Work by Kroger et. al. has indicated that in myc/ras
transformed NIH3T3 cells, inhibition of cyclin D expression mediates IRF-1’s tumour-
suppressive activities [33]. Interestingly, in the ras/mycNIH3T3 cells, expression of cy-
clin E and Cdk4 is not affected by IRF-1 expression [33] indicating that the function of
IRF-1 is cell type specific.
IRF-1 also upregulates p27 which, besides its traditional role as a CdkI (similar to
p21), also mediates IRF-1’s downregulation of human telomerase reverse transcriptase
(hTERT) [31]. As active telomerase is thought to be necessary for tumourigenesis [72],
this could play a large role in IRF-1’s tumour suppressor capabilities.
The role of IRF-1 in cell cycle control is still, however, unclear. Work by other authors
has observed that IRF-1 does not affect cell cycle: In MCF7 and T47D cells, dnIRF-1 en-
hanced proliferation and apoptosis but had no effect on cell cycle profile [23] [57], while
in Capan 1 pancreatic cells, IFN-γ upregulated IRF-1, showed antiproliferative and tu-
mour suppressive effects but did not affect the cell cycle profile [73]. Similarly, Kirchoff
et. al. noticed that inhibition of proliferation of C243 cells by IRF-1 was not mediated
by cell cycle arrest [74]. The effects of IRF-1 on cell cycle could be cell line dependent -
requiring cofactors that are only present in certain cells/after activation by certain stimuli.
Alternatively, the activating stimulus could dictate whether cell cycle arrest occurs; per-
haps when IRF-1 is overexpressed without stimulus, post-translational regulatory events
or activation of cooperating factors is missing. Kroger et. al. also observed differences
between non-transformed NIH3T3 cells and transformed cells. IRF-1 had very little ef-
fect on the cell cycle profile of the non-transformed cells. After transformation, however,
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a high proportion of cells were in S phase, and expression of IRF-1 caused G1/S cell cy-
cle arrest, resulting in a reversion of the cell cycle profile to non-transformed proportions
[75].
The above suggests that IRF-1 is part of a complex regulatory network that controls
cell cycle arrest. Many factors, activated as a result of transformation, or DNA damage,
or IFN-γ etc. may cooperate to activate cell cycle arrest, and in certain cell lines, or
after certain stimuli, a sufficient combination of factors (including IRF-1) will be upreg-
ulated/activated and cell cycle arrest will ensue. In some cases, where overexpression of
IRF-1 results in arrest, IRF-1 is the limiting factor, in other cases, where IRF-1 does not
cause arrest, other factors are limiting.
1.4.3 DNA Damage Response
As well as being involved in inducing cell cycle arrest in response to DNA damage,
IRF-1 upregulates various factors involved in DNA repair. The induction of IRF-1 itself
after IR (ionising radiation) or etoposide mediated DNA damage involves an ATM kinase
signalling pathway resulting in enhanced IRF-1 mRNA levels and a prolonged half-life
of IRF-1 protein [76].
Hepatocytes lacking IRF-1 are deficient in their ability to repair DNA [77] and in co-
operation with the loss of p53, loss of IRF-1 results in increased susceptibility to mutation,
implying that IRF-1 may be involved in maintaining genetic stability [22].
Recently, some of the proteins responsible for the DNA repair activity of IRF-1 have
been identified. BRIP1 is a Fanconi Anaemia protein involved in Interstrand Crosslink
Repair (ICR) which has been shown to be under the regulation of IRF-1. siIRF-1 treat-
ment confers hypersensitivity to the DNA crosslinking agent mephalan to cells (a hall-
mark of a defective ICL repair pathway). Other DNA repair pathway genes were shown
to be regulated by IRF-1 in the same ChIP-chip study that identified BRIP1, however,
these have not been studied in as much detail [43].
DNA polymerase η (Polη) is especially important for error-free bypass of pyrimi-
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dine dimers introduced by UV. As it has a low fidelity, it must be carefully regulated to
minimise the introduction of mutations into the genome. IRF-1 transactivates Polη in re-
sponse to a chemical carcinogen MNNG [44] and, although this is perhaps an undesirable
event leading to the accumulation of mutations after exposure to the carcinogen, it may
indicate IRF-1 could have a genuine role in the appropriate regulation of Polη for example
in response to UV damage. In support of this, cells lacking IRF-1 show impaired DNA
repair after UV damage [77]. Finally, IRF-1 upregulates PCNA [43], which also forms
part of the UV-induced DNA damage repair machinery, along with Polη [44].
1.4.4 Inhibition of Metastasis
Downregulation of IRF-1 has been linked with increased metastatic potential of tumours,
for example, there was a correlation between loss of IRF-1 and lymph node metastasis
in oesophageal cancer [42] and an invasive phenotype in breast cancer [23]. Further-
more, immunotherapy can result in regression of melanoma metastasis; this was linked to
upregulation of IRF-1 and genes involved in antigen presentation [78].
Thus, two mechanisms are possible for IRF-1’s suppression of metastasis: The metastatic
potential of the cell could be suppressed, and/or the immune recognition of metastatic
cells could be enhanced. Relevant to the first mechanism, IRF-1 suppresses the Matrix
Metalloprotease-9 (MMP9) promoter through competition for binding with the activator
NF-κB [45]. Suppression occurs in both tumour cells (Ewing’s sarcoma derived)[45] and
stromal cells (monocytes) [79]. MMP9 has been shown to be secreted by tumour cells
(e.g. MDA-MB-231 breast cancer cells [80]) and additionally, macrophages co-cultured
with breast cancer cells released TNF-alpha-induced MMP-9, resulting in increased inva-
siveness of the MCF-7 and SK-BR-3 cells [81]. Elsewhere, the presence of inflammatory
cells in cancer stroma has been linked to poor prognosis, despite being indicative of a
defense reaction against the tumour [82].
IRF-1 is also involved in enhancing the immune recognition of metastatic cells. Im-
munotherapy can result in regression of melanoma metastasis [83], a property which has
been linked to the activation of IRF-1 and subsequent upregulation of genes involved in
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antigen presentation [78].
The role of IRF-1 in the suppression of metastasis in a mouse model has been studied
in some detail by Ksienzyk et. al.. They show that IRF-1 enhances Natural Killer (NK)
cell recruitment to, and NK cell mediated cell death of, infiltrating tumour cells by a num-
ber of coordinately functioning receptor-ligand interactions. The expression of IRF-1 by
metastatic cells has effects on both tumour and NK cell receptor/ligand gene expression
[46].
1.4.5 Immune Surveillance
The immune system has a role in tumour suppression and can act to reject tumours. IRF-1
impinges on this both through its immunomodulatory function, and through its effects on
gene expression.
IRF-1 is required for the development and function of the immune system (reviewed in
[29]). It also regulates the recruitment of the immune system to potentially tumourigenic
cells, and is involved in the apoptotic death of these cells.
The immune-mediated effects of IRF-1 tumour suppression have been observed in
vivo. IRF-1 WT mice were protected from death due to lymphoid neoplasia induced by
chemical carcinogen compared to IRF-1−/− mice. It was shown that IRF-1−/− mice were
unable to upregulate cytokines involved in immune surveillance and that replacement
of IL-12, one of the cytokines regulated by IRF-1, was able to somewhat restore the
protective effects of IRF-1 [24]. IL-12 had previously been shown to inhibit tumour
formation in mouse models through immune mediated rejection [84].
IRF-1 controls the expression of MHC Class I and II genes [28], and genes encoding
proteins involved in antigen processing i.e. immunoproteasome subunits LMP2 [25] and
MECL1 [26] and antigen transporter TAP1 [25]. CD40L (CD40 ligand) is involved in the
processing and expression of tumour antigens to T cells. It is currently in clinical trials
as a cancer therapeutic. IRF-1 has been shown to be responsible for the upregulation of
antigen transporters and immunoproteasome subunits associated with the CD40 response.
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Engagement of the CD40 ligand activates NF-κB dependent upregulation of IRF-1 [85].
In Hepatocellular Carcinoma (HCC), MHC Class I genes were upregulated by IRF-
1, and T cell memory was induced. IRF-1 expressing tumour cells were subjected to
specific Cytotoxic T Lymphocyte (CTL) killing in vivo resulting in suppression of a
highly tumourigenic HCC cell line in vivo [86]. Similarly, expression of IRF-1 in a non-
immunogenic sarcoma cell line resulted in enhanced MHC Class I expression, and re-
duced tumour growth. Tumour growth was more strongly impeded in immunocompetent
mice than immunodeficient mice [27].
As discussed in the previous section, IRF-1 has a role in apoptosis induced by immune
cell signals. It is evident from the diverse mechanisms of tumour suppression mentioned
above that IRF-1 is a very powerful antioncogenic agent. Its pleiotropic functions mean
that expression of IRF-1 can effect tumour suppression not merely when replacing lost
IRF-1, but across a range of unrelated cancer types.
There is, however, a caveat. Enhanced expression of IRF-1 could be advantageous
for the treatment of cancer but it has been linked to autoimmune disorders. It was noted
that in myelodysplasia patients, low expression of IRF-1 confers some protection against
autoimmune manifestations [87]. IRF-1−/− mice have reduced susceptibility to antigen-
induced autoimmune diseases type II collagen-induced arthritis and experimental allergic
encephalomyelitis (an animal model for multiple sclerosis [88] [89]. Thus, instead of non-
specifically activating IRF-1 activity, it is important to understand the regulation of this
protein in order to allow the development of therapeutics which can selectively exploit
the desired attributes.
1.5 Regulation of IRF-1
1.5.1 Regulation at the Promoter Level
IRF-1 is constitutively expressed at low levels, and its half life is rapid - around 30 mins
[111], [112]. Thus, upregulation of IRF-1 gene expression is an important method of









































Figure 1.3: IRF-1 is transcriptionally upregulated by a wide variety of stim-
uli. Black arrows indicate activation of IRF-1, green arrows indicate posi-
tive feedback where IRF-1 upregulates factors involved in its postive regulation.
[90],[91],[92],[93],[94],[95],[96],[97],[98],[99],[100],[101],[85],[102],[103],[104],[105],[106],
[107],[108],[76],[109],[110].
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control. IRF-1 can be induced by a wide varitey of stimuli. These are depicted in detail
in Fig 1.3 but include interferons, other cytokines and bacterial/viral antigens through
Toll Like Receptors (TLRs). The signalling pathways governing IRF-1 upregulation are
not known in all cases, but the GAS (gamma activated sequence) element in the IRF-1
promoter responds to various STAT (Signal Transduction and Activator of Transcription)
combinations, depending on the activating signal [113], [114], [110], [115], [31], [108],
[104]. A NF-κB site can mediate the upregulation of IRF-1 in response to alternative
signals such as [116], [85], [117]. The combination of response elements in the IRF-1
promoter allows cooperative upregulation of IRF-1 as a result of a combination of signals,
for example, TNF-α (Tumour Necrosis Factor-α) and IFN-γ together result in higher
levels of IRF-1 than is possible with individual stimuli [118].
1.5.2 Post-translational regulation
Although the accumulation of IRF-1 protein is clearly crucial, post-translational modifi-
cations are also important for the regulation of IRF-1 activity. This was first evident in
a paper by Watanabe et. al. who observed that induction of IRF-1 by IFN-β or TNF-α
or even a combination of the two was not sufficient for activation of an IRF-E (IRF-1
response element)-dependent reporter construct in L929 cells. In the presence of a virus,
IRF-1 was both induced and activated. When IRF-1 is pre-accumulated, activation of the
IRF-E can occur even in the presence of cycloheximide, arguing that a post-translational
modification is the missing activatory signal since protein synthesis is not required. As
this activation is blocked by a broad spectrum kinase inhibitor, phosphorylation is a likely
candidate [112].
Casein kinase II (CKII) is known to phosphorylate IRF-1 in the C-terminus. This
phosphorylation is required for transactivation activity. The exact role for CKII phospho-
ryation is unknown but it is suggested that it may be important for the activation of IRF-1
by cytokines [119]. PKC might also phosphorylate IRF-1 as, in the presence of a dom-
inant negative PKC isoform, a 2D gel shows IRF-1 with fewer acidic residues, and the
presence of constitutively active (CA)-PKC enhances the IRF-1 mediated transactivation
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of the CIITA (MHC class II Transactivator) promoter [120].
After DNA damage, the rate of proteasomal degradation of IRF-1 is reduced resulting
in accumulation of protein (in combination with elevated mRNA levels). It is thought
that ATM kinase might be involved in this regulation as in ATM−/− cells, DNA damage
does not affect IRF-1 half life [76]. Whether ATM directly phosphorylates IRF-1 is not
known.
The TLR adaptor protein MyD88 may facilitate phosphorylation of IRF-1. In den-
dritic cells (DCs), TLR2/6/9 activation cannot induce IRF-1 but it does enhance the activ-
ity of IRF-1 induced by IFN-γ. It is suggested that the effect of MyD88 is to increase the
rate of nuclear translocation of IRF-1 and, as co-expression of IRF-1 and MyD88 results
in additional acidic charges on IRF-1 it is likely that phosphorylation is responsible for
this [96].
Work in the Ball laboratory has demonstrated that IRF-1 is a phosphoprotein. Dr
Sarah Meek has shown that IRF-1 exists as various phosphoisoforms on a 2D gel, and
can be collapsed to a small number of spots by a phosphatase (Fig 1.4A). In addition,
treatment with the phosphatase inhibitor okadaic acid results in hyperphosphorylation of
IRF-1, visualised as a retarded migration on SDS-PAGE (Fig 1.4B).
Since the work for this PhD was started, it has been shown in the Ball laboratory that
phosphorylation of the IRF-1 C-terminus regulates the binding to the chaperone Hsp70.
This is particularly interesting since Hsp70 has been shown to cooperate with Hsp90 to
regulate IRF-1 activity, stability and localisation (Vikram Narayan, unpublished observa-
tions, and [121]). The significance of this regulation is considered in more detail in the
discussion.
Ubiquitination of a protein can target it for degradation, or modify its activity. IRF-1
is degraded by the 26S proteasome in response to its polyubiquitination. The C-terminal
region of the protein is found to determine its stability [122] but is not itself ubiquiti-
nated [123] and it has been suggested that phosphorylation in this region may signal for
ubiquitination; this mechanism has been shown to operate for IRF-3 [122].










Figure 1.4: IRF-1 is a phosphoprotein. (A) Nuclear fraction was extracted from HCT116 cells,
treated +/- lambda phosphatase (400U, 30mins, 30◦C) and analysed by 2D gel electrophore-
sis/immunoblot using anti-IRF-1 antibody (BD biosciences). Phosphatase treatment results in
collapse of acidic isoforms of IRF-1 to a single spot, implying IRF-1 exists as a phosphoprotein
in cells. (B) IRF-1 expressed in insect cells was treated +/- the phosphatase inhibitor okadaic acid
(OA) and analysed by SDS-PAGE/immunoblot using anti-IRF-1 (BD biosciences). Treatment re-
sults in the retardation of IRF-1; the lower mobility isoform likely represents hyperphosphorylated
IRF-1 (P-IRF-1) (experiments performed by Sarah Meek).
SUMOylation or covalent attachment of “Small Ubiquitin-like MOdifier” to proteins
can also affect activity. PIAS3 (Protein Inhibitor of Activated STAT-3), a SUMO ligase,
and Ubc9 (Ubiquitin Conjugating Enzyme-9), an E2 conjugating enzyme, were found to
elevate levels of SUMOylated IRF-1 with the result of suppression of transactivational
activity [124]. Elevated levels of SUMOylated IRF-1 in tumour cells result in accumu-
lation of the protein as SUMOylation possibly competes with ubiquitination for lysine
residues. Since SUMOylated IRF-1 is unable to activate apoptosis, this may contribute to
the uncontrolled growth of these cells [125].
Acetylation of IRF-1 by p300 has been observed in vitro [126]. In NIH3T3 cells,
PCAF (p300/CBP Associated Factor) binds IRF-1 and enhances its activity at the ISRE.
The Histone Acetyl Transferase (HAT) region of PCAF is required for this increase in
IRF-1 activity [127]. The acetylation of IRF-1 in the DNA binding domain by CBP in
response to MNNG treatment stabilises the IRF-1 protein and leads to its accumulation
in the absence of any change in mRNA levels [44].
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1.5.3 Co-factor Binding
As well as acetylation of transcription factors, CBP/p300 and PCAF can acetylate histone
proteins to ”activate” chromatin, making it accessible to transcription factors [128]. There
are a number of cases where IRF-1 binds a HAT protein but direct acetylation has not
been investigated or has been ruled out [129] [130], [131]. In these cases, IRF-1 could
cooperate in the recruitment of the HAT to modify the chromatin, modify itself, or to
modify another co-factor such as NF-κB [131] or p53 [67]. It is likely that future work
will demonstrate further the importance of IRF-1 in recruitment of HATs as the HPV
E7 oncoprotein functions to inactivate IRF-1 by recruiting HDACs to the IRF-1-bound
promoter [16]. This implies that acetylation of substrates by IRF-1-recruited HATs is a
common activatory mechanism.
IRF-1 binds a variety of other co-factors to carry out its transactivatory activity. The
enhanceosome which synergystically activates the /em IFN-beta promoter is composed
of IRF-1, NF-κB, ATF2/cJun and p300. These factors cooperate to generate much higher
levels of transcription than is achieved by the sum of their individual contributions [130].
IRF-1 and NF-κ-B interact at several other promoters. For example, at the iNOS promoter
in macrophages stimulated with IFN-γ and TNF-α, IRF-1 and NF-κB physically interact
and cause bending of the promoter DNA. The combination of signals produces synergistic
activation of iNOS [132].
STAT1 homodimers can activate IRF-1 expression in response to interferon and other
stimuli [113], [115], [31]. However, as a monomer STAT1 can cooperate with IRF-1 at a
series of promoters. At the gbp2 promoter, both IRF-1 and STAT1 are required for maxi-
mal transcription [133]. Interaction between IRF-1 and STAT1 seems to enhance binding
to the LMP2 promoter [134] and again, both factors are required for transcription [25].
IRF-1 and STAT1 participate in a positive feedback loop as they cooperate to activate the
STAT1 promoter [135].
In contrast to the recruitment of HATs by IRF-1 mentioned above, the chromatin
remodelling enzyme BRG1 (Brahma-related gene 1) is required to recruit IRF-1 to the
promoter of the antiviral E3 ligase TRIM22 [136].
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Figure 1.5: Various mechanisms exist to regulate promoter selection of IRF-1. A particular stim-
ulus, such as IFN-γ could direct IRF-1 to a particular subset of promoters through a variety of
mechanisms. Any one or a combination of these mechanisms could operate in response to a par-
ticular stimulus. (A) Stimulus induces phosphorylation of IRF-1; phosphorylation directs IRF-1
to promoters by causing a specific conformational change in the protein. (B) Stimulus induces
phosphorylation of IRF-1; phosphorylation creates a binding site for a cofactor which directs
IRF-1 to a particular promoter and could modulate its activity. (C) Stimulus upregulates IRF-1
and a cofactor; enhanced intracellular concentrations of these factors promotes their interaction
and the cofactor directs IRF-1 to a particular promoter. (D) Stimulus induces phosphorylation of
a cofactor; phosphorylated cofactor binds IRF-1 and directs it to a particular promoter.
1.5.4 Regulation by Other Factors
IRF-1 can also be negatively regulated. Binding of NPM (nucleophosmin) inhibits its
DNA binding and transcriptional activity [15] and LPA (Lysophosphatidic Acid) can also
block the binding of IRF-1 to DNA [137]. The nuclear translocation of IRF-1 is mediated
by importin-α1[138].
In summary, there is a wide repertoire of mechanisms existing in the cell to regulate
IRF-1 activity. This is not surprising since so many signals converge on IRF-1 and it
upregulates a diverse set genes. Complex regulation allows specific IRF-1 dependent
genes to be upregulated in response to a particular stimulus. This can be achieved through
post-translational modifications altering DNA and co-factor binding. Alternatively, or in
addition, IRF-1 co-factors can be upregulated or modified in response to the same signal,
thereby directing IRF-1 activity to particular promoters. This is illustrated in Fig 1.5.


















Figure 1.6: Domain organisation of IRF-1. IRF-1 activity is regulated by many overlapping do-
mains whose position is indicated here. Of particular interest to this thesis is the C-terminal
multifunctional multiprotein binding interface Mf1 which has been shown to regulate both tran-
scriptional activity (activatory and repressive) and steady state levels of IRF-1.
1.6 IRF-1 Structure and Function
IRF-1 is a multi-domain protein; its domain structure is illustrated in Fig 1.6. The N
terminal 120 amino acids comprise the DNA binding domain [139]. This region, which
contains a tryptophan cluster, is arranged in a helix-turn-helix motif and is conserved
across the IRF family [140]. The first 60 amino acids of IRF-1 also contain a repressor
domain which inhibits the transactivatory activity of the protein [141].
Adjacent to the DNA binding domain, between 117-141, are two potential NLS se-
quences. Deletion of these sequences forces IRF-1 to remain in the cytoplasm, while
expression of this region as a fusion protein with GFP localises it to the nucleus [142].
IRF-1 has also been shown to interact with importin-1α; this protein may mediate the
nuclear translocation of IRF-1 [138].
Towards the centre of the primary structure are homodimerisation [143], heterodimeri-
sation [142] and a highly disordered multifunctional protein binding (Mf2) domain [144].
A variety of positive and negative interacting factors target this region: IRF-8 [142], NPM
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[144] and YB-1 [144] binding inhibit IRF-1 activity, while CHIP binding facilitates ubiq-
uitination of IRF-1 after certain stresses [145].
A transcriptional activation domain resides between 185-256, and an enhancer domain
between 257-329 [141]. Thus the C-terminus of IRF-1 is particularly important for its
transcriptional activity. Work by Eckert et. al. has suggested that the enhancer domain
in fact comprises residues 257-300 while the final 25 residues (of the human protein)
constitute another repressor domain (at least for the IFN-β promoter).
The Ball laboratory has been particularly interested in these final 25 amino acids of
IRF-1, termed the Mf1 domain (Fig 1.6). It has been shown that residues 301-314 are
required for repression of Cdk2, and this activity is pivotal for growth suppression, but
does not impinge on the transcriptional activatory potential of IRF-1. A co-regulator
binding motif (LXXLL) also resides within this region. This may indicate that assembly
of a repressor complex at the Cdk2 promoter is orchestrated by IRF-1 [70]. The LXXLL
motif is also recognised by the co-factor p300 and the IRF-1-p300 complex has been
shown to enhance transcription of the p21 promoter through cooperation with p53 [67].
The region 301-311 has been suggested to contain a degradation motif which is recog-
nised by components of the proteasome machinery after IRF-1 has been polyubiquitinated
[123]. Hsp70 interacts with the LXXLL motif of IRF-1 and, together with Hsp90, pos-
itively regulates IRF-1. Notably, inhibition of Hsp90 results in the Hsp70-dependent
degradation of IRF-1 while overexpression of Hsp90 causes nuclear accumulation of
IRF-1. Interestingly, IRF-1 activity is regulated by Hsp90 independently of the effects
on steady-state protein levels [121].
Transactivatory activity of IRF-1 is regulated by a number of different motifs within
the Mf1 domain. A C-terminal point mutation (P325A) is sufficient to dramatically
change the half life of IRF-1 from around 30mins to less than 15mins (Fig 1.7A). In-
terestingly, when protein levels were normalised, this mutant is also more active in a dual
luciferase reporter assay at the TLR3 promoter (Fig 1.7B) [146]. Previous work by Eck-
ert et. al. has also shown that deletion of a negative regulatory domain within the Mf1
domain leads to transcriptional activation [70].
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Figure 1.7: A single point mutation of the last residue (P325) of IRF-1 increases both turnover and
activity of the protein. (A) IRF-1 P325A has accelerated turnover. HeLa cells were transfected
with 0.5µg IRF-1 WT or IRF-1 P325A. After 24h, they were treated with 30µg/ml cyclohex-
imide and harvested after the intervals indicated. Cells were lysed and lysate subjected to SDS-
PAGE/immunoblot using anti-IRF-1 (BD Biosciences) (experiment performed by Emma Pion).
(B) IRF-1 P325A has enhanced transactivatory activity. Left panel: HeLa cells were transfected
with a titration of 0-0.25µg IRF-1WT or 0-0.5µg IRF-1P325A (giving normalised IRF-1 protein
levels), 120ng TLR-3-luc reporter plasmid and 60ng control CMV-Renilla-luc. Reporter gene ac-
tivity was measured in relative light units (RLU) and normalised to CMV-Renilla-luc activity.
Results are given as mean +/- half the range. Right panel: Expressed protein levels were visu-
alised by SDS-PAGE/immunoblot using anti-IRF-1 (BD Biosciences) and anti-GAPDH (Abcam)
as a gel loading control (experiment performed by Angeli Moeller)[146].
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Finally, exogenous manipulation of the Mf1 domain can alter IRF-1 activity. Treat-
ment of HeLa cells with an intracellular antibody which recognises an epitope spanning
310-317 results in activation of endogenous IRF-1 activity at a number of promoters with-
out change in IRF-1 levels (Fig 1.8) [146]. It is tempting to speculate that here, the anti-
body may mimic the effects of a post-translational modification.
The presence of internal regulatory elements within the IRF-1 structure argues strongly
that post-translational modifications will modulate the activity of IRF-1 by altering the
contribution of each element to the overall activity.
Thus, given the very limited information available on the post-translational regulation
of IRF-1, coupled with the growing body of evidence that post-translational events in the
Mf1 domain critically regulate IRF-1 function, it is clear that there is a need for dedicated
investigation into this topic. This thesis advances the current understanding of IRF-1 post-
translational modifications by presenting evidence that phosphorylation at specific sites in
the Mf1 domain is induced by IRF-1 activating stimuli. Such phosphorylation activates
IRF-1 activity at specific promoters and enhances its capacity as a tumour suppressor,
both through suppression of colony formation and inhibition of metastasis.















































Figure 1.8: Intracellular nanobodies to IRF-1 C-terminus can activate IRF-1 without altering pro-
tein levels. Epitope of intracellular nanobody targeting IRF-1 Mf1 domain is indicated. HeLa cells
were transfected with a titration of 0-250ng EGFP-scFv3 (Mf1 domain epitope) or EGFP-scFvN
(N-terminal epitope), 120ng TLR3-Luc reporter plasmid and 60ng control CMV-Renilla-luc. Re-
porter gene activity was measured in relative light units (RLU) and normalised to CMV-Renilla-
luc activity. Results are given as mean +/- half the range. Expressed protein levels visualised
by SDS-PAGE/immunoblot using anti-GFP (Living Colours), anti-IRF-1 (BD Biosciences) and
anti-GAPDH (Abcam) as a gel loading control (experiment performed by Angeli Moeller)[146].
Chapter 2
Materials and Methods
2.1 Chemicals and Reagents
All general chemicals were purchased from Sigma unless otherwise stated. Peptides were
from Chiron Mimotopes and were N-terminal biotin tagged with an SGSG spacer.
2.2 Antibodies
Protein Target Source Supplier (product code) Dilution
IRF-1 mouse (monoclonal) BD biosciences (20/IRF-1) 1:1000
IRF-1 rabbit (polyclonal) Santa Cruz (C-20) 1:1000
IRF-3 rabbit (polyclonal) NEB (43025) 1:1000
GAPDH mouse (monoclonal) Abcam (9484) 1:25000
GFP mouse (monoclonal) Living Colours (JL-8) 1:1000
p300 rabbit (polyclonal) Santa-Cruz (N-15) 1:1000
Hsp70 rabbit (polyclonal) Stressgen (SPA-812) 1:1000
Hsp90 rabbit (polyclonal) Stressgen (SPS-771) 1:1000
AMPK rabbit (polyclonal) Millipore (07-250) 1:500
IRF-2 mouse (monoclonal) Abcam 1:500
Table 2.1: Primary Antibodies
Secondary antibodies rabbit anti-mouse (260) and swine anti-rabbit (217) were pur-
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chased from Dako.
2.3 DNA constructs
pcDNA3.1: IRF-1 WT1, IRF-1 S317A1, IRF-1 S317D1 IRF-1 W11R4
pDEST14: IRF-1 WT2
pDEST15: coIRF-1 WT3
pTrcHis B: IRF-1 1-1242, IRF-1 118-2562
pCold(His): coIRF-1 WT3
px luc: pIRF-E luc5, pTLR3 luc6, pIL7 luc7, pIFN-β luc8, pCDK2 luc9, pMMP9
luc10
pCMV: p30011
1 From Dr. Mijram Eckert
2 From Dr. Angeli Moeller
3 From Dr. Vikram Narayan
4 From Dr. Emma Pion
5 From Panomics Solutions
6 [147]
7 [95]
8 Gift from Dr. T. Fujita (Kyoto University)
9 Gift from Dr. van Wijnen (University of Massachusetts)
10 Gift from Ju-Ming Wang (National Cheng Kung University, Taiwan)
11 From Mauro Giacca (ICGEB, Italy)
co - codon optimised
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2.4 Cloning
2.4.1 Site Directed Mutagenesis
Mutagenesis was performed by mixing template, primers and Pfu master mix according
to instructions below, then subjecting to the PCR programme described. Template DNA
was then digested by Dpn1, leaving only the mutated product . This was transformed
into competent DH5α cells (see below) and plated on LB-Agar with ampicillin. A single
colony was picked, grown in LB broth with ampicillin and plasmid DNA was purified
from the bacteria using QIAGEN mini-prep kit. The mutated plasmid was sequenced by
Source Biosciences (Cambridge) before use.
Reaction Mix
12.5µl Pfu Master Mix
0.13µl 100µM forward primer






55◦C 1min 15 cycles68◦C 12mins
68◦C 30mins
Mutagenic Primers
Altered codons are underlined. Sequence is 5′ to 3′.
IRF-1 WT→ IRF-1 T311A
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for mammalian expression vectors
Forward:ACAGCCTGCTGGCACCAGTCC
Reverse:GGACTGGTGCCAGCAGGCTGT
IRF-1 WT→ IRF-1 T311D
for mammalian expression vectors
Forward:ACAGCCTGCTGGACCCAGTCC
Reverse:GGACTGGGTCCAGCAGGCTGT
for codon optimised E. Coli expression vectors
Forward:ATAGCCTGCTGGATCCGGTGC
Reverse:GCACCGGATCCAGCAGGCTAT
IRF-1 WT→ IRF-1 S317D
for codon optimised E. Coli expression vectors
Forward:TGCGTCTGCCGGATATTCAGG
Reverse:CCTGAATATCCGGCAGACGCA
IRF-1 WT→ IRF-1 W11R
for codon optimised E. Coli expression vectors
Forward:TATGCGTCCGCGGCTGGAAATG
Reverse:CATTTCCAGCCGCGGACGCATA
Dpn1 Digestion of Amplification Products
To digest methylated template DNA, Dpn1 was added at 0.4U/µl to amplification products
(0.5µl of 20U/µl per 25µl reaction). Reaction was incubated at 37◦C for 1 hour, then
transformed into DH5α E. Coli cells.
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2.4.2 Heatshock Transformation
50µl of competent bacterial cells (see below for method of preparation of competent
cells) was mixed gently with 1µl of Dpn1-digested amplification product. Mixture was
incubated on ice for 30mins then heatshocked at 42◦C for 1min. Cells were returned to
ice for 2mins and finally added to 0.5ml of LB broth.
Cells were grown in LB broth for 2 hours at 37◦C with shaking (225rpm) then plated
on LB Agar/50µg/ml ampicillin plates. Plates were incubated at 37◦C overnight.




Sterilised in autoclave at 121◦C, 20 mins.




Sterilised in autoclave at 121◦C, 20 mins.
2.4.3 Generation of Competent Cells: Heatshock Method
E. Coli (DH5α or BL21-AI) were inoculated into 3ml LB broth (without antibiotic) and
grown overnight at 37◦C with shaking (220rpm). 250µl of this starter culture was added to
50ml LB broth (without antibiotic) and incubated again until the OD600 reached 0.4. The
bacterial cells were pelleted by centrifugation at 4000RCF (relative centrifugal force),
15mins, 4◦C. The pellet was resuspended in 16ml ice cold Buffer I and incubated for
10mins on ice. Cells were pelleted as before, and pellet resuspended in 2ml ice cold
Buffer II, incubated on ice for 10mins then 50µl aliquots were placed into chilled, sterile














Adjusted to pH 6.5 using NaOH then sterilised by fitration
2.4.4 DNA preparation
QIAGEN miniprep and maxiprep kits were used as directed in manufacturer’s handbook.
2.4.5 Sequencing Reaction
The sequencing reaction was performed by mixing template, a single primer and Big
Dye buffer and Big Dye Mix (contains dNTPs, polymerase and terminating, dye-linked
nucleotides) according to instructions below, then subjecting to the thermal cycling pro-
gramme described. Dye-terminated extension products were subsequently cleaned up
by ethanol/EDTA precipitation as detailed below before sending to Source Biosciences
(Cambridge) for DNA Sequencing.
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Reaction Mix
0.5µl 3.2µM primer (see below for sequences)
1µl 100 ng/µl DNA
2µl Big Dye Buffer (5x)






50◦C 5s 25 cycles60◦C 4mins
Sequencing Primers
For mammalian sequence 5′ to 3′.
IRF-1 S1 (Forward, binds at base 209)
GGAGCCAGATCCCAAGACGTG
IRF-1 S2 (Forward, binds at base 499)
CAGGCTACATGCAGGACTTGGAG
IRF-1 S6 (Reverse, binds at base 891)
GGTGGCATCCATGTTCTTCAG
IRF-1 S7 (Reverse, binds at base 380)
CTCTTAGCATCTCGGCTGG
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For codon coptimised E. Coli sequence 5′ to 3′.
IRF-1co S2 (Forward, binds at base 500)
CGGGCTATATGCAGGATCTGGAA
IRF-1co S6 (Reverse, binds at base 892)
GGTCGCATCCATGTTTTTCAG
IRF-1 S7 (Reverse, binds at base 380)
CTTTTCGCATCGCGGCTGC
For IRF-1 domains in pTrcHis vector.




Extension products were centrifuged briefly to collect liquid at bottom of tube.
2.5µl 125mM EDTA was added.
30µl 100% ethanol was added.
Tube was vortexed and incubated at room temperature for 15mins.
Mixture was centrifuged at 16000RCF for 20mins to pellet precipitated DNA.
Ethanol was removed.
Tube was spun at 16000RCF for 2mins.
Residual ethanol was removed.
DNA was washed with 30µl 70% ethanol.
Mixture was spun at 16000RCF for 2 mins.
Ethanol was removed.
Tube was spun at 16000RCF for 2 mins.
Residual ethanol was removed.
DNA was allowed to air-dry before being posted to Source Biosciences (Cambridge) at
ambient temprerature.
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2.5 Protein Expression and Purification
2.5.1 In vitro Protein Expression using TNT-coupled lysate systems
IRF-1 WT, T311D, S317D and T311D/S317D and p300 were expressed from pcDNA3.1
plasmid in Promega TNT reticulocyte or wheatgerm lysate according to manufacturer’s
instructions.
2.5.2 In vitro Protein Expression and Purification using the E. Coli-
based PURExpress in vitro protein synthesis kit (NEB)
Untagged IRF-1 was expressed and purified from the PURExpress in vitro protein syn-
thesis kit. 250ng pDEST14 IRF-1 was used as the template. Protein is expressed in the
cell-free system, then the His-tagged transcription/translation machinery is removed us-
ing Ni-agarose beads leaving the purified protein. Protocol was as per manufacturer’s
instructions.
2.5.3 E. Coli Protein Expression and Purification
Protein Expression
BL21-AI cells (for pDEST15 or pTrcHisB vectors) or BL21-DE3 cells (for pCold vector)
were transformed (see above) with appropriate vector. The following day, a single colony
was picked and used to inoculate a starter culture (50ml) in LB with ampicillin (50µg/ml).
The starter culture was grown overnight at 37◦C with shaking (220rpm) then inoculated
into 2 litres LB with ampicillin and grown under the same conditions until the OD600
reached 0.6. Expression of protein was induced using arabinose(0.2%(w/v)) for BL21-AI
cells or 0.5nM IPTG for-DE3 cells. For expression of proteins from pDEST15 or pTrcHis
vectors, cultures were incubated for 3 hours at room temperature with shaking (220rpm)
before collection of bacterial cell pellet by centrifugation at 6000RCF, 20mins, 4◦C. For
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expression of proteins from pCold vector, cells were acclimitised at 15◦C for 15mins prior
to induction with IPTG. Following addition of IPTG, cells were incubated for 15mins at
15◦C with shaking (220rpm) and pellet was collected as above.
Protein Purification: His-tagged proteins
IRF-1 Domain Purification
The bacterial cell pellet from 2L of culture was resuspended in 10ml lysis buffer (see be-
low). The lysate was subjected to freeze-thaw in liquid nitrogen and sonicated followed
by clarification by centrifugation at 12000RCF, 15mins, 4◦C. Clarified lysate was filtered
through a 0.45µm filter to remove debris, then mixed with 1ml of pre-equilibrated Ni-
NTA agarose bead slurry (Qiagen). Lysate and beads were incubated at 4◦C for 1 hour
on a rotating table. The beads were collected by centrifugation at 400RCF , 5mins, 4◦C
and the flowthrough was removed. The beads were washed with 3x10ml wash buffer,
1x10ml wash buffer with detergent and 2x10ml wash buffer. 3ml of elution buffer was
then added to the beads and incubated for 30mins at 4◦C on a rotating table. The beads
were pelleted by centrifugation as above and the eluate collected. Purified domains were
stored at -80 ◦C. The presence of purified IRF-1 domains was detected by SDS-PAGE
followed by immunoblot or Coomassie Staining (see below).







1X Protease Inhibitor Mix (PIM)
(1X PIM: 20µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml pepstatin, 1mM benzamidine,
10µg/ml soybean trypsin inhibitor, 2M pefabloc and 0.5M EDTA.)
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His-IRF-1 Purification (from pCold vector)
The bacterial cell pellet from 2L of culture was resuspended in 10ml of lysis buffer.
The lysate was subjected to freeze-thaw in liquid nitrogen and sonicated followed by
clarification by centrifugation at 12000RCF, 15mins, 4◦C. Clarified lysate was filtered
through a 0.45µm filter to remove debris, then passed over a 2ml Ni-NTA column twice
at 0.4ml/min. The column was washed with 10CV Buffer I, 5CV Buffer I+ATP/MgCl2
(to remove chaperones), 10CV Buffer I, 20CV Buffer II, 10CV Buffer III and eluted in
5CV elution buffer. Purified protein was buffer exchanged into storage buffer and stored
at -80◦C. The presence of purified IRF-1 was detected by SDS-PAGE followed by im-
munoblot or Coomassie Staining (see below).
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1X Protease Inhibitor Mix (PIM)
(1X PIM: 20µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml pepstatin, 1mM benzamidine,
10µg/ml soybean trypsin inhibitor, 2M pefabloc and 0.5M EDTA.)
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Protein Purification: GST-tagged proteins
The bacterial cell pellet from 2L of culture was resuspended in 10ml lysis buffer (see
below). The lysate was subjected to freeze-thaw in liquid nitrogen and sonicated fol-
lowed by clarification by centrifugation at 12000RCF, 15mins, 4◦C. Clarified lysate was
filtered through a 0.45µm filter to remove debris, then mixed with 1ml of pre-equililbrated
glutathione-sepharose 4B bead slurry (GE Healthcare). Lysate and beads were incubated
at 4◦C for 1 hour on a rotating table. The beads were collected by centrifugation at
400RCF , 5mins, 4◦C and the flowthrough was removed. The beads were washed with
5x10ml wash buffer then 3ml of elution buffer was then added to the beads and incubated
for 30mins at 4◦C on a rotating table. The beads were pelleted by centrifugation as above
and the eluate collected. Purified domains were stored at -80 ◦C. The presence of puri-
fied IRF-1 domains was detected by SDS-PAGE followed by immunoblot or Coomassie
Staining (see below).
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1X Protease Inhibitor Mix (PIM)
(1X PIM: 20µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml pepstatin, 1mM benzamidine,
10µg/ml soybean trypsin inhibitor, 2M pefabloc and 0.5M EDTA.)













Protein concentration was quantified using either BCA Assay Kit (Pierce) or Bradford’s
Reagent (Bio-Rad) following the manufacturer’s instructions. Abosrbance was measured
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using a Victor 3 plate reader (Perkin Elmer).
2.7 SDS-PAGE
Polyacrylamide gels were prepared using the MiniProtean kit from Bio-Rad, following
the manufacturer’s instructions and using the reaction mixes detailed below. Acrylamide
mix was from National Diagnostics. Sample concentrations were determined as described
above, and the appropriate volume of sample was mixed 1:1 with 2X sample buffer then
heated at 85◦C for 2mins. Samples were loaded on the gel along with pre-stained protein
ladder (Fermentas PageRuler) and gels were run in 1X Tris/Glycine running buffer at




0.24M Tris pH 6.8
400mM DTT
few grains bromophenol blue
10% Separating Gel
10%(w/v) Acrylamide mix
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Resolving Gel
5%(w/v) Acrylamide mix








2.8 Visualisation of Proteins
2.8.1 Coomassie staining
Gels were fixed and stained in Coomassie stain for 20mins at room temperature. Gels
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2.8.2 Western Blotting
Proteins in SDS-PAGE gels were transferred to nitrocellulose membrane (Protran) in 1X
transfer buffer using Bio-Rad Mini TransBlot apparatus. Transfer was for 1 hour at 100V
with cooling or 20mA overnight. Once the proteins had been transferred to the mem-
brane, they were ink stained and then blocked for 0.5 hours using either 5% skimmed
milk powder (Marvel) in PBS for conventional antibodies, or 3% BSA/PBS for phos-
phospecific antibodies. After blocking, membranes were probed with primary antibody
diluted in blocking buffer for 1 hour at room temperature or overnight at 4◦C. Phospho-
specific antibodies were incubated for 24 hours at 4◦C. The membranes were washed 3x
5mins in PBS-T (PBS with 0.1%(v/v) Tween-20) then incubated with secondary antibody
for 1 hour at room temperature. Membranes were washed 3x5 mins in PBS-T before de-
tecting peroxidase-conjugated secondary antibodies with enhanced chemiluminescence
(ECL) reagent. ECL solutions I and II were mixed 1:1 and incubated with the membrane
for 2mins. The solution was removed and X-Ray film (SLS) or Hyperfilm (Amersham)
was exposed to the membrane. Film was developed using a Konica Medical Film Proces-










100mM Tris pH 8.5
0.02% H2O2
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2.9 Cell lines and cell culture
Cell lines and maintenance conditions used are listed below (Table 2.2):
Cell Line Source Media* Conditions
A375 malignant melanoma (human, skin) DMEM 37◦C, 10% CO2
H1299 non-small cell lung carcinoma (human, lung) RPMI 37◦C, 5% CO2
HeLa epithelial adenocarcinoma (human, cervix) DMEM 37◦C, 5% CO2
MDA-MB-231 epithelial adenocarcinoma (human, breast) DMEM 37◦C, 5% CO2
Table 2.2: Cell lines and maintenance conditions
*All media were sourced from GIBCO and were supplemented with 10%(v/v) FBS (Au-
togen Bioclear) and 1% P/S (Invitrogen).
2.9.1 Sub-culturing
Cells were sub-cultured when they reached 100% confluence. Cells were rinsed in sterile
PBS and detached using trypsin-EDTA (Invitrogen) (2ml/10cm plate). The trypsin was
neutralised using complete medium and a 1:10 dilution was replated in fresh medium.
2.9.2 Long-term storage
For long-term storage, cells were frozen and kept in liquid nitrogen vapour phase. A
confluent 10cm plate of cells was trypsinised and the cells collected by centrifugation at
1000RCF, 5mins, room temperature. The medium was discarded and cells were resus-
pended in 1ml of freezing medium. The cells were then placed in cryotubes (Nunc) and
frozen slowly in a Nalgene cryo-freezing container for 1 day before being transferred to
the liquid nitrogen vapour phase for long-term storage.
Freezing Medium
Complete culture medium
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supplemented with 5% DMSO
2.9.3 Transient Transfection
Transient transfections of DNA were carried out using Attractene (Qiagen) according to
manufacturer’s instructions.
2.10 Cell Treatments
Cells were treated with the following activators of IRF-1 (Table 2.3):
Treatment Concentration Solvent Length
Interferon-γ (GIBCO) 100U/ml 0.1% BSA, 40mM Tris pH 7.4 4 hours
Etoposide (Sigma) 10µM 50% DMSO 4 hours
p(I:C) (Invivogen) 50µg/ml PBS 4 hours
Table 2.3: Concentrations and duration of IRF-1 activating treatments
Drugs were diluted in 1ml cell culture medium, then added to 9ml medium on cells.
2.10.1 Cell Lysis








1X Protease Inhibitor Mix (PIM)
(1X PIM: 20µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml pepstatin, 1mM benzamidine,
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Additional phosphatase inhibitors were added when the phosphorylation state of IRF-1
was particularly important.
1% NP-40 Mammalian Cell Lysis Buffer






1X Protease Inhibitor Mix (PIM)
(1X PIM: 20µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml pepstatin, 1mM benzamidine,
10µg/ml soybean trypsin inhibitor, 2M pefabloc and 0.5M EDTA.)
2.11 Kinase Assay
In vitro phosphorylation of recombinant IRF-1 by cell lysate or purified kinases was per-
formed by kinase assays.
2.11.1 Kinase assays using cell lysate
HeLa cells were lysed in 1% NP-40 mammalian cell lysis buffer and the protein con-
centration of the lysate was quantified using Bradford’s Reagent. Cell lysate or purified
kinase was incubated with substrate (GST-IRF-1 or His-IRF-1-domain) and ATP in reac-
tion buffer (see below). The final volume was 9µl to which 1µl ATP/[γ32P]ATP mix was
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added to initiate the reaction. Reactions were incubated at 30◦C for 30mins in a water-
bath and then terminated by addition of SDS-PAGE sample buffer. Samples were then
resolved by SDS-PAGE, gels were fixed and stained by Coomassie, dried onto filter pa-
per on a vacuum drier and the image transferred to a phosphorimager screen (Amersham
Biosciences). Incorporation of 32P labelled phosphate into IRF-1 was visualised using a
Storm 840 phosphorimager (Amersham Biosciences) and ImageQuant software.
Kinase Assay Reaction Mix
450ng/500ng/1µg as indicated Substrate (GST-IRF-1 or His-IRF-1-domain)
4µl 1mg/ml Cell lysate
2µl 5x Kinase Assay Buffer
1µ ATP mix (0.2mM)*
10µl
*ATP mix: Added at end to initiate reaction
2mM ATP pH8 + 1:50 γ[32P]ATP. As [32P]ATP decays, dilutions of up to 1:25 were used.





2.11.2 Kinase assays using purified kinase
Chk1
Reaction performed as above except cell lysate replaced with 0.25µl Chk1 (Kudos Phar-
maceuticals).
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AMPK
Reaction performed as above except AMPK kinase assay mix and AMPK assay buffer
was used.
AMPK Kinase Assay Mix
1µg Substrate
40U AMPK (Upstate)
1µl ATP mix (0.1mM)*
xµl AMPK buffer
10µl
*ATP mix: Added at end to initiate reaction
1mM ATP pH8 + 1:50 γ[32P]ATP. As [32P]ATP decays, dilutions of up to 1:25 were used.







2.12 Ammonium Sulphate Precipitation
Saturated ammonium sulphate solution (BDH) was added to cell lysate to a final concen-
tration of 25% and equilibrated with stirring for 15mins. Supernatent was collected after
spinning at 12000RCF, 15mins, 4◦C and precipitate discarded. Saturated ammonium sul-
phate solution was added to supernatent to a final concentration of 40% and precipitate
collected after spinning as before. Precipitate from 40% cut was resuspended in resus-
pension buffer and dialysed for 2h in dialysis buffer to reduce salt concentration.











(1X PIM: 20µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml pepstatin, 1mM benzamidine,
10µg/ml soybean trypsin inhibitor, 2M pefabloc and 0.5M EDTA.)
Resuspension Buffer
1X PIM replaced with 1mM Benzamidine
2.13 Anion Exhange Chromatography
A375 cells were lysed in 0.5% Triton mammalian cell lysis buffer. 23mg of lysate was
filtered through a 0.4µm syringe filter and loaded onto a HiTrap Q Sepharose HP column
(GE Healthcare) pre equilibrated in Buffer A. Column was washed with Buffer A and
protein eluted over a 20CV gradient to Buffer B (0.05-1.2M NaCl gradient) followed by
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As Buffer A except 1.2M NaCl
2.14 Acetone Precipitation
4X sample volume of ice cold (-20◦C) acetone (300µl fraction, 1.2ml acetone) was added
to the sample. Sample was vortexed and incubated for 1 hour at -20◦C. After the in-
cubation, the sample was centrifuged at 16000RCF, 10 mins, 4◦C and supernatent was
removed. Residual acetone was allowed to evaporate at room temperature for 30 mins,
following which the sample was resuspended in 60µl 1X sample buffer.
2.15 2D Gel Electrophoresis
2.15.1 Sample Preparation
Cells were rinsed in 250mM sucrose/10mM Tris pH7.5 then lysed in 2D gel lysis buffer
(500µl for a 10cm plate) with a 10min incubation on ice. DNA was sheared by passing
lysate through a 0.6mm gauge needle until free flowing.





1x Protease Inhibitor Mix (PIM)
few grains bromophenol blue
2.15.2 First dimension: Isoelectric Focusing (IEF)
Sample was loaded onto 7cm pH4-7 IPG strips (GE Healthcare). 40µl of lysate was
mixed with 90µl of rehydration buffer and incubated with the IPG strip overnight at room
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temperature. IEF was carried out on a Multiphor II Electrophoresis system (GE Health-
care). Conditions were:
200V 0.01h







few grains bromophenol blue
2.15.3 Second dimension: SDS-PAGE
The IPG strip was equilibrated first in equilibration buffer + DTT, then equilibration buffer
+ iodoacetamide. The IPG strip was then transferred to a single well 10% Tris/glycine
minigel and run, transferred and immunoblotted as previously described for SDS-PAGE
gels.
2D Gel Equilibration Buffer
6M Urea
50mM Tris pH 8.4
2%(w/v) SDS
30%(v/v) Glycerol
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All reagents used in 2D gel protocol were from GE Healthcare. Chemicals were from the
PlusOne range.
2.16 Phosphatase Treatment
Experiment carried out by Sarah Meek.
HCT116 cells were harvested and nuclear fraction was extracted: cells were rinsed in
250mM sucrose/10mM Tris pH 7.5 and lysed for 10mins on ice in hypotonic lysis buffer.
Lysate was centrifuged 2500g, 5mins, 4◦C and the pellet resuspended in nuclear lysis
buffer. This was incubated on ice for 30 mins then spun 13000RCF, 10mins, 4◦C. Super-
natant is the nuclear fraction.
The nuclear fraction was treated with lambda phosphatase 400U, 30mins, 30◦C then
separated by 2D gel electrophoresis on a pH3-10NL IPG strip and immunoblotted using
anti-IRF-1 (BD biosciences).
Hypotonic Lysis Buffer







1X Protease Inhibitor Mix (PIM)
(1X PIM: 20µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml pepstatin, 1mM benzamidine,
10µg/ml soybean trypsin inhibitor, 2M pefabloc and 0.5M EDTA.)
2.17 Dual Luciferase Reporter Assays 52
Nuclear Lysis Buffer








1X Protease Inhibitor Mix (PIM)
(1X PIM: 20µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml pepstatin, 1mM benzamidine,
10µg/ml soybean trypsin inhibitor, 2M pefabloc and 0.5M EDTA.)
2.17 Dual Luciferase Reporter Assays
Cells were co-transfected with pcDNA3 IRF-1 or control (pcDNA3.1 empty vector (EV)),
pCMV-Renilla/Luc vector as an internal control and either pIRF-E-, pTLR3, pIFNβ-,
pCDK2- or -Firefly/Luc. Various ratios of px-Firefly/Luc:pCMV-Renilla were used in
order to get optimum signal to noise ratio (Table 2.4. DNA levels were normalised using
empty vector. Reporter gene (luciferase) activity was measured 24 hours after trans-
fection using the Dual Luciferase Assay system (Promega) according to manufacturer’s









Table 2.4: Ratios of px-Firefly/Luc:pCMV-Renilla used for different px-Firefly constructs.
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2.18 Geneticin Dose-Response Curves
The dose-response curves for geneticin were determined for cell lines to find the optimum
concentration to be used to select for transfected cells containing geneticin-resistance
elements in the protein expression vector. Cells were seeded in 6 well dishes and allowed
to adhere overnight. A titration of geneticin (Invitrogen) was added to successive wells
and the growth of the cells monitored at 3 and 5 days after treatment.
2.19 Clonogenic Assays
2.19.1 Anchorage-dependent Colony Formation Assay
Cells were grown in 6 well plates and transfected with IRF-1 WT or mutant. After
48 hours, cells were trypsinised and seeded into 10cm dishes in appropriate complete
medium supplemented with 3% geneticin (Invitrogen) for A375 cells, or 1.5% geneticin
for H1299 cells. Medium was changed after 4 days to maintain geneticin selective pres-
sure, and after 10 days, assays were developed. Colonies were washed with PBS and
fixed with 100% methanol (-20◦C) for 30mins at room temperature. Colonies were then
stained with 10% Giemsa stain (diluted in water) for 15mins at room temperature, washed
thoroughly and allowed to air-dry. Colony counting and area measurement was performed
using Image J software (NIH).
2.19.2 Anchorage-independent Colony Formation Assay
Cells were grown in 6 well plates and transfected with IRF-1 WT or mutant. After 48
hours, cells were trypsinised and 1x104 cells were added to 2ml of methylcellulose (R&D
systems) in complete MEM (GIBCO) with 3%(A375) or 1.5%(H1299) geneticin (Invit-
rogen). This was layered onto 2ml of 0.9% Agarose (Invitrogen) in complete MEM also
with geneticin in 6 well tissue culture plates. Cells were incubated for 6-8 days to allow
colonies to form. Colony counting and area measurement was performed using Image J
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software (NIH).
2.20 Protein Half Life Determination
Cells were grown in 6 well plates and transfected with 1.2µg IRF-1 or mutant. After 24
hours, cells were treated with 30µg/ml cycloheximide and harvested after 0, 15, 30, 45,
60, 75 and 90mins of treatment. Cells were lysed using 0.5% Triton X-100 mammalian
cell lysis buffer and half life of IRF-1 visualised by immunoblotting of SDS-PAGE gels
using anti-IRF-1 (BD Biosciences). For fractionated half lives, the cells from each time
point were harvested, fractionated using Calbiochem ProteoExtract subcellular fractiona-
tion kit according to manufacturer’s instructions and visualised as above.
2.21 Inverse Invasion Assays
2.21.1 Setting up Transwells
Transwell inserts (Corning) in 24 well plates were filled with 100µl of ice cold Matrigel
(BD) diluted 1:2 with ice cold PBS which was allowed to set for 30mins at 37◦C. Tran-
swells were then inverted and 5x104 cells in 100µl of complete medium were used to coat
the bottom of the filter. Cells were left for 4 hours at 37◦C to adhere to the inverted Tran-
swell. Transwells were washed in 2x 1ml serum free medium and then a gradient was
prepared by placing the transwell right way up in 1ml serum free medium and pipetting
100µl of complete medium on top of the Matrigel. Plates were incubated for 3 days to
allow invasion. Experiment was performed in quadruplicate.
2.21.2 Staining Cells
Cells were stained with Calcein-AM (Invitrogen). 0.5ml of medium containing 4µM
Calcein-AM was pippeted into a well, Transwells were placed in the wells and 0.5ml of
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4µM Calcein-AM in medium was pipetted on top. Cells and stain were incubated for 1
hour at 37◦C before being visualised using a confocal microscope.
2.21.3 Visualising and Quantifying Invasion
Z-sections were scanned at 15µM intervals from the base of the filter using a Leica TCS
MP5 confocal microscope. Image J was used to quantify invasion. The total area of
stained cells at the confluent monolayer on the filter was designated 100% and the area of
stained cells at each z-section was normalised to this. Data was represented as percent of
cells invaded through 45µm.
2.22 Cell Cycle Analysis
1x106 cells were resuspended in 300µl 50% FBS in PBS and fixed by adding 900µl ice
cold 70% ethanol while vortexing then incubating at 4◦C for 1 hour. Cells were then
washed in 3ml PBS and pellet resuspended in 300µl propidium iodide staining solution
and incubated in the dark for 1hour at 4◦C. Samples were then analysed on a FACSAria
II Flow Cytometer (BD Biosciences).





A senescence-associated β-galactosidase staining kit (NEB) was used as per manufac-
turer’s instructions.
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2.24 Adhesion Assay
Cells were transfected with EV or pcDNA3-IRF-1 WT or T311D/S317D. After 24h, cells
were harvested and counted and 100µl of a suspension of 8x105 cells/ml of A375 cells
placed in wells of a 96 well plate. Cells were allowed to attach for 1h at 37◦C, 10% CO2
then washed twice with PBS, fixed for 15 mins with 50µl ice cold methanol and stained
with 50µl 10% Giemsa stain for 1h. Cells were washed 5 times with PBS then lysed in
50µl 0.2% SDS in PBS to solubilise the stain. Absorbance at 595nm was detected as a
measure of attached cells.
2.25 Polyclonal Antibody Production and Purification
Antibodies to phosphorylation sites in the C-terminus of IRF-1 were raised in rabbits by





Upon receipt of final bleed, antisera was purified first against non-phosphorylated
IRF-1 peptide to remove non-phosphospecific IRF-1 antibodies. The flowthrough from
this step was then purified against either p308S, p311T or p317S phosphorylated IRF-1
peptide to isolate phosphospecific antibodies.
2.25.1 Purification against non-phosphorylated peptide
0.5µl of 5mg/ml biotinylated IRF-1 C-terminal peptide (aa301-325) (Chiron Mimotopes)
in 200µl PBS was incubated with 100µl streptavidin agarose bead slurry (GE Healthcare)
for 1 hour at room temperature on a rotating table. Beads were then washed with 3 x 1ml
PBS, and 2ml of serum was added to beads. Beads and serum were incubated for 1 hour
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at 4◦C on a rotating table. Mix was poured into 1ml mobicol column with 90µm filter
(MoBiTec) and the flowthrough was collected.
2.25.2 Purification against phosphorylated peptide
Coupling of peptide to beads
2.5mg of phosphorylated non-biotinylated IRF-1 peptide was added to 0.5ml of CDI-
Agarose beads (Pierce) in 0.1M sodium borate buffer (pH9) and mixed overnight at room
temperature on a rotating table. Beads were collected by centrifugation (500RCF, 5mins,
room temperature), supernatent was removed and 1ml of 1M Tris pH8.8 was added to the
beads for 8 hours at room temperature with mixing to quench non-reacted sites. Beads





adjust pH to 9
Purification of antibody
Phosphatase inhibitors (50mM NaF and 50mM β-glycerophosphate) and 50µ of phosphopeptide-
coupled beads were added to 2ml of flowthrough from previous purification. Serum and
beads were mixed overnight at 4◦C, then beads were collected by centrifugation (500RCF,
5mins, 4◦C), supernatant was removed and beads were washed 3x 0.5ml PBS-T + phos-
phatase inhibitors (50mM NaF and 50mM β-glycerophosphate). Phosphospecific anti-
body was eluted using low pH. Beads were placed in a 1ml mobicol column with 90µm
filter (MoBiTec) and 6x 100µl 0.1M glycine pH2.5 was passed over the column. Anti-
body was collected in 6x low bind tubes (Eppendorf) containing 10µl 1.5M Tris pH8.8 to
immediately neutralise the acid.
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2.26 ELISA (Enzyme-linked immunosorbant assay)
ELISAs were used to test the specificity of phosphospecific antibodies. 96 well microtitre
plates were coated with streptavidin (1µg/well) in 50µl PBS by overnight incubation at
37◦C. Wells were washed 3x with 200µl PBS-T (PBS with 0.1%(v/v) Tween-20). Bi-
otinylated peptides (phosphorylated or non-phosphorylated) (Chiron Mimotopes) were
bound to streptavidin coated wells. Peptides (in DMSO) were diluted in 50µl PBS and
incubated in the wells at the concentrations indicated in the figures for 1 hour at room
temperature. Wells were washed again with 3x 200µl PBS-T and non-specific interac-
tions blocked with 200µl 3% BSA/PBS for 1 hour. The peptides were detected with 50µl
phosphospecific antibody diluted 1:2000 in 3% BSA/PBS for 1 hour at room tempera-
ture. The wells were washed again as above and incubated with 50µl HRP-conjugated
secondary anitbody diluted 1:1000 in 3% BSA/PBS for 1 hour at room temperature. Wells
were wased once more as above and antibody binding was detected using 50µl ECL mix
(for recipe see Western Blotting protocol) on a Fluoroskan Ascent FL luminometer (Lab-
systems).
2.27 EMSA (electrophoretic mobility shift assay)
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CTTAACAAGTACATTTACTTAACTAGTTGGA
2.27.2 Probe Labelling
Probe was labelled with [γ32P] ATP by incubating in Labelling Buffer (see below) for 2
hours at 37◦C, then adding 15.5µl TE buffer and 4.5µl KCl and heating to 95◦C for 2min.
Labelled probe was cooled slowly to room temperature, purified by passing through a
Micro-Biospin 30 column (BioRad) and stored at 4◦C.
Labelling Buffer
0.6µl 1µg/µl probe (sense)
0.6µl 1µg/µl probe (antisense)
1µl T4 DNA kinase buffer (NEB)
1µl T4 DNA kinase (NEB)
0.4µl 10mCi/ml [γ32P] ATP
10µl
2.27.3 Binding and Visualisation
Protein (4-6µl protein-expressing reticulocyte lysate) and DNA were mixed and allowed
to bind for 30mins at room temperature in EMSA Reaction Buffer (see below) along
with non-specific DNA (see binding mix). After 30mins, DNA loading dye (NEB) was
added and complexes were resolved by running on a 6% acrylamide gel (see below)
at 35mA for 2.5 hours run in EMSA running buffer (see below). When the gel had
finished running, it was dried onto filter paper (80◦C, 1 hour) and the locations of probe or
probe/protein complexes were visualised using a Storm 840 phosphorimager (Amersham
Biosciences) and ImageQuant software. In order to verify IRF-1 binding to the probe, 1µl
or as indicated of anti-IRF-1 antibody (BD Biosciences) was added to the reaction mix
to supershift IRF-1 containing complexes. Peptide competition EMSAs were also carried
out. Here, a titration of IRF-1 C-terminal peptide (Chiron Mimotopes) was added to the
reaction mix.









2µl 6x Reaction buffer
1µl 1µg/µl p[d(I:C)]















4µl IRF-1-expressing reticulocyte lysate was mixed with 3µl p300-expressing reticulo-
cyte lysate and 2µM acetyl CoA. Mix was heated to 30◦C for 10mins to allow acetylation
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to occur, then incubated for 20mins at room temperature to allow DNA/protein interaction
to continue. EMSA then continued as above.
2.27.5 Statistical Analysis
The tests indicated in the figure text were carried out using GraphPad or R statistical
software.
Chapter 3
Development of Tools to Study the
C-terminal Phosphorylation of IRF-1
3.1 Introduction
Interferon Regulatory Factor-1 (IRF-1) has many anti-oncogenic activities, targeting both
tumours that are lacking IRF-1, and also non-related tumours. Thus, drugs that activate
IRF-1 are clearly going to be useful, however, indiscrimately activating this protein would
be illadvised since upregulation of IRF-1 has been linked to various autoimmune disor-
ders including MS [89] and autoimmune manifestations in myelodysplasia [87]. There-
fore, investigation into the selective activation of IRF-1 is important to allow development
of anti-cancer drugs without auto-immune side-effects.
As a key post-translational modification, phosphorylation is likely to play a role in
the regulation of IRF-1. Indeed there is some evidence that this is the case, but detailed
investigations have never been pursued. In this chapter, various techniques were used
to study the phosphorylation of IRF-1. Two lines of inquiry were pursued: a neutral
approach and a targeted approach. The first involved setting up assays to identify IRF-1
kinases in cell lysate with the aim of determining the physiological phosphorylation sites
of IRF-1 using mass spectrometry and classifying the kinases. The targeted approach
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investigated candidate IRF-1 kinases, identified from binding partner screens or previous
work in the laboratory, in an attempt to map phosphorylation sites and the function of
such phosphorylations. In parallel, phosphospecific antibodies were raised and validated
to study signal-specific, site-specific phosphorylation of IRF-1.
3.1.1 Purification of recombinant IRF-1
In order to study phosphorylation of IRF-1 in vitro, purified GST-IRF-1 and His-tagged
domains of IRF-1 were used as substrates. In later experiments in this thesis, His-IRF-1
expressed from a pCold vector is used as this system yields undegraded IRF-1 at high
levels of purity. The protocols for GST-IRF-1 and His-domain purifications can be found
in the materials and methods, but, as an example, the purification of His-IRF-1 from the
pCold vector (optimised by Dr. Vikram Narayan) is described here in more detail.
In this system, protein expression is under the control of a cold shock protein promoter
containing a lac operator. Thus, the protein is efficiently expressed at low temperatures
after induction by IPTG. The use of low temperature protein expression is thought to
enhance protein yield by improving solubility. It has been suggested that a reduced trans-
lation rate at lower temperatures allows more time for correct folding and also that cold
shock inhibits expression of most E. Coli proteins thus making more chaperones available
for folding the recombinant protein. In addition, low temperatures reduce degradation of
proteins by heat shock proteases [148].
As illustrated in Fig 3.1 ,the pCold-His-IRF-1 plasmid is transformed into BL21-DE3
E. Coli cells, and these are grown at 37◦C with shaking until they are in the logarithmic
phase of growth. This protocol involves a very short protein induction period so the
bacteria are grown until they are at a higher density than usual. Therefore there are more
bacteria present to produce protein, and in the short incubation, the bacteria do not have
time to reach the end of the logarithmic phase.
Once the OD600 has reached 0.6, the bacteria are cooled to 15◦C for 30 mins. This
allows acclimitisation and ensures temperature equilibration throughout the cell suspen-
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sion. After 30 mins, IPTG is added to induce protein expression. IRF-1 protein is targeted
by a protease 15 mins after its induction (V. Narayan, unpublished observations). There-
fore, an induction time of 15 mins is used, and all subsequent steps are performed on ice
with chilled buffers/equipment to minimise protease activity.
After induction, bacteria are lysed and His-IRF-1 is purified on a nickel affinity col-
umn. Multiple wash steps with high and low salt concentrations, with and without de-
tergents and with magnesium ions and ATP to remove chaperones result in a very clean
product, as can be seen from the coomassie stained SDS-PAGE gel in Fig 3.1.
3.2 IRF-1 as a Kinase Substrate
3.2.1 Cellular Kinases
There is some evidence in the literature that phosporylation is important for IRF-1 activity
and, as described in the introduction, previous work in the Ball laboratory has corrobo-
rated this.
At the start of this project, cell lysate was used to show that cellular kinases could
phosphorylate IRF-1 directly. Kinase assays using γ[32P]-ATP were set up where in-
corporation of the labelled phosphate into IRF-1 by phosphorylation is detected using a
phosphorimager. GST-IRF-1 was used as a substrate, and phosphorylation of IRF-1 can
be seen after incubation with HeLa cell lysate (Fig 3.2A). His-tagged subdomains of IRF-
1 had previously been created in the laboratory and these were expected to be a useful tool
in narrowing down the phosphorylation sites of specific kinases purified from cell lysate.
In order to check that the domains would be substrates for phosphorylation, these were
also included in the kinase assay. Interestingly, in cell lysate, the DNA binding domain
(amino acids 1-124) in lane 2 is not efficiently phosphorylated whereas the central domain
(118-256) in lane 3 (which contains a highly disordered, potentially regulatory, domain)
is an excellent substrate (Fig 3.2A).
As a first step towards purification of kinases from cell lysate, an ammonium sulphate
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Figure 3.1: Purification scheme for His-IRF-1. Scheme is discussed in detail in the text.
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Figure 3.2: IRF-1 is phosphorylated by cellular kinases in vitro. Full length GST-IRF-1 and His-
IRF-1 domains 1-124 and 118-256 were purified from E.Coli, then 450µg of each was incubated
with 4µg of HeLa lysate and γ[32P]ATP for 30 mins at 30◦C. Phosphorylated GST-IRF-1 and
His-118-256 are indicated by arrowheads. His-1-124 was not phosphorylated. (B) To concentrate
kinases, an ammonium sulphate fractionation was carried out. Ammonium sulphate was added
to lysate to a concentration of 25%, precipitated protein was pelleted and discarded. Additional
ammonium sulphate was added to the supernatent up to a concentration of 40%. Precipitated pro-
teins from the 40% cut were collected, resuspended and dialysed to remove salt. (C) The 40%
ammonium sulphate cut was used to phosphorylate GST-IRF-1 and His-IRF-1 domains. After
concentration of kinases by this method, phosphorylation of His-1-124 IRF-1 was visible in ad-
dition to phosphorylation of full length GST-IRF-1 and His-118-236. Data representative of two
independent experiments.
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precipitation was carried out. This removes denatured proteins and other contaminants,
concentrating the native proteins. Preliminary experiments indicated that all IRF-1 ki-
nases were concentrated in the 40% cut. A schematic of the ammonium sulphate precip-
itation is shown in Fig 3.2B. Briefly, ammonium sulphate is added to the lysate up to a
final concentration of 25% (Step 1), after stirring to equilibrate the solution, precipitated
denatured proteins/contaminants are collected by centrifugation (Step 2) and discarded
(Step 3). The supernatent should contain properly folded, active proteins. These are con-
centrated by precipitation after addition of ammonium sulphate up to a concentration of
40% (Step 4) and collected by centrifugation (Step 5). These proteins are resuspended in
buffer and, after dialysis to reduce salt concentration, are used in the kinase assay (Step
6). The concentration at which the “salting out” occurs depends on the physical char-
acteristics of the proteins, and so no selection for particular attributes other than native
conformation is taking place.
After ammonium sulphate precipitation, Fig 3.2C shows that phosphorylation of the
DNA binding domain (amino acids 1-124, lane 2) occurs as well as phosphorylation of
full length IRF-1 protein (lane 1) and the central domain (118-256, lane 3). Therefore,
IRF-1 kinases have been enriched by the ammonium sulphate precipitation.
3.2.2 Purified Kinases
In parallel with setting up the assay to search for cellular kinases, the ability of purified
kinases to phosphorylate IRF-1 was investigated. Chk1, previously identified in the labo-
ratory as an IRF-1 kinase was used as a positive control to ensure the assay was working
(Fig 3.3A). Chk1 autophosphorylation produces a strong signal which can be seen in the
first lane in the absence of IRF-1, however, phosphorylation of IRF-1 by Chk1 can be
seen just above the autophosphorylation band (lane 2). Chk1 preferentially phosphory-
lates sites in the central domain of IRF-1; N-terminal phosphorylation is very weak (lanes
4 & 5).
AMPK (AMP dependent protein kinase) was identified as a binding partner of IRF-1
in a phage display screen (Angeli Moeller, unpublished observations). In this technique,
3.2 IRF-1 as a Kinase Substrate 68
IRF-1 domains were incubated with a peptide phage display library. The library con-
sists of bacteriophage displaying randomly generated peptide sequences on their surfaces,
fused to the N-terminus of a coat protein. After the incubation, unbound phage are then
washed away and bound phage are eluted. These phage are amplified in E. Coli and again
incubated with IRF-1 domains to select for high affinity interactions. The identity of the
peptide is determined by sequencing of the peptide/coat protein fusion gene [149].
To determine if AMPK could phosphorylate IRF-1, a kinase assay was performed
(Fig 3.3B). AMPK phosphorylates full length IRF-1 (lane 2), the phosphoryation site(s)
appears to be in the N-terminal binding domain as there is no incorporation of 32P into the
central domain (lanes 5 & 6). Since the AMPK was only partially purified (manufactur-
ers claim 15% purity), various controls were performed to ensure AMPK was responsible
for the phosphorylation. First, AMP was omitted from the assay buffer (Fig 3.3B lane
4). In the absence of AMP, without which AMPK cannot function, no phosphorylation
is seen. Furthermore, the AMPK inhibitor compound C titratably inhibits the phosphory-
lation of IRF-1 (Fig 3.3C). Next, 20 amino acid long peptides spanning the IRF-1 DNA
binding domain were used to finely map the AMPK phosphorylation sites in IRF-1. In
vitro, residues between 21-50, 91-110 and 106-124 are phosphorylated (Fig 3.3D). Thus,
AMPK appears to be a kinase for IRF-1 in vitro.
As a first step towards determining if AMPK was an IRF-1 kinase in cells, A375
cell lysate was fractionated on an anion exchange column, and the fractions assayed for
kinase activity against purified IRF-1. The same fractions were probed with an anti-
AMPK antibody. As shown in (Fig 3.3E), AMPK co-elutes with cellular IRF-1 kinase
activity (fraction 7) implying that it may have a role in IRF-1 regulation in cells.
In summary, in this section, assays were set up to search for kinases that could phos-
phorylate IRF-1. Using these assays, it was possible to show that cellular kinases can
phosphorylate IRF-1 within its N-terminal and central domains, and that AMPK, a bind-
ing partner of IRF-1, could be one of these kinases.
At this stage, a decision had to be made about whether to focus on the search for IRF-
1 kinases as described above, or on the study of site-specific phosphorylation of IRF-1
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Figure 3.3: IRF-1 is a substrate for purified kinases Chk1 and AMPK. (A) Chk1 phosphorylates
IRF-1. 500ng GST-IRF-1, His-IRF-1(1-124) or His-IRF-1(118-256) were incubated with Chk1
and γ[32P]ATP for 30mins at 30◦C. Phosphorylated substrate is indicated by arrowheads. (B)
AMPK phosphorylates IRF-1. 1µg GST-IRF-1, His-IRF-1(1-124) or His-IRF-1(118-256) were
incubated with 40U AMPK (Upstate) and γ[32P]ATP for 30mins at 30◦C. 300µM AMP (AMPK
cofactor) was included in the reaction mix where indicated. Phosphorylated substrate is indicated
by arrowheads. (C) Phosphorylation of IRF-1 by AMPK is inhibited by Compound C. As for (B)
except that AMPK inhibitor Compound C was included at concentrations indicated. (D) Peptides
spanning the IRF-1 DNA binding domain are selectively phosphorylated by AMPK. As for (B)
except that 1µg peptide was used as substrate. (E) After anion exchange chromatography, AMPK
co-elutes with IRF-1 kinase activity. A375 cell lysate was fractionated on an anion exchange
column (HiTrap Q Sepharose HP, GE Healthcare). Alternate fractions were assayed for kinase
activity against GST-IRF-1 (as in (A)) and also concentrated by acetone precipitation and probed
with anti-AMPK (Millipore). Data representative of (A) one (B) one (C) two (D) two (E) one
independent experiments.
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described below, which was being pursued concomitantly. Both avenues would have
entailed an interesting project, but it was decided that the investigation of site-specific
phosphorylation was progressing more rapidly, and so this line of research was continued.
3.3 Phosphospecific Antibodies
3.3.1 Antibody design
IRF-1 is a multidomain protein with complex regulation (Fig 3.4). The Ball laboratory is
particularly interested in the C-terminus of IRF-1 and, more specifically, a region within
this - the Mf1 domain - which is involved in regulation of steady state levels and transcrip-
tional activity. As described in the introduction, the Mf1 domain is vital to the regulation
of IRF-1 activity and the aim of this work is to discover cellular mechanisms involv-
ing phosphorylation in the Mf1 domain that contribute to this regulation. To this end,
phosphomimetic antibodies were raised to sites in the Mf1 domain. The sites chosen are
highlighted in red in Fig 3.4. The LXXLL (cofactor binding) motif at residues 306-310
has been shown to be essential for IRF-1’s growth inhibitory activity [70] and is involved
in p300 binding [67]. Thus, the residues Ser308 and Thr311 are likely candidates for sites
of phosphorylation that could control binding of factors to this motif. In addition, Thr311
is part of a TP motif, a substrate motif phosphorylated by many kinases including those of
the MAPK family. Ser317 was also chosen as it had already been shown in the laboratory
that Chk1 phosphorylated this site in vitro.
3.3.2 Antibody production and purification
Phosphospecific antibodies were raised to phosphorylated peptide antigens by Eurogentec
using a 3 month immunisation protocol in rabbit. At the end of the protocol, serum was re-
ceived for purification (Fig 3.5A). A two-step purification scheme was optimised for these
antibodies. This is summarised in Fig 3.5B. First, IRF-1 specific but non-phosphospecific
antibodies were removed from the antisera by capture on immobilised IRF-1 peptide. The
















Figure 3.4: Modular structure of IRF-1. The IRF-1 protein is organised into many domains in-
cluding a C-terminal multifunctional, multiprotein binding interface (Mf1) which has been shown
to regulate both transcriptional activity and steady state levels. Antibodies have been raised to the
speculative phosphorylation sites highlighted in red.
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flowthrough from this step was then passed over untagged phosphorylated peptide, bound
phosphoantibodies were washed and the purified antibody was eluted using low pH. The
second step was repeated twice to ensure selection of the correct phosphospecific anti-
bodies.
The success of the purification was tested in a number of ways. First the serum
(load - L) which had been loaded on the phosphorylated peptide purification column,
and flowthrough (FT), were compared to the elutions (E1-6) on a coomassie stained
SDS-PAGE gel. BSA standards were also included to allow estimation of elution con-
centration. As seen in Fig 3.6A, most of the antibodies in the crude serum do not bind
the phosphorylated peptide. Most other contaminants also do not bind the column, and
a relatively pure product is collected. The major contaminant runs at the same size as
BSA and is likely to be rabbit serum albumin which should not interfere with antibody
function. Antibody concentration of E1-3 is an average of 0.4mg/ml.
The progression of the purification can be followed by comparing the specificity of
the crude serum to serum after the first step of purification and the fully purified anti-
body. Fig 3.6B reveals that the first step of purification (removal of IRF-1 specific, non-
phosphospecific antibodies) has little effect on the specificity of the serum for the cognate
phosphopeptide, while purification of antibody against phosphopeptide greatly enhances
specificity. The experiments in Fig 3.6 are useful as a proof of concept but were carried
out using phosphoantibodies from a trial immunisation. These were able to recognise the
native form of the protein in ELISAs but proved to be unable to detect denatured protein
by immunoblot blot. Therefore, new antibodies were produced by the method described
in Fig 3.5 and the validation of these will be described next.
3.3.3 Validation of Antibodies
After purification, the antibodies were validated. Phosphospecificity was verified by
ELISA: biotinylated phosphorylated (either p308S, p311T or p317S) and non-phosphorylated
peptide was immobilised on the plate, and the phosphospecific antibodies were added in
the mobile phase. These experiments were only carried out two times as the activity of the



























Purication of phosphospecic antibodies:
A
B
Figure 3.5: Phosphospecific antibody preparation. (A) Production of phosphospecific antibodies.
Purified, unlabelled, phosphorylated IRF-1 C-terminal peptides (top panel) were used to induce
an antibody response in rabbit. After 3 months and four immunisations, serum containing an-
tibodies was collected. Upon receipt of serum, it was purified as in (B). (B) Crude anti-serum
was passed over biotinylated IRF-1 WT peptide immobilised on streptavidin-agarose beads. Non-
phosphospecific, IRF-1 specific antibodies were sequestered on the beads, and the flowthrough
(containing non-IRF-1 specific and phosphospecific IRF-1 antibodies) was collected. Phosphatase
inhibitors (50mM NaF and 50mM β-glycerophosphate) were added to the flowthrough and it was
passed over phosphorylated (p308S, p311T or p317S) peptide immobilised on CDI-agarose beads.
Bound phosphospecific antibody was washed thoroughly and then eluted using low pH which was
immediately neutralised.
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Figure 3.6: Antibody purification technique produces highly pure antibody and greatly enhances
substrate specificity. (A) Commassie stained SDS-PAGE gel showing efficiency of purification of
antibody from antibody serum. Crude antibody serum (L) and flowthrough from phosphorylated
peptide purification column (FT) were compared to column elutions (E1-6). Most antibody pro-
teins, and other serum proteins are removed by the purification. A contaminant suspected to be
rabbit serum albumin remains. BSA standards are included to allow estimation of purified anti-
body concentration (B) ELISA was used to observe the progression of antibody purification. Un-
phosphorylated peptide, and peptides phosphorylated at the indicated site were coated in ELISA
plate wells and detected by anti-p311T antibody followed by HRP-conjugated swine anti-rabbit
secondary (Dako) and ECL. Detection was normalised to the recognition of the cognate phos-
phopeptide (p311T). Purification clearly enhances specificity for cognate phosphopeptide. These
figures are included as an illustration of the efficiency of the purification process but the antibod-
ies used were found to not be active on western blot and so subsequent figures (except fig 3.8 use
a new batch of antibodies. Data representative of a single experiment. Error bars are standard
deviation of three repeats.
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anitbodies became undetectable before a third experiment oculd be carried out. See below
for a discussion on the possible reasons for this. As seen in Fig 3.7A, anti-p308S can-
not differentiate between p308S and non-phosphorylated peptide, indicating that phos-
phospecific antibodies were not present in the antisera. However, both anti-p311T and
anti-p317S recognise only the phosphorylated peptide.
Next, the binding of the antibodies to each phosphopeptide was compared. Again,
anti-p308S binds non-specifically to each peptide while anti-p311T and anti-p317S both
recognise only their cognate phosphopeptide (Fig 3.7B). This confirms that anti-p311T
and anti-p317S are each specific for their site of interest and do not simply recognise any
phosphorylation in the context of the C-terminus.
Using an ELISA format, the ability of phosphospecific antibodies to detect in vitro
phosphorylation of IRF-1 was measured. This experiment, like Fig 3.6 used the first
batch of antibodies which were found to not be active on western blot and was only car-
ried out once. Chk1 has previously been shown in the laboratory to phosphorylate the
Ser317 site of IRF-1, so IRF-1 phosphorylated by Chk1, and unphosphorylated IRF-1
were coated on an ELISA plate. Protein was detected with anti-p311T, anti-p317S and,
as a control, a commercial IRF-1 antibody raised to the C-terminus (Santa Cruz, C20) (Fig
3.8). Detection of phosphorylated IRF-1 compared to unphosphorylated by the commer-
cial antibody is inhibited. This suggests that efficient phosphorylation has taken place,
and partially blocks the epitope for this antibody. Detection of phosphorylated protein
by anti-p317S exceeded that of the unphosphorylated protein, although there was some
background recognition of unphosphorylated protein (according to the peptide ELISAs
in Fig 3.7, the new batch of anti-p317S does not recognise unphosphorylated peptide).
Anti-p311T antibody has very low recognition of both unphosphorylated and Chk1 phos-
phorylated protein, as would be expected as neither contain its epitope. However, it does
recognise Chk1 phosphorylated protein to a greater extent than unphosphorylated, and in
a titratable manner. This could be due to slight non-specificity of the antibody, or to a
non-specificity of Chk1 under in vitro conditions resulting in some phosphorylation at the
Thr311 site. It will be interesting to see if the recognition of its phosphorylated epitope
in the context of the protein is significantly greater than the binding seen here to p317S,
















































































































































Figure 3.7: Anti-p311T and anti-p317S are specific for their cognate phosphopeptide. (A) To test
specificity of antibodies for phosphorylated IRF-1 over non-phosphorylated, a titration of phos-
phorylated or unphosphorylated biotinylated peptide was bound to streptavidin coated ELISA
plate wells. Binding of the phosphospecific antibody to the peptides was detected using HRP-
conjugated anti-rabbit secondary antibody (Dako) and ECL. (B) To test specificity of antibodies
for their cognate phosphorylation over other C-terminal phosphorylations, a titration of all three
phosphopeptides were bound to streptavidin coated ELISA plate wells. Binding of phosphos-
pecific antibody was detected as above. Data is representative of two independent experiments.
Error bars are standard deviation of duplicates.
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but at present, no Thr311 kinases have been validated.
3.3.4 Discovery of Stimulus-Specific Phosphorylation of IRF-1 Using
Antibodies
With confidence in the specificity of the anti-p311T and anti-p317S antibodies, they were
next used to identify signal specific phosphorylation of IRF-1 by immunoblot (Fig 3.9).
Signals that are known to activate IRF-1 (Interferon-gamma (IFN-γ), pIpC and etoposide)
were used to treat A375 cells, and the lysates were resolved by SDS-PAGE. After western
blotting with the antibodies, a striking increase in phosphorylation can been seen at both
the 311T and 317S sites after IFN-γ treatment. IFN-γ treatment also causes an increase
in the protein levels of IRF-1 but it is clear that the bands are due to IFN-γ-induced
phosphorylation, and not a non-specific signal resulting from the increased IRF-1 levels,
as treatment with pIpC induces IRF-1 to a similar extent but no phospho-specific signal
is detected by either the anti-p311T or -p317S antibodies. Etoposide (a DNA damage
mimetic) treatment results in much lower levels of IRF-1 induction, but it does cause
significant phosphorylation at the 317S site.
To confirm that IFN-γ induces phosphorylation of IRF-1, IFN-γ and control treated
lysates were separated on a 2D gel and probed with pan-IRF-1 antibody. A 2D gel sep-
arates proteins based on charge in addition to the usual separation by weight observed
in a 1D SDS-PAGE gel. The sequence of events is illustrated in Fig 3.10A. A sample,
for example, cell lysate is first loaded onto an immobilised pH gradient (IPG) strip. After
loading, proteins are arranged randomly on the strip (Fig 3.10A, Step 1). Next, an electric
field is applied. Proteins have a net postive or negative charge depending on the balance
of positively and negatively charged amino acids in their primary structure. At different
pH, however, this charge will vary. At acidic pH, proteins carry a more positive charge
whereas at basic pH, they carry a more negative charge. Therefore, at a certain pH, each
protein will have no net charge - this is known as the pI of the protein. As the current
passes through the IPG strip, it moves the protein towards the point on the pH gradient
matching the pI. If the protein is, for example, holding a net positive charge, it is in a
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Figure 3.8: Recognition of Chk1 phosphorylated protein by phosphospecific antibodies. A titra-
tion (50-250ng) of GST-IRF-1 or P-GST-IRF-1 phosphorylated by Chk1 in a kinase assay and
250ng GST were coated onto ELISA plate wells. Protein was detected by commercial IRF-1
antibody (Santa Cruz, C20) (1:1000), anti-p311T and anti-p317S antibodies (1:50) followed by
HRP-conjugated swine anti-rabbit antibody (Dako) and ECL. This data is from a single experi-
ment. Error bars are standard deviation of three repeats.












































Figure 3.9: Signal specific phosphorylation of IRF-1. A375 cells were treated with the stimuli
indicated, and the lysates subjected to SDS-PAGE. Purified recombinant IRF-1 expressed in the
E. Coli-based cell free PURExpress system was also included on the gel as a non-phosphorylated
control. No GAPDH exists in this system, so no loading control is possible, but total IRF-1 levels
were normalised to IFN-γ/pIpC- treated levels. After western blotting, membranes were incubated
with either anti-p311T IRF-1, anti-p317S IRF-1 or anti-IRF-1 (BD Biosciences). Membranes
were also probed with anti-GAPDH (Abcam) as a loading control. Data representative of three
independent experiments.
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region more acidic than its pI, and the current carries it towards the cathode. The pH of
the IPG strip becomes more basic towards the cathode, so eventually the protein reaches
its pI and stops moving as it no longer holds a charge (Fig 3.10A, Step 2). Thus proteins
are separated on the basis of their intrinsic charge. Phosphorylation of a protein confers a
negative charge; as a result, phosphoisoforms of a protein appear nearer the acidic (ann-
ode) end of the IPG strip. After isoelectric focusing, proteins are denatured and the strip
is loaded directly onto an SDS-PAGE gel for further separation by molecular weight (Fig
3.10A, Step 3).
Due to the induction of IRF-1 protein by IFN-γ, the signal is not comparable, so a
much longer exposure of the control lysate, using ECL+ (Amersham) for enhanced signal
was used. In the presence of IFN-γ, many phosphoisoforms of IRF-1 are apparent. There
is a spread of spots of similar intensity across the immunoblot (Fig 3.9B). By comparison,
in the absence of IFN-γ, IRF-1 appears to exist as a single phosphoisoform. Previous 2D
gel analysis has shown around four isoforms (Fig 1.4), and perhaps if more lysate was
loaded, the additional isoforms would also be seen. It is still clear, however, that IFN-
γ treatment of IRF-1 causes a significant increase in the number of phosphoisoforms of
IRF-1.
3.4 Creation and Expression of Phosphomimetic and Non-
Phosphorylatable Mutants
On the basis of the findings in the previous section, a series of mutants were created by
site directed mutagenesis to study the effects of phosphorylation at the relevant sites. The
mutants comprised: T311A, T311D, S317A, S317D, T311D/S317D (Fig 3.11A). The
S/T → D mutation constitutes a phosphomimetic mutation since the negative charge of
the Asp sidechain mimics the effect of addition of a negatively charged phosphate group
to the residue. The S/T→ A mutation creates a non-phosphorylatable mutant as alanine
has no hydroxyl group and hence cannot be phosphorylated.
Changes in the Mf1 domain have been shown to affect the steady state levels of IRF-
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Figure 3.10: 2D gel analysis of IRF-1: Effect of IFN-γ treatment. (A) Schematic of 2D gel
electrophoresis. Theory is described in detail in the text. Briefly, proteins are loaded onto an
immobilised pH gradient (IPG) strip (Step 1) and separated by isoelectric point in the first dimen-
sion (Step 2). Phosphorylated proteins, having a more negative charge, have a more acidic pI and
migrate further towards the acidic/cathode end of the IPG strip. After separation based on pI, the
second dimension separates proteins by weight by conventional SDS-PAGE (Step 3). (B) HeLa
cells were treated with IFN-γ or control (0.1% BSA, 40mM Tris pH 7.4). Whole cell lysate anal-
ysed by 2D gel electrophoresis followed by immunoblotting with anti-IRF-1 (BD Biosciences).
IFN-γ blot exposed for 1 min with ECL, control blot exposed for 1h with ECL+ (Amersham).
This data is representative of two independent experiments.
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1. The Ball laboratory have previously shown that deletion of the Mf1 domain causes
the half life of IRF-1 to more than double, although it is not itself ubiquitinated. It is
suggested that the Mf1 domain contains binding sites for components of the ubiquitin
pathway which facilitates polyubiquitination of IRF-1 elsewhere. [123]. Phosphorylation
in the Mf1 domain could potentially occlude or create a binding site for components of the
ubiquitin pathway and thus modulate IRF-1 degradation. For example, for IRF-3, phos-
phorylation in the C-terminus accelerates degradation [150]. The mutants were designed
to study the effects of phosphorylation of IRF-1 on activity, however, differential rates
of degradation would pose problems for comparing activity of mutants. Therefore, as a
preliminary experiment, the mutants were expressed in the various expression systems
expected to be used: mammalian cells, reticulocyte and wheatgerm lysates and bacterial
cells, and the expression levels compared. As can be seen from (Fig 3.11B), expression
levels are broadly similar.
3.4.1 Half Lives of Phosphomutants
To confirm that phosphorylation at the Thr311 and Ser317 sites does not impact on the
stability of IRF-1, the half lives of the phosphomimetic mutants were determined. Ini-
tially the half life in whole cell lysate was assayed by cycloheximide chase (Fig 3.12A).
As this showed only a small difference in half life between IRF-1 WT and mutants, sub-
cellular fractionation was carried out to determine the half lives in different cellular com-
partments. An example of the half life of IRF-1 in the cytoplasm and nucleus is shown
in Fig 3.12B left and right panels respectively. This experiment has been carried out a
number of times, as it is technically challenging, and the half lives of the mutants have
never been found to be reproducibly or significantly different (cytoplasm p=0.205, nu-
cleus p=0.915 by one-way ANOVA). Therefore, it seems that although the C-terminus of
IRF-1 regulates degradation, phosphorylation at the Thr311/Ser317 sites is not involved
in modulation of this. This is advantageous from a practical point of view since expres-
sion levels in most systems are, as a result, comparable and minimal normalisation will
be required before studying other aspects of IRF-1 activity.
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Figure 3.11: Phosphomimetic and non-phosphorylatable mutants of IRF-1. (A) Phosphomimetic
(S/T→ D) and non-phosphorylatable (S/T→ A) mutants of IRF-1 were created by site directed
mutagenesis. (B) top panel Expression of WT IRF-1 and all mutants from pcDNA3 vector in
mammalian cells (H1299 cells) resulted in extremely similar expression levels. IRF-1 was de-
tected using anti-IRF-1 (BD biosciences) and GAPDH was detected as a loading control by
anti-GAPDH (Abcam). middle panels Expression of IRF-1 WT and phosphomimetic mutants
in reticulocyte lysate and WT and T311D/S317D IRF-1 in wheatgerm lysate was also efficient
and comparable. lower panel Expression of IRF-1 WT and T311D/S317D from pColdHis vector
in E. Coli cells was efficient (as described in Fig 3.1), however, after elution of His-IRF-1 at the
end of purification, levels were not so comparable. Protein concentrations were normalised before
use in assays. Data representative of two (wheatgerm lysate) or more than three (mammalian cells,
reticulocyte lysate and E. Coli) independent experiments.
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In summary, in this section, C-terminal phosphorylation of IRF-1 in cells has been
shown using phosphospecific antibodies. In response to this, reagents have been devel-
oped for mammalian and E. Coli expression. These have been used to demonstrate that
the C-terminal phosphorylation has no effect on the half life of IRF-1. Thus, it will now
be possible to investigate the effects of phosphorylation on IRF-1 transcriptional activity
and tumour suppressor functions.
3.5 Discussion
Phosphospecific antibodies have been succesfully created to two sites in the C-terminus
of IRF-1, namely p311T and p317S. 311T is a TP (common phosphorylation motif) site
immediately adjacent to the LXXLL coactivator binding motif and 317S has previously
been shown to be phosphorylated in vitro. Both sites are within the C-terminal Mf1 do-
main which is a key regulator of steady-state levels and transcriptional activity. The effect
of phosphorylation on these attributes is discussed below and in the following chapter.
The phosphospecific antibodies have revealed for the first time that endogenous IRF-1
is a substrate for stimulus-specific phosphorylation at 311T and 317S. Interferon-gamma
(IFN-γ) treatment results in phosphorylation at both sites, while etoposide (a DNA dam-
age agent) induces phosphorylation at Ser317 (Fig 3.9).
Although few phosphorylation sites have been experimentally verified for IRF-1, web-
based prediction programs suggest IRF-1 is a substrate for many kinases. Fig 3.13 indi-
cates the Ser/Thr/Tyr residues predicted to be substrates for known kinases. Two pre-
diction sites (KinasePhos2.0 and PPSP) even suggest kinases for every phosphorylatable
residue within IRF-1.
IFN-γ is an efficient activator of IRF-1 expression and phosphorylation (Fig 3.9). The
sequence of events leading to activation of IRF-1 by IFN-γ is shown in Fig 3.14A. Bind-
ing of IFN-γ (a homodimer) to two IFNGR1 (IFN-γ receptor 1) results in their dimeri-
sation. This creates binding sites for IFNGR2 subunits, which bind IFNGR1, along with
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Figure 3.12: Effects of mutations on half life of IRF-1. (A) H1299 cells were transfected
with pcDNA3 IRF-1 WT or mutant. After 24h, they were treated with 30µg/ml cycloheximide
and harvested after the intervals indicated. Cells were lysed and lysates subjected to SDS-
PAGE/immunoblot using anti-IRF-1 (BD Biosciences). Immunoblots were scanned and densit-
ometry performed using Image J to give values for the intensity of each band which were then
graphed. (B) Half life determined as for A except after harvesting, cell lysates were fractionated
using Calbiochem ProteoExtract kit. Differences in half lives of mutants are not significantly
different: cytoplasm p=0.205, nucleus p=0.915 by one-way ANOVA. Data representative of one
experiment for whole cell half-life and three independent experiments for fractionated half-life.
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1 MPITRMRMRPWLEMQINSNQIPGLIWINKEEMIFQIPWKHAAKHGWDINKDACLFRSWAIHTGR 64 
 
65 YKAGEKEPDPKTWKANFRCAMNSLPDIEEVKDQSRNKGSSAVRVYRMLPPLTKNQRKERKSK 126 
 
127 SSRDAKSKAKRKSCGDSSPDTFSDGLSSSTLPDDHSSYTVPGYMQDLEVEQALTPALSPCA 187 
 
188 VSSTLPDWHIPVEVVPDSTSDLYNFQVSPMPSTSEATTDEDEEGKLPEDIMKLLEQSEWQP 248 
 
249 TNVDGKGYLLNEPGVQPTSVYGDFSCKEEPEIDSPGGDIGLSLQRVFTDLKNMDATWLDSL 309 
 
310 LTPVRLPSIQAIPCAP 325 
Kinasephos2.0 + PPSP 
KinasePhos2.0 + PPSP + NetPhos2.0 
Figure 3.13: Predicted phosphorylation sites of IRF-1. Phosphorylation sites were predicted for
IRF-1 using the NetPhos2.0 [151], KinasePhos2.0 [152] and PPSP [153] web-based prediction
programs. KinasePhos2.0 and PPSP predicted kinases for all phosphorylatable residues of IRF-1
(red) while NetPhos2.0 predicts phosphorylation of only a subset of these (orange).
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trans-phosphorylation and activation of JAK1 and JAK2. (Fig 3.14A, Step 1). Activated
JAK1 and JAK2 then proceed to phosphorylate the C-terminus of IFNGR1, creating a
binding site for a STAT1 monomer. (Fig 3.14A, Step 2). A STAT1 monomer associates
with each IFNGR1 and is phosphorylated by JAKs (Fig 3.14A, Step 3). After phos-
phorylation, STAT1 monomers dissociate from IFNGR2 and form a homodimer which
translocates to the nucleus and activates transcription by binding to a GAS (gamma acti-
vated sequence) element in the IRF-1 promoter (Fig 3.14A, Step 4). This is reviewed in
[90].
A number of kinases are also activated after IFN-γ treatment (Fig 3.14B). The mech-
anism by which IFN-γ activates these kinase pathways is not known; Jak kinases could
be responsible, or STAT1 activation could result in upregulation of kinase or activator
expression. It would be interesting to investigate the effect of inhibition of these kinases
during IFN-γ treatment in order to identify the kinases responsible for IRF-1 phosphory-
lation. As described in the thesis discussion, a literature search has been performed on the
Thr311 and Ser317 kinases (predicted by the web-based tools) to find kinases that have
been shown to be activated by IFN-γ (Table 6.1).
At this stage, the antibodies would have been used to determine if inhibition of the
kinases mentioned above can inhibit IRF-1 phosphorylation at Thr311 or Ser317. Unfor-
tunately, further experiments using the phosphospecific antibodies were not possible as
specific binding was rapidly lost. Repurification from stored aliquotted crude anti-sera
does not resolve the problem so it must be concluded that the phospho-specific antibodies
were only a small subpopulation of the total antibodies in the serum, and that they lost
their activity during storage. In keeping with this assumption, a large amount of lysate
(80ug) was required to observe phosphorylation.
The antibodies were not isotyped, but it is likely that they were the fairly unstable IgM.
Some antigens can only elicit an IgM response, particularly if they are highly conserved,
due to lack of T-cell stimulation and so no isotype switching of B cells. Although this
is a peptide antibody, the Mf1 domain is highly conserved between humans and rabbits,
and as a regulatory region, it is likely to be exposed. Thus it is possible that the antigenic
phosphopeptides are viewed as autoantigens and so only IgM antibodies are produced
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Figure 3.14: IFN-γ activates IRF-1 and protein kinases. (A) IFN-γ downstream signalling path-
way. 1) Binding of IFN-γ to the IFNGR1 (Interferon-gamma receptor 1) causes multimerisation
of receptor subunits resulting in auto- and trans-activation of JAKs (Janus kinases) as a result
of their proximity. 2) Activated JAKs phosphorylate IFNGR1 creating a binding site for STAT1
monomers. 3) STAT1 monomers bind phosphorylated IFNGR1 and are phosphorylated by JAKs.
4) Phosphorylated STAT1s form homodimers, translocate the to nucleus and activate transcription
by binding GAS (gamma activated sequence) elements, for example in the IRF-1 promoter [90].
(B) IFN-γ is known to activate kinase signalling pathways. IFN-γ treatment has been shown to
activate PI3K and Akt [154]. PI3K has also been shown to activate PKCδ in response to IFN-γ
treatment [155]. IFN-γ activates Pyk2 which initiates a MEKK4, MKK6, p38 MAPK cascade
[156] and IFN-γ activated MEKK1 activates ERK1/2 via MEK1 [157]. These kinases could be
involved in the phosphorylation of IRF-1 in response to IFN-γ treatment.
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[158]. Antibodies can lose activity and stability during storage by a number of processes
including deamidation, oxidation and fragmentation [159]. It is possible that some or all
of these mechanisms contributed to the loss of activity or stability of the phosphospecific
antibodies.
It would also have been very interesting to determine if both the phosphorylation
events at 311T and 317S which occur after IFN-γ treatment are to be found on one
molecule of IRF-1. To do this, IRF-1 phosphorylated at one site could be extracted from
cell lysate using an immobilised phosphospecific antibody, the selected IRF-1 could then
be probed with the second antibody and a pan-IRF-1 antibody to see if both sites are
simultaneously phosphorylated. If that were the case, a time course of IFN-γ treatment
could reveal if one phosphorylation primed for another.
Despite the lack of phosphospecific antibodies, the effects of kinase inhibitors on IRF-
1 activity could be assayed in future. In fact, recently, work by Khaldoon Al-Samman in
the Ball laboratory using a kinase inhibitor library has found that a number of kinase in-
hibitors impact on IRF-1’s transactivatory activity. The top hits were a CK2 inhibitor and
an EGFR kinase inhibitor. These leads are promising as CK2 has already been shown to
phosphorylate IRF-1 [119] and activation of EGFRs activate IRF-1 [110]. Furthermore,
CK2 has been shown to be activated by IFN-γ, although it is not predicted to phospho-
rylate IRF-1 at Thr311 or Ser317. If other kinases implicated have been shown to be
activated by IFN-γ treatment, kinase assays using WT protein and non-phosphorylatable
mutants could be carried out to interrogate their importance at the IFN-γ induced phos-
phorylation sites.
Further work could then investigate the effects of the kinases/kinase inhibitors on the
cellular activity of IRF-1. A little work has been done looking at the effect of inhibitors
on protein levels of IRF-1 downstream targets likely to be affected by IFN-γ such as PKR
and Cdk2. So far, no effects have been seen, but optimisation of inhibitor concentrations
may yield results.
A more effective approach could be to use a focused microarray to look at the effects
of specific kinase inhibitors on the mRNA transcript levels of a large number of genes in
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IRF-1 associated pathways. It would be important in this case to be able to verify that the
effects were due to altered IRF-1 activity and not effects on other transcription factors.
Although the phosphomimetic mutations at the IFN-γ-stimulated phosphorylation
sites did not have any effect on half life on the protein, it may have effects on the activity
of the protein, without changing steady state levels. This would agree with the nanobody
data that indicates that the C-terminus of IRF-1 is rate-limiting for activity and imposes
a negative regulation that can be released by interventions such as antibody binding or
potentially phosphorylation. This is investigated in the following chapter.
In conclusion, this chapter has described the development of a number of tools to
study the role of phosphorylation in regulating IRF-1 activity. Kinase assays were set
up to allow identification of cellular kinases with activity against IRF-1, and to allow
validation of kinases found as binding partners of IRF-1. Phosphospecific antibodies were
produced and were used to discover stimulus-specific phosphorylation of endogenous
IRF-1 at Thr311 and Ser317. IFN-γ and DNA damage response pathways were identified
as physiological signalling pathways upstream of these phosphorylation sites. Following
this, phosphomimetic and non-phosphorylatable mutants of IRF-1 were created by site-
directed mutagenesis. Expression of the mutants has been tested in various environments,
and their comparable stability confirmed. These will be used in subsequent chapters to
investigate the effect of phosphorylation of IRF-1 on activity.
Chapter 4
Effects of C-terminal phosphorylation
of IRF-1 on transcriptional activity
4.1 Activity of Phosphomimetic Mutants in Reporter As-
says
4.1.1 Introduction
As a transcription factor, IRF-1 regulates the expression of many downstream genes in-
volved in a wide variety of pathways such as immune response, cell cycle control and
tumour suppression. To ensure these genes are only switched on/off under the appropri-
ate conditions, IRF-1 must be strictly regulated, however, it is not known what form this
regulation takes.
On the basis of the stimulus-specific phosphorylation discussed in the previous chap-
ter, the series of mutants described were used to study the effects of phosphorylation at
these sites. The results below indicate that phosphorylation could be one form of post-
translational regulation affecting IRF-1 activity.
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4.1.2 Comparison of Transactivatory Potential of Phosphomimetic
Mutants
The transactivatory potential of IRF-1 phosphomimetic mutants was measured using the
dual luciferase reporter assay system. As this system uses live cells to provide the nec-
essary transcriptional machinery, there is the potential for other trancription factors to
interact with the promoter being studied. To minimise the possiblity of this happening,
a very specific synthetic minimal IRF-1 promoter was used (IRF-E). To test the speci-
ficity of the minimal promoter, IRF-3, another member of the IRF family was used as a
control since the IRF family all have highly conserved DNA binding domains and thus
very similar recognition sequences [160]. As shown in Fig 4.1A, when H1299 cells were
transfected with the IRF-E-luciferase construct, and a titration of IRF-1 or IRF-3, there is
no activity at the promoter in the absence of transfected IRF-1 and IRF-3 cannot activate
the promoter but IRF-1 gives a titratable response.
Having established the specificity of the promoter construct, it was initially used to
check that the activity was a product of DNA binding. H1299 cells were again transfected
with IRF-E-luciferase and a titration of IRF-1 WT or IRF-1 W11R. IRF-1 W11R has
previously been shown to lack DNA binding ability [161]. No activity was seen with the
W11R mutant, but again, IRF-1 gives a titratable response (Fig 4.1B).
Next, the IRF-E promoter was used to compare the activity of IRF-1 WT to the phos-
phomimetic mutants described in the previous chapter. When the three mutants were
titrated into H1299 cells, IRF-1 WT and IRF-1 T311D activities were similar while all
mutants showed higher activity than IRF-1 WT (Fig 4.2A), with the dual phosphomimetic
mutant IRF-1 T311D/S317D having the highest activity; on average 5x greater than WT
when 400ng protein is transfected. Under these conditions, it seems that the S317D mu-
tation is dominant as this mutant’s activity is most similar to IRF-1 T311D/S317D (10x
greater than WT activity at 400ng protein transfected), although the T311D mutation still
contributes some activity.
Transcription factors can work both by binding directly to DNA and modulating tran-
scription, or by affecting another transcription factor bound to the promoter. To confirm
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Figure 4.1: Verification of IRF-E promoter. (A) H1299 cells were transfected with pcDNA3 EV
(200ng) or a titration of pcDNA3-IRF-3 or IRF-1 WT (as indicated). 50ng IRF-E-luc reporter
plasmid and 0.833ng control CMV-Renilla-luc was co-transfected. After 24h, reporter gene ac-
tivity was measured in relative light units (RLU) and normalised to CMV-Renilla-luc activity.
Results are expressed as mean +/- half the range for duplicate experiments. Expressed proteins
were detected by SDS-PAGE/immunoblot using anti IRF-1 (BD Biosciences), anti-IRF-3 (NEB)
and anti-GAPDH (Abcam) as a loading control. (B) H1299 cells were transfected with 400ng
pcDNA3 EV or a titration of pcDNA3-IRF-W11R or IRF-1 WT (as indicated). Luciferase re-
porter transfection, measurement of activity and detection of protein were as in (A). Black line
indicates lanes run at same time but not adjacent. Data representative of (A) a single experiment
(B) two independent experiments
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that this assay was looking at DNA binding to the IFR-E and therefore the direct effects
of IRF-1, a reporter assay was set up using the DNA-binding-dead W11R mutant in both
IRF- WT and T311D/S317D backgrounds. Fig 4.2B clearly demonstrates that the DNA
binding ability of IRF-1 is absolutely required for activity of both IRF-1s at this promoter
and the enhanced activity of the mutant requires DNA binding.
The activities of the phosphomimetic mutants (T311D, S317D, T311D/S317D) were
compared across cell lines and with a set of non-phosphorylatable mutants where Ser
or Thr was replaced with Ala (T311A, S317A) (Fig 4.3A&B). It is interesting to note
that there may be a difference in relative activities between cell lines. In H1299 cells
(Fig 4.3A), IRF-1 T311D/S317D has the highest activity, followed by IRF-1 S317D then
IRF-1 T311D and WT which have the lowest activity. In contrast, in A375 cells (Fig
4.3B), IRF-1 WT and T311D/S317D activities appear to be more similar, while the single
mutants have higher activities. The comparison has only been performed once for the
single mutants and twice for IRF-1 WT and T311D/S317D but differences in relative
activities between cell lines are perhaps not surprising, as different cell lines will have
different co-factor expression, and will be preferentially expressing a different subset of
genes.
The non-phosphorylatable mutants (T/S-A) were included to give more insight into
how the phosphomimetic mutations enhance the activity of IRF-1. For example, in H1299
cells (Fig 4.3A), T311D activity is the same as T311A. An explanation for this is that
phosphorylation could block a binding site for repressor proteins that requires the pres-
ence of the Thr residue, so substituting T311A has a similar blocking effect. Conversely,
S317D has higher activity than S317A (S317A is similar to WT). This suggests that phos-
phorylation creates a binding site, or causes a conformational change specific to the phos-
phorylation, and S317A cannot substitute.
4.1.3 Activity at naturally occurring promoters
As the previous experiments were all performed using the minimal promoter (IRF-E),
the next step was to confirm if the same effects are seen at naturally occurring IRF-
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Figure 4.2: Phosphomimetic mutations of IRF-1 enhance transcriptional activity at the IRF-E pro-
moter in a DNA-binding-dependent manner. (A) H1299 cells were transfected with pcDNA3 EV
or a titration of pcDNA3-IRF-1 WT, T311D, S317D or T311D/S317D. 50ng IRF-E-luc reporter
plasmid and 0.833ng control CMV-Renilla-luc was co-transfected. After 24h, reporter gene ac-
tivity was measured in relative light units (RLU) and normalised to CMV-Renilla-luc activity.
Results are expressed as mean +/- half the range for duplicate experiments. Expressed proteins
were detected by SDS-PAGE/immunoblot using anti IRF-1 (BD Biosciences), and anti-GAPDH
(Abcam) as a loading control. Significant differences between activities by randomised block
ANOVA followed by Tukey’s test are indiciated. (** p=<0.01, *** p=<0.001) (B) As for (A)
except that pcDNA3 EV or IRF-1 W11R-WT or IRF-1 W11R D/D was transfected. Data repre-
sentative of two independent experiments for (A) and (B).




























































































































Figure 4.3: Activity of phosphomimetic and non-phosphorylatable mutants may be cell line de-
pendent. (A) H1299 cells were transfected with pcDNA3 EV or a titration of pcDNA3-IRF-1
WT, T311A, T311D, S317A, S317D or T311D/S317D. 50ng IRF-E-luc reporter plasmid and
0.833ng control CMV-Renilla-luc was co-transfected. After 24h, reporter gene activity was mea-
sured in relative light units (RLU) and normalised to CMV-Renilla-luc activity. Results are ex-
pressed as mean +/- half the range for duplicate experiments. Expressed proteins were detected
by SDS-PAGE/immunoblot using anti IRF-1 (BD Biosciences), and anti-GAPDH (Abcam) as
a loading control. Significant differences between activities by randomised block ANOVA fol-
lowed by Tukey’s test are indiciated. (** p=<0.01, *** p=<0.001). (B) as for (A) using A375
cells. Data are representative of (A) five independent experiments for phosphomimetic mutants
and three independent experiments for non-phosphorylatable mutants (B) data from a single ex-
periment for single mutants and representative of two independent experiments for IRF-1 WT and
T311D/S317D. Black line indicates lanes run at same time but not adjacent.
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1-responsive promoters. TLR3 is a well characterised target for IRF-1 with an IRF-1
responsive element located at -97 → -89, very close to the transcription start site [95].
When the hTLR3 promoter was transfected into H1299 cells, it showed a much higher
background activity than the artificial promoter, possibly due to background activity of
other transcription factors. The construct comprises -588 → +12 and contains potential
binding sites for other transcription factors such as Sox, STAT1, Ets etc., but has been
shown to be highly inducible by IRF-1 [95]. However, the general pattern of activity
in H1299 cells was the same as for the IRF-E, with IRF-1 WT having the lowest, and
T311D/S317D having the highest activity (Fig 4.4A). As a result of this, for simplicity,
IRF-1 WT and T311D/S317D were chosen to examine the effects at other promoters.
IL7 is a cytokine functioning within the intestinal mucosa, involved in immune reg-
ulation. The IL7 promoter contains an IRF-E which is required for constitiutive activity,
regulated by IRF-2, and inducible activity in response to IFN-γ-induced IRF-1 [147].
IFN-β is involved in regulating immune responses to virus infection. The IFN-β pro-
moter was, in fact, the first promoter shown to be IRF-1-responsive [1].
Titration of IRF-1 WT and T311D/S317D into H1299 cells co-expressing the IL7
and IFN-β promoter reporter constructs again reveals enhanced activity of T311D/S317D
IRF-1 at these promoters, although this is less striking that at the IRF-E promoter. At
the IL7 promoter, mutant IRF-1 is, on average, 1.6x more active, while at the IFN-β
promoter, 1.8x more active. In both cases, this activity is dependent on DNA binding
as the activity of the W11R mutants is similar to background. There is more obvious
background activity at each of these promoters than at the IRF-E promoter. For the IL7
promoter, this is probably due to endogenous IRF-2 [147] and at the IFN-β promoter,
NF-κB or ATF-2/c-jun whose binding sites are also within the promoter construct [130]
(Fig 4.4B&C).
The promoters described above are all from immune related genes, and as IRF-1 ac-
tivity is increased by the phosphomimetic mutation at all these promoters, it appears that
immune related stimuli could act as a signal to upregulate IRF-1 activity by its C-terminal
phosphorylation. This is particularly relevant as IFN-γ originally induced the phospho-
rylation at these sites, prompting further investigation using phosphomimetic mutants.





























































































































































Figure 4.4: Activity at naturally occurring IRF-1 activated promoters. (A) H1299 cells were
transfected with a titration of pcDNA3-IRF-1 WT or mutant. 70ng TLR3-luc reporter plasmid
and 30ng control CMV-Renilla-luc was co-transfected. Data representative of three independent
experiments.(B and C) H1299 cells were transfected with a titration of pcDNA3-IRF-1-WT or
-T311D/S317D. 100ng IL7-luc (B) or IFN-β-luc (C) and 50ng control CMV-Renilla-luc was
co-transfected After 24h, reporter gene activity was measured in relative light units (RLU) and
normalised to CMV-Renilla-luc activity. Results are expressed as mean +/- half the range for du-
plicate experiments. Expressed proteins were visualised by SDS-PAGE/immunoblot using anti
IRF-1 (BD Biosciences) and anti-GAPDH (Abcam) as a loading control. Data representative of
three independent experiments for (A), (B) and (C). Significant differences between activities by
randomised block ANOVA followed by Tukey’s test are indiciated. (* p=<0.05, ** p=<0.01).
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To be sure that the enhanced activity at the immune related promoters is not due to a
non-specific enhanced activity of the IRF-1 T311D/S317D mutant, unrelated promoters
were assayed. Cdk2 and MMP9 promoter constructs were chosen as IRF-1 represses these
promoters, so the effects of MF-1 domain phosphorylation on IRF-1 repressor activity
could be studied. Cdk2 is a cyclin dependent kinase which has previously been shown
to be repressed by IRF-1. The mechanism of repression has been shown to be through
inhibition of Sp1 activation of this promoter [32]. This study implied that the inhibition
of Cdk2 is not through direct promoter binding of IRF-1, however, studies from our lab
have shown that repression of Cdk2 requires DNA binding of IRF-1 since a DNA-binding
refractive mutant IRF-1-YLP/A cannot repress the Cdk2 promoter [70]. EMSAs using a
Cdk2 promoter probe would constitute a simple experiment to directly assess the binding
of IRF-1 to the Cdk2 promoter, and the effect of IRF-1 on Sp1 binding.
MMP9 is a martix metalloprotease involved in extracellular matrix degradation; it is
overexpressed in many human cancers. IRF-1 mediates interferon-induced inhibition of
MMP9 expression through competition with NF-κB for promoter binding [45].
When IRF-1 was titrated into H1299 cells co-expressing the Cdk2 or MMP9 promot-
ers, activity at these promoters is inhibited. Interestingly IRF-1 WT and T311D/S317D
both inhibit the promoters to the same extent - around a 4 fold inhibition at 200ng of pro-
tein for the Cdk2 promoter, and 2 fold inhibition at 200ng for the MMP9 promoter (Fig
4.5A&B). Amino acids 301-314 of IRF-1 have been shown to be required for inhibition
of Cdk2. Thus, it would be interesting to determine the effect of the T311D mutation
alone on repression.
These data indicate that the effect of phosphorylation on IRF-1 activity is a promoter
specific, and therefore likely regulatory effect. It seems unlikely, therefore, that the mu-
tations could be causing a gross, non-physiological change that indiscriminately affects
IRF-1 activity.




























































































Figure 4.5: Activity at naturally occurring IRF-1 repressed promoters. (A) H1299 cells were
transfected with a titration of pcDNA3-IRF-1 WT or mutant. 100ng Cdk2-luc reporter plasmid
and 10ng control CMV-Renilla-luc was co-transfected. (B) H1299 cells were transfected with a
titration of pcDNA3-IRF-1-WT or mutant. 100ng MMP9-luc and 25ng control CMV-Renilla-luc
was co-transfected After 24h, reporter gene activity was measured in relative light units (RLU)
and normalised to CMV-Renilla-luc activity. Results are expressed as mean +/- half the range for
duplicate experiments. Expressed proteins were visualised by SDS-PAGE/immunoblot using anti
IRF-1 (BD Biosciences) and anti-GAPDH (Abcam) as a loading control. No significant difference
between IRF-1 WT and T311D/S317D was found at any DNA concentration for either promoter
by randomised block ANOVA. Data representative of three independent experiments for (A) and
(B).
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4.1.4 Repression of IRF-1 WT and T311D/S317D by IRF-2
The activity of IRF-1 is repressed by IRF-2 [2]. The enhanced activity of IRF-1 T311D/S317D
may be linked to an ability to escape this repression, therefore, the effect of IRF-2 co-
expression on IRF-1 WT and T311D/S317D activity was investigated.
A titration of IRF-2 was co-transfected with constant (200ng) IRF-1 WT and T311D/S317D.
The effect was compared in H1299 and HeLa cells and at the IRF-E and TLR3 promoters.
In these cells, at these promoters, there was no significant dirference between IRF-1 WT
and T311D/S317D. When using the TLR3 promoter, the amount of IRF-1 T311D/S317D
transfected was reduced in an attempt to normalise the IRF-1 WT and T311D/S317D
activities in case the higher activity of T311D/S317D made it less susceptible to inhibi-
tion by IRF-1. Despite this, no significant difference in activity was observed. The data
is shown as a bar graph of activity to represent absolute inhibition, and also as a line
graph of activity normalised to -IRF-2. This more clearly visualises the inhibition (Fig
4.6A&B).
Since the activity of IRF-1 T311D/S317D is significantly higher than that of WT, the
amount of IRF-1 T311D/S317D transfected was reduced in an attempt to normalise IRF-
1 WT and T311D/S317D promoter activities to see if this might accentuate the effect.
The TLR3 promoter was also used, as previous lab members had seen inhibition of IRF-1
activity by IRF-2 at this promoter. These changes enhance the difference between IRF-1
WT and T311D/S317D inhibition by IRF-2 in both HeLa and H1299 cells (Fig 4.6C&D).
4.2 Effect of phosphomimetic mutations on the DNA-binding
capacity of IRF-1
4.2.1 Introduction
The enhanced transactivatory potential of the IRF-1 phosphomimetic mutants may be
a result of improved DNA binding caused by the mutation. To determine if this is the
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Figure 4.6: Inhibition of IRF-1 WT and T311D/S317D by IRF-2. H1299 (A)&(C) and HeLa
(B)&(D) cells were transfected with 200ng pcDNA3-IRF-1 WT or 200 ng (A)&(B) or 100ng
(C)&(D) IRF-1 T311D/S317D. (A)&(B) 50ng IRF-E-luc reporter plasmid, 0.835ng control CMV-
Renilla-luc and a titration of pcDNA3-IRF-2 was co-transfected. (C)&(D) 70ng TLR3-luc, 30ng
control CMV-Renilla-luc and a titration of pcDNA3-IRF-2 was co-transfected. After 24h, reporter
gene activity was measured in relative light units (RLU) and normalised to CMV-Renilla-luc ac-
tivity. Results are expressed as mean +/- half the range for duplicate experiments. Lower graph
displays activity normalised to activity in absence of IRF-2. Expressed proteins were visualised
by SDS-PAGE/immunoblot using anti IRF-1 (BD Biosciences), anti-IRF-2 (Abcam) and anti-
GAPDH (Abcam) as a loading control. No significant difference between inhibition of IRF-1
WT and IRF-1 T311D/S317D was observed by randomised block ANOVA. Data representative
of three independent experiments for (A), (B), (C) and (D).
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case, gel shift assays were carried out using IRF-1 expressed in reticulocyte lysate. In
a gel shift assay, protein is incubated with 32P-labelled DNA probe, and protein/DNA
complexes are allowed to form. As a control, antibody can be included in the mix. The
protein/DNA(/antibody) mix is then run on a native gel to maintain complexes. Separation
occurs based on weight so the free probe runs furthest, then the probe with protein bound
higher up the gel (it is ”shifted”) and finally the DNA/protein/antibody complex runs near
the top of the gel (it is ”supershifted”). The presence of these three complexes is detected
by phosphorimager analysis of the gel allowing detection of the 32P-labelled DNA probe.
4.2.2 Relative binding affinities
Initially, binding of IRF-1 WT and phosphomimetic mutants IRF-1 T311D/S317D, T311D
and S317D at the optimised C1 probe [162] (Fig 4.7A) was compared. The assays were
optimised and carried out in an excess of free probe, however, only the top portion of
the phosphorimage is shown. From Fig 4.7B (left panel), it appears that all the mutants
bind DNA with higher affinity than IRF-1 WT, however, the difference is quite subtle,
especially after supershift. Due to the presence of a non-specific band running with the
non-supershifted IRF-1/DNA complex (see control, lane 1), it is easier in this instance
to compare the binding of the supershifted complexes. Using densitometry, the differ-
ence in binding between IRF-1 WT and IRF-1 T311D and S317D was found to be re-
producible but not significant across three experiments. The enhanced binding of IRF-1
T311D/S317D compared to IRF-1 WT, is however, significant (data from nine experi-
ments), reflecting enhanced affinity or stability of the DNA/protein complex. Further ex-
periments have shown a larger difference in the binding of IRF-1 WT and T311D/S317D
(for example Fig 4.7B right panel) and, on average, the binding of IRF-1 T311D/S317D
is 1.7x more stable than IRF-1 WT.
The difference in IRF-1 WT and T311D/S317D DNA binding is titratable (Fig 4.7B
(right panel)). In this case, IRF-1 T311D/S317D binds with an average of 2.3 times more
affinity/stability across the three points of the titration.
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Figure 4.7: Comparison of IRF-1 mutants binding to C1 promoter. (A) Sequence of C1 promoter
with the 4 tandemly arranged hexamer repeats highlighted. (B) Left panel: Binding of IRF-1 and
mutants to C1 probe. IRF-1 WT, T311D/S317D, T311D and S317D were expressed in reticulocyte
lysate and 32P-labelled C1 probe binding to 6µl of lysate was determined by EMSA (Lanes 3,5,7
and 9). IRF-1-DNA complex is supershifted by anti-IRF-1 antibody (BD Biosciences) (Lanes
4,6,8 and 10). Expression levels of all four IRF-1 constructs was visualised by immunoblotting
using anti-IRF-1 (Santa Cruz, C20). Difference between IRF-1 WT and IRF-1 T311D/S317D
binding is significant (** p=<0.01 by paired t-test). Right panel: DNA binding of IRF-1 WT
and T311D/S317D is titratable. 2, 6 and 12µl of reticulocyte lysate expressing indicated IRF-1
construct was incubated with 32P-labelled C1 probe. IRF-1-DNA complex is supershifted by anti-
IRF-1 (Santa Cruz). Expression levels of proteins as for left panel. Data representative of: (B) left
panel three experiments for all mutants and nine experiments for IRF-1 WT/ IRF-1-T311D/S317D
comparison and (B) right panel one experiment.
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4.2.3 Mechanism of DNA Binding
To investigate the mechanism of the enhanced DNA binding of IRF-1 T311D/S317D
further, an IRF-1 WT C-terminal peptide (last 20 amino acids of IRF-1) was titrated into
the EMSA as a competitor. It was hoped that this would help distinguish between different
mechanisms.
Four potential mechanisms of enhanced DNA binding were considered. These mech-
anisms are illustrated in Fig 4.8, along with the effects of addition of the peptide
One possibility is that a negative charge in the C-terminus could enhance a conforma-
tional regulation that has a positive effect on DNA binding (Fig 4.8A). IRF-1 could exist
in an equilibrium between a less favourable DNA binding conformation (for example,
with the C-terminus free) (light blue), and a more favourable DNA binding conforma-
tion (for example, with the C-terminus bound to an acceptor site elsewhere in the protein)
(dark blue). If this was mediated by an intramolecular interaction between the C-terminus
(black line) and a C-terminus binding site (purple spot), phosphorylation could enhance
this interaction by increasing its affinity. Thus the equilibrium would change such that al-
most all the protein is in the favourable DNA binding conformation. If this was the case,
addition of WT C-terminal peptide (green line) to the mix would inhibit DNA binding
of WT IRF-1. The peptide is identical to the IRF-1 WT C-terminus and thus has similar
affinity for the acceptor site. Therefore, the peptide will compete with the C-terminus
for binding to the acceptor site, and shift the equilibrium further to the side of the less
favourable DNA binding conformation.
For IRF-1 T311D/S317D, the equilibrium is far to the side of the favourable DNA
binding conformation (due to the proposed high affinity interaction between the nega-
tively charged C-terminus and the acceptor site). When the peptide is added, little protein
is in the less favourable DNA binding conformation with the acceptor site exposed for
binding to the peptide, and the peptide also has a lower affinity for the acceptor site than
does the phosphoprotein’s C-terminus, so will be less likely to bind. In this case, there
will be some inhibiton of DNA binding as a small proportion of the protein is held in the
less favourable DNA binding conformation by binding of the peptide; however, it will be
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Figure 4.8 (following page): Four potential mechanisms of enhanced IRF-1 T311D/S317D DNA binding
compared to IRF-1 WT and effect of peptide competition with on DNA binding.
(A) Negative charge in the C-terminus enhances a conformational positive regulation. Favourable
(dark blue) and less favourable (light blue) DNA binding conformations for IRF-1 exist in equilibrium.
This is mediated by a positive regulatory intramolecular interaction between the C-terminus (black line)
and a C-terminus binding site (purple spot). Negative charge in the C-terminus (phosphorylation or S/T→D
mutation) increases the affinity of the interaction, stabilising the favourable DNA binding conformation
(dark blue), thus enhancing DNA binding of IRF-1 T311D/S317D. Effect of addition of IRF-1 C-terminal
peptide: For IRF-1 WT, peptide and protein C-terminus have the same affinity for the C-terminus binding
site. Peptide competes for binding to this site, and more protein adopts the unbound, less favourable DNA
binding (light blue), resulting in inhibition of DNA binding. For IRF-1 D/D, peptide cannot compete as
effectively with the high affinity intramolecular interaction, and IRF-1 D/D DNA binding is less affected.
(B) Negative charge in the C-terminus releases a conformational negative regulation. Favourable (dark
blue) and less favourable (light blue) DNA binding conformations for IRF-1 exist in equilibrium. This
is controlled by a negative regulatory interaction between the C-terminus (black line) and a C-terminus
binding site (purple spot). A negative charge in the C-terminus interferes with the negative regulatory in-
teraction, thus enhancing the DNA binding of IRF-1 T311D/S317D. Effect of addition of IRF-1 C-terminal
peptide: The peptide will have different effects, depending on whether the favourable DNA conformation
results from the C-terminus binding site (purple spot) being free (1) or the C-terminus (black line) being free
(2). For IRF-1 WT, if free C-terminus binding site induces the favourable DNA binding conformation (1),
peptide occupies the C-terminus binding site and maintains the less favourable DNA binding conformation,
resulting in inhibited DNA binding. In contrast, if free C-terminus is required for favourable DNA binding
(2), peptide binds the C-terminus binding site, resulting in more free C-terminus and therefore enhanced
DNA binding. For IRF-1 T311D/S317D, the effects are very similar except that for situation (2), since the
negatively charged C-terminus already interacts less with the binding site, peptide competition results in a
smaller increase in DNA binding.
(C) Negative charge in the C-terminus enhances binding of a positive cofactor. Binding of a positive
cofactor at the C-terminus of IRF-1 enhances DNA binding. In the absence of C-terminal phosphoryla-
tion, little co-factor (navy circle) binds and IRF-1 is in a less favourable DNA binding conformation (light
blue). Negative charge creates a superior co-factor binding site, and enhanced co-factor interaction re-
sults in more IRF-1 in a favourable DNA binding conformation (dark blue). Effect of addition of IRF-1
C-terminal peptide: For IRF-1 WT, peptide and real C-terminus have the same affinity for the cofactor
so peptide competes with IRF-1 and DNA binding is inhibited. For IRF-1 T311D/S317D, the negatively
charged IRF-1 C-terminus has a higher affinity for the co-factor and so peptide competes less efficiently
resulting in less inhibition of DNA binding.
(D) Negative charge in the C-terminus inhibits binding of a negative cofactor. Binding of a negative
cofactor (purple circle) at the C-terminus of IRF-1 inhibits DNA binding. In the absence of phosphoryla-
tion, co-factor binds tightly so IRF-1 maintains a less favourable DNA binding conformation (light blue).
Negative charge repels the negative cofactor, resulting in more IRF-1 in a favourable DNA binding con-
formation (dark blue). Effect of addition of IRF-1 C-terminal peptide: For IRF-1 WT, peptide and IRF-1
C-terminus have the same affinity for the negative co-factor; peptide competes with IRF-1 for co-factor
binding resulting in more IRF-1 in the favourable DNA binding conformation. For IRF-1 T311D/S317D,
less co-factor binds already, so although the peptide competes with IRF-1 for co-factor binding, the increase
in DNA binding is less obvious.
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less than seen for the WT protein (Fig 4.8A lower panel)
Alternatively, the negative charge in the C-terminus could inhibit a conformational
regulation that has a negative effect on DNA binding (Fig 4.8B). In this hypothesis, in-
stead of the interaction between the C-terminal binding site and the C-terminus maintain-
ing a favourable DNA binding conformation, it favours the less favourable DNA binding
conformation. Addition of peptide to this system would have different effects on both
types of IRF-1, depending on the exact mechanism of the negative regulation. If, for ex-
ample, release of the interaction between binding site and C-terminus promotes the more
favourable DNA binding conformation because the C-terminal binding site is unoccupied
(Fig 4.8B(1)), addition of the peptide to IRF-1 WT will have an inhibitory effect on DNA
binding since the peptide will occupy the binding site. Exactly the same inhibition will
occur if the peptide is added to IRF-1 T311D/S317D since phosphorylation cannot affect
peptide binding to the C-terminus binding site.
On the other hand, if release of the interaction between binding site and C-terminus
promotes the more favourable DNA binding conformation because the C-terminus is free
to adopt any position it choses, (Fig 4.8B(2)), addition of the peptide to WT IRF-1 will
enhance DNA binding as it competes with the protein C-terminus for the binding site.
For IRF-1 T311D/S317D, the same competition will occur, but since less protein exists
in the less favourable DNA binding state to begin with (due to the negative charge in the
C-terminus), the increase in DNA binding will be less pronounced.
The protein used in the EMSAs was prepared in reticulocyte lysate as this was found
to produce the least degraded IRF-1, and will have all post-translational modifications
required for DNA binding. As a result, co-factors may be present as contaminants. These
were taken into consideration when suggesting mechanisms for the enhanced DNA bind-
ing of T311D/S317D IRF-1.
Phosphorylation in the C-terminus could create a high affinity binding site for a
positive cofactor (Fig 4.8C). In the absence of this co-factor, IRF-1 could adopt a less
favourable DNA binding conformation (light blue). As IRF-1 WT binds to the co-factor
with lower affinity, it spends more time in this state. Positive co-factor (navy circle) bind-
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ing (enhanced by phosphorylation) could stimulate transition to, or stabilise occupation
of the favourable DNA binding conformation (dark blue). Addition of peptide (green
line) to IRF-1 WT would inhibit DNA binding by inhibiting the low affinity interaction
between IRF-1 and co-factor. For IRF-1 T311D/S317D, however, addition of peptide
would inhibit DNA binding to a lesser degree as the WT peptide is less able to compete
with the high affinity phospho-C-terminus-co-factor interaction (Fig 4.8C lower panel).
Finally, phosphorylation in the C-terminus could inhibit binding site of a negative
cofactor (Fig 4.8D). For IRF-1 WT, the negative co-factor (purple circle) binds tightly so
IRF-1 maintains a less favourable DNA binding conformation (light blue). The negative
charge in the C-terminus resulting from phosphorylation could repel the negative cofactor,
allowing more IRF-1 to take the favourable DNA binding conformation (dark blue). If
peptide is added to IRF-1 WT, peptide and protein C-terminus have the same affinity
for the negative co-factor so peptide competes with IRF-1 for co-factor binding resulting
in more IRF-1 in the favourable DNA binding conformation. For IRF-1 T311D/S317D,
less co-factor binds already, so although the peptide competes with IRF-1 for co-factor
binding, the increase in DNA binding is less striking.
The peptide competition EMSA was performed by including a titration of WT IRF-
1 C-terminal peptide in the binding mix for IRF-1 WT and IRF-1 T311D/S317D. In
the assay (repeated twice), the C-terminal WT IRF-1 peptide titratably reduced binding
of both IRF-1 WT and T311D/S317D to C1 probe (Fig 4.9 upper panel), but it was a
more effective inhibitor of IRF-1 WT binding. Due to the increased initial binding of
IRF-1 T311D/S317D, this is most clearly seen after densitometry when the densities are
normalised to “no peptide” values (Fig 4.9 lower panel). In this experiment, as one of the
supershifts did not work (due to a pipetting error), the densities of the non-supershifted
bands were compared, and the background non-specific intensity was assumed to be equal
for all lanes.
The overall inhibitory effect of the peptide, and enhanced inhibition of IRF-1 WT
binding indicate that the mutation/phosphorylation could enhance a conformational posi-
tive regulation as shown in Fig 4.8A, or create a binding site for a positive regulator whose
binding subsequently causes a favourable conformational change in IRF-1 (Fig 4.8C).
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Figure 4.9: Mechanism of IRF-1 T311D/S317D enhanced DNA binding: Peptide competition
EMSA. Upper panel: 6µl of reticulocyte lysate expressed IRF-1 was pre-incubated for 10 mins
at room temperature with a titration of 2.5-25µM of C-terminal IRF-1 peptide (20aa), water [-] or
DMSO control [D] before EMSA was carried out to assess binding to 32P-labelled C1 probe. IRF-
1-DNA complex could be supershifted with anti-IRF-1 (BD Biosciences). Normalisation of IRF-
1 WT and T311D/S317D protein was visualised by immunoblot using anti-IRF-1 (Santa Cruz,
C20). Lower panel: Intensity of IRF-1-DNA complexes was determined by densitometry using
Image J, normalised to [-] contol and plotted on a graph. Data representative of two independent
experiments.
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It should be noted that the differences in DNA binding between the IRF-1 WT and
T311D/S317D proteins may be slightly less pronounced than expected as some of the
T311D and S317D sites in the WT protein may have been phosphorylated in the reticu-
locyte lysate, causing it to act like the mutant protein. Making a non-phosphorylatable
mutant might solve this problem, but these mutations could have their own effects such
as destroying a binding site that required the Ser or Thr residues.
To differentiate between the two mechanisms indicated above, further EMSAs were
performed: If the DNA binding ability of IRF-1 was being modulated by co-factors from
the reticulocyte lysate, IRF-1 from sources other than reticulocyte lysate should not show
a difference in binding. Although plants do have orthologues of the transcriptional reg-
ulatory proteins p300/PCAF [163], it was hoped that these would be different enough to
their mammalian counterparts to not be able to interact with IRF-1. This seems to have
been the case (see below).
IRF-1 from wheatgerm extract, and His-tagged IRF-1 purified from E.Coli were as-
sayed. The purification of His-IRF-1 was described in Chapter 3. When His-IRF-1 is
allowed to bind to DNA, similar IRF-1 WT and IRF-1 T311D/S317D DNA binding is
seen. The relative density of IRF-1WT-probe complex:IRF-1 D/D-probe complex is, on
average, 1:0.98. (Fig 4.10 left panel). With untagged IRF-1 expressed in wheatgerm
extract, both proteins bind DNA with very similar affinity (Fig 4.10 right panel). This
time the relative densities are 1:0.9, although this comparison has only been performed
once. Taken together, these results suggest that a factor in the rabbit reticulocyte lysate is
contributing to the enhanced DNA binding activity of IRF-1 T311D/S317D.
The wheatgerm EMSA used 35S labelled protein rather than 32P-probe and, although
this did not affect the enhanced IRF-1 T311D/S317D binding with reticulocyte lysate
protein (data not shown), it would still be helpful to repeat the wheatgerm assay using
32P-probe.
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Figure 4.10: Mechanism of IRF-1 T311D/S317D enhanced DNA binding: Direct or indirect con-
formational change. IRF-1 WT and T311D/S317D were expressed in E.Coli (left panel) and
wheatgerm lysate (right panel) and binding to 32P-C1 probe observed by EMSA. IRF-1 DNA
complexes could be supershifted by anti-IRF-1 (BD Biosciences) (ss= supershifted complexes).
No significant difference between IRF-1 binding for E. Coli expressed protein was observed across
three experiments. DNA binding of IRF-1 expressed in wheatgerm extract was only compared
once; in this experiment no difference in binding was observed.
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4.2.4 Effect of p300 on IRF-1 DNA binding
IRF-1 has previously been shown to interact with the co-factor p300 [67], [130] although
the effect of this interaction on IRF-1 DNA binding has never been investigated. p300 is
a histone acetylase, and so the effect of addition of acetyl coA to the binding mixture to
allow p300 to acetylate IRF-1 was also studied.
In this experiment, p300, expressed in reticulocyte lysate, was incubated with IRF-1
WT and IRF-1 D/D and C1 probe. Acetyl CoA was also included in the mix in some
tubes. The results of this experiment are shown in Fig 4.11. Addition of p300 to IRF-1
modestly enhanced its DNA binding ability. For IRF-1 WT, the increase in binding was
1.2 fold, for IRF-1 D/D, 1.4 fold. Further addition of the p300 substrate acetyl CoA re-
sulted in another moderate increase in DNA binding. For IRF-1 WT, the binding was 1.3x
binding in the absence of p300, for IRF-1 D/D, 1.5x. Enhanced DNA binding is more ev-
ident for IRF-1 T311D/S317D (illustrated in Fig 4.11 lower panel). This could argue in
favour of the negative charge improving binding of positive co-factors; as described in
Fig 4.8C. As addition of acetyl CoA further enhances DNA binding, it is possible that
acetylation of IRF-1 stabilises the favourable DNA binding conformation. This experi-
ment does, however, need to be repeated to confirm these findings; enhanced binding as
a result of p300 addition, and the increased susceptibility of IRF-1 T311D/S317D to this
effect has been observed in two independent experiments, while the effect of inclusion of
acetyl CoA has only been performed once. In this experiment, no HDAC inhibitors were
used. If they were included in future experiments, the results might be more obvious
4.2.5 Comparison of IRF-1 Binding at Naturally Occurring Promot-
ers
Next, probes using the IRF-1 binding element of other naturally occuring promoters were
compared to see if the effects of IRF-1 phosphorylation are similar at all promoters.
Probes comprising the ISG15, caspase 8 and TLR3 promoters had already been created
in the lab and their binding of IRF-1 confirmed. Therefore, these probes were used here.
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Figure 4.11: Effect of p300 on IRF-1 DNA binding. Upper panel: Cofactor p300 was included in
EMSA. 4µl rabbit reticulocyte lysate expressing EV, IRF-1 WT or T311D/S317D was incubated
with 3µl EV (lanes 3,6) or p300-expressing reticulocyte lysate (lanes 1,4,7) while binding probe
(30mins, room temp). For acetylation reaction (lanes 2,5,8), EV/IRF-1 WT/IRF-1 T311D/S317D
and p300 reticulocyte lysate were mixed with 2µM acetyl CoA and incubated at 30◦C, 10mins
for acetylation and binding then 20mins, room temp, to complete binding. Lower panel: Intensity
of IRF-1-DNA complexes was determined by densitometry using Image J, normalised to binding
in the absence of p300 and plotted on a graph. Enhanced binding of IRF-1 WT and further en-
hanced binding of IRF-1 T311D/S317D as a result of addition of p300 has been observed in two
independent experiments. The effects of inclusion of acetyl CoA have only been analysed once.
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For ISG15 and caspase 8 promoters, binding of IRF-1 T311D/S317D was significantly
more stable (1.7x and 1.8x respectively). At the TLR3 promoter, it seems that IRF-1 WT
binds with more stability, however this was only performed once (Fig 4.12).
More stable binding of IRF-1 WT than IRF-1 T311D/S317D at the TLR3 promoter
would imply the regulation is through co-factor binding (as discussed above and in Fig
4.8C), and not simply through the negative charge causing a direct conformational change
in the protein (Fig 4.8A). This is because despite IRF-1 T311D/S317D’s lower affinity for
the TLR3 promoter sequence, its transactivatory activity at this promoter is higher than
IRF-1 WT (Fig 4.2A). An explanation for this discrepancy would be the absence of the
necessary co-factors in the reticulocyte lysate. Even if the result at the TLR3 promoter
is not reproducible, earlier results where transactivatory activity at the same promoters
in different cell lines is differentially affected by the mutation (Fig 4.1), also suggest the
regulation is at the level of co-factor binding.
4.2.6 Insights into IRF-1 DNA Binding from Antibody Supershift
It has been very noticible in these EMSAs that after supershift with anti-IRF-1 antibody,
a DNA-IRF-1 doublet appears, for example see Fig 4.7A. The simplest explanation is that
IRF-1 binds DNA as a dimer, and that the lighter band is dimer with one antibody bound;
the heavier band is dimer with one antibody bound to each IRF-1 molecule.
To test this theory, a titration of anti-IRF-1 antibody was added to IRF-1 and DNA. It
was expected that at lower concentrations of antibody, any supershifted complexes would
have one antibody bound, i.e. would be in the lower position, and as the concentration
increased, more complexes would bind two antibodies until all complexes were in the
upper position.
As shown in Fig 4.13, this is not the case. At the lowest antibody concentrations, only
the higher (heavier/larger) band is present. Then, with increasing antibody concentration,
the lower (lighter/more compact) band apppears, and eventually an equilibrium of about
50:50 is reached.
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Figure 4.12: Comparison of IRF-1 binding at naturally occuring promoters. IRF-1 WT and
T311D/S317D was expressed in rabbit reticulocyte lysate. Binding of IRF-1 to 32P-labelled probe
based on naturally occuring ISG15, caspase 8 and TLR3 promoters was observed by EMSA. IRF-
1-DNA complexes could be supershifted by anti-IRF-1 antibody (BD Biosciences) (ss = super-
shifted complexes). Load was detected by western blotting of reticulocyte lysate using anti-IRF-1
(Santa-Cruz, C20). Binding of IRF-1 T311D/S317D to the ISG15 and caspase 8 promoters was
significantly more stable across three experiments (* p=<0.05, ** p=<0.01 by paried t test). The
comparison of binding to the TLR3 promoter has only been performed once.
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Figure 4.13: Investigating the doublet of DNA-bound IRF-1 appearing after supershift. Rabbit
reticulocyte lysate-expressed IRF-1 WT or T311D/S317D was incubated with 32P-labelled C1
probe in an EMSA reaction along with a titration of anti-IRF-1 antibody (BD Biosciences). Titra-
tion was: 6.25, 12.5, 25, 62.5, 250, 500 µg of antibody per reaction. This experiment has only
been performed once.
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There are various explanations for these observations, depending on whether IRF-1
binds DNA as a monomer or dimer. Both are observed in the literature [3], [164], although
for different lengths of promoters. For a dimer, anti-IRF-1 could initially bind to only one
molecule in the complex creating the single supershifted band observed. Subsequently,
when the antibody concentration is high enough (at 0.25ul per reaction in this case), it
could bind to the second IRF-1 molecule. Instead of producing a slower migrating band,
if the antibody caused a conformational change in the complex, a higher motility band
would be formed. For example, binding of antibody to IRF-1 could cause IRF-1 to adopt
a conformation that forces the DNA to bend further. As this kind of conformation is likely
to be fairly unstable, the equilibrium would never reach 100%; indeed, from the EMSA,
it seems that a 50:50 state is optimal.
Alternatively, if IRF-1 binds monomerically to the DNA, the doublet could be pro-
duced if two different states of IRF-1-DNA exist. One state could be more compact, but
less favourable, and thus is not clearly seen before supershifting. However, the binding of
antibody could stabilise this state and so, after supershift, and above a certain concentra-
tion of antibody, this higher motility DNA-IRF-1-antibody complex could appear along
with the more stable complex.
4.3 Discussion
In this chapter, the effects of the C-terminal phosphorylation of IRF-1 induced by IFN-γ
have been investigated using phosphomimetic mutants. Phosphomimetic mutants gener-
ally have enhanced transactivatory potential at various promoters compared to IRF-1 WT,
although this is cell line dependent and promoter. Moreover, IRF-1 T311D/S317D is also
more resistant to inhibition by IRF-2.
IRF-2 is a repressor of IRF-1 activity, although there is some debate about its mech-
anism of action. An intriguing theory, put forward by Senger et. al. (2000) ([165]),
is that IRF-2 prevents recruitment of the CBP/p300 co-activator and subsequently RNA
Pol II to the promoter. They propose IRF-2 is present along with IRF-1 in the IFN-β
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enhanceosome and that positively charged residues in the “repression domain” of IRF-
2 repulse CBP. Furthermore, they show that IRF-3(5D), a more transcriptionally active
form of IRF-3 known to have higher affinity for CBP/ p300, is only weakly inhibited by
IRF-2. IRF-3(5D) contains 5 S→D mutations in the C-terminus and it was suggested
that the increased negative charge created a favourable microenvironment for CBP/p300
binding [165]. The inhibition of IRF-2 repression for IRF-1 T311D/S317D is less obvious
than for IRF-3(5D) but perhaps this is due to the presence of only two phosphomimetic
mutations compared to IRF-3(5D). It would be useful to repeat the competition experi-
ments for IRF1/2 at the IFN-β promoter rather than at the IRF-E/TLR3 promoters. It may
be that in the context of the enhanceosome formed at IFN-β promoter, the relaxation of
repression is most clearly seen.
The discovery that phosphorylation enhanced transcriptional activity prompted an in-
vestigation into the mechanism underlying this effect. EMSAs were used to study the
DNA binding of IRF-1 WT and mutants. the dual T311D/S317D phosphomimetic mu-
tants has enhanced DNA binding and, with repeated experiments, it may be possible to
show that T311D and S317D mutations also have a positive effect on DNA binding (Fig
4.7). When naturally occuring promoters were assayed, promoter specific differences in
relative affinities for IRF-1 WT and T311D/S317D were observed, although at this stage,
these cannot be said to be statistically significant, despite being reproducible. ChIP stud-
ies in cells transfected with IRF-1 WT and T311D/S317D would allow comparison of
relative promoter occupation. This would give some insight into the spectrum of promot-
ers preferentially bound by IRF-1 T311D/S317D and so predictions could be made about
which genes would be upregulated by this species after IFN-γ treatment. Looking to the
future, this could inform us about likely side effects of activating IRF-1 by phosphoryla-
tion at this site.
It is also obvious from Fig 4.7 that IRF-1 T311D/S317D has a higher motility than
IRF-1 WT. This could be an indication of a conformational change in the mutant that
makes the protein more compact and allows it to move faster through the native EMSA
gel. An alternative explanation would be that the two extra negative charges introduced
by the mutation cause the protein to move faster towards the positive electode. This is less
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likely as a very precise jump is observed. If all phosphorylation events caused such large
jumps, phosphorylated protein from reticulocyte lysate would appear as a large smear on
the gel rather than as a fairly resolved band. In addition, if the charge was the major
factor causing the shift, IRF-1 S317D and T311D would be expected to be the same, and
intermediate, in motility. This is not the case.
There are a number of mechanisms by which phosphorylation could cause enhanced
DNA binding. If purified IRF-1 were being used, these would be limited to intrinsic con-
formational changes (Fig 4.8A&B). However, since rabbit reticulocyte lysate was being
used to make the protein, other factors were present. This opened the possibility that in-
teraction with a positive or negative cofactor could be modulating DNA binding activity
(Fig 4.8C&D). A peptide competition EMSA suggested that enhanced interaction with a
positive cofactor was responsible for the enhanced DNA binding of IRF-1 T311D/S317D
(Fig 4.9 and 4.8C). Consistent with this, expression of IRF-1 in two different systems,
E.Coli (His-purified IRF-1) and wheatgerm lysate (untagged IRF-1, unpurified) (both
lacking the factors present in reticulocyte lysate) resulted in binding of IRF-1 WT and
T311D/S317D that was more similar than in reticulocyte lysate (Fig 4.10A).
Since IRF-1 T311D/S317D was less susceptible to inhibition by IRF-2, which, as de-
scribed above, may involve enhanced cofactor p300/CBP interaction, p300 was included
in the DNA binding reaction. Addition of p300 enhanced the binding of IRF-1 to DNA,
and this was more pronounced for IRF-1 T311D/S317D. DNA binding could be further
augmented by the addition of acetyl CoA to the reaction (Fig 4.10B). Thus, p300 may
bind to, and acetylate IRF-1 in order to enhance its DNA binding and transcriptional
activity.
In support of this, it has previously been shown that, not only does p300 bind to the
IRF-1 enhancer in vitro [67], but phosphorylation of IRF-1 at 317S and 308S enhances
p300 binding to peptides from the Mf1 domain (as suggested by peptide competition
EMSA) (Fig 4.14). Further, IRF-1 is a substrate for p300 acetylation in vitro [126]. This
is similar to the situation for p53 where phosphorylation of Thr18 and 20 (close to the
LXXLL motif) enhances p300 binding, resulting in sequence specific DNA dependent










Figure 4.14: C-terminal phosphorylation of IRF-1 enhances p300 binding in vitro. (A) Biotiny-
lated IRF-1 C-terminal 20aa peptide (CT1), or phosphorylated C-terminal 20 aa peptide (CT1-
Ser317-P/-Ser309-P) was bound to streptavidin coated ELISA wells. A titration of p300 protein
(0-1ng) was incubated in the wells, and binding of p300 to IRF-1 peptide was detected by anti-
p300 antibody (Santa-Cruz) and quantified by chemiluminescence (R.L.U. +/- SD). (Experiment
performed by David Dornan). (B) Diagram of IRF-1 showing location of the three p300 interag-
tion sites CT1, 2 and 3 determined by David Dornan [67].
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of IRF-1 with p300 warrants further investigation.
Interestingly the Mf1 domain is not the highest affinity interaction site in IRF-1 for
p300. Two motifs within IRF-1 (CT2 and CT3) (Fig 4.14B) were shown to have higher
affinity binding to p300; these domains were shown to be required for p300 to stimulate
IRF-1 activity at the IFN-β promoter. [67]. Our current hypothesis is that binding of
p300 to the C-terminus (Mf1/CT1 domain) regulates its binding to the higher affinity CT2
and CT3 domains, perhaps by causing conformational change that exposes these p300-
binding sites. This would allow the interaction of p300 and IRF-1 to be tightly controlled,
for example, C-terminal phosphorylation of IRF-1 in response to an activatory signal (e.g.
IFN-γ) could create a binding site for p300. Binding of p300 to IRF-1, and potentially
acetylation of IRF-1 by p300, could cause a conformational change in IRF-1, exposing
the previously occluded CT2 and CT3 sites. Binding of p300 to these sites may then
enhance IRF-1 DNA binding and transactivatory activity.
CBP/p300 is a broad-spectrum transcriptional cofactor which is thought to act through
a variety of mechanisms: It can bridge transcription factors and basal transcription ma-
chinery; provide a scaffold for assembly of multiprotein initiation complexes or acetylate
chromatin and transcription factors to enhance transcriptional activity [167]. Such ef-
fects could be promoter specific and are not necessarily mutually exclusive. In the IFN-β
enhanceosome, IRF-1, along with other factors, recruits p300 to the promoter where it
bridges the enhanceosome and RNA Pol II [130]. Such a process could be responsible for
the enhanced transactivatory activity of IRF-1 T311D/S317D, but since acetylation is im-
portant, and DNA-binding activity is directly affected, it is likely that p300 has additional
roles here. The repressor activity of IRF-1 is not affected by T311/S317 phosphorylation
suggesting that co-repressor binding to IRF-1 is regulated by different means.
In order to more clearly define the IRF-1-p300 interaction, the effects of p300 on
IRF-1 DNA binding should first be repeated with purified proteins in the EMSA. Then,
the interaction of p300 with IRF-1 WT, IRF-1 T311D/S317D, IRF-1 T311D and IRF-1
S317D full length proteins should be investigated by immunoprecipitation and ELISA
to confirm that C-terminal phosphorylation does enhance the interaction. Next, the ef-
fect of acetylation on DNA binding should be more thoroughly defined using in vitro
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acetylation assays and the location of the acetylation determined using IRF-1 peptides
and domains or mass-spectrometry. The relative importance/role of p300 binding and
acetylation of IRF-1 in cells could be assessed by modulation of p300 expression (tran-
sient p300 expression and siRNA knock down) and inhibition of HAT (acetyl transferase)
activity (∆HAT-p300 expression and p300 inhibitor treatment). Finally, mutants of IRF-
1 that cannot bind p300 (perhaps T311A/S317A) and non-acetylatable mutants K→R
should exhibit reduced DNA-binding activity.
Acetylation could cause direct conformational change in IRF-1 which stabilises it in
a DNA-binding conformation, or it could modulate binding of other factors which could
affect IRF-1 activity. It should be possible to use biophysical techniques such as intrinsic
fluorescence or thermal denaturation to determine if conformational change in IRF-1 re-
sults from the phosphomimetic mutation/phosphorylation or acetylation. Unfortunately
these techniques require substantial amounts of purified protein which is not compatible
with expression in reticulocyte lysate. Purifying protein from E. Coli is the obvious solu-
tion, however, the results will need to be carefully considered as E. Coli lack the protein
phosphorylation machinery of mammalian cells, and thus IRF-1 may not be in its native
conformation, especially if important intramolecular interactions are missing. In addi-
tion, E. Coli contain proteases which rapidly degrade IRF-1 as quickly as 30 mins after
induction (Dr. Vikram Narayan, unpublished observations) and any purified protein is a
mixture of full length IRF-1 and different degradation products which may have different
conformations if important interactions are lost.
It is likely that other factors apart from p300 are differentially bound to WT and
phosphorylated IRF-1. In fact, Hsp70 has recently been shown to bind more strongly to
the WT Mf1 peptide (Dr. Vikram Narayan, unpublished observations). This observation
is considered in more detail in the discussion.
Conventionally, screening for binding partners would involve expression of exoge-
nous tagged protein in cells and purification of protein-binding partner complexes by, for
example, tandem affinity purification. For IRF-1, this technique is not possible as studies
in the lab have determined that the expression levels in cells are not high enough. For this
study, stable cell lines were created in an attempt to create a population of efficient IRF-1
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expressing cells, but these lost IRF-1 expression very quickly, despite maintainence in
selective medium. Therefore, an alternative screening technique has been developed for
IRF-1 [144]. IRF-1 peptide aptamers are immobilised on a suppport to create an affinity
purification column, and cell lysate is passed over the column to find interacting proteins.
Proteins eluted from the column are identified by mass spectrometry. This technique
could be used to identify phosphospecific binding partners for IRF-1. For p53, acetyla-
tion by p300 affects cofactor binding[168]. If the acetylation site of IRF-1 can be mapped,
the binding partners of acetylated peptide could be identified.
In conclusion, IFN-γ-induced phosphorylation of the IRF-1 Mf1 domain has been
shown to enhance its transcriptional activatory activity. This is most likely through cre-
ation of a binding site for p300 which enhances DNA binding of IRF-1, perhaps through
acetylation, and might, by analogy to events in the IFN-β enhanceosome [130], recruit
RNA Pol II.
Chapter 5
Effects of C-terminal phosphorylation
of IRF-1 on tumour suppressor activity
Since IRF-1 is an effective tumour suppresssor through its regulation of downstream
genes, and phosphorylation of IRF-1 impacts on its transactivatory activity [119], [120],
Chapter 4, the effect of C-terminal phosphorylation of IRF-1 on its tumour suppressor
activity was investigated.
5.1 Anchorage-dependent Colony Formation Assays and
Cell Adhesion Assays
Anchorage-dependent colony formation assays measure the ability of cells to establish
and grow colonies in the presence of a substrate. They are effectively a measure of cell
survival and long-term cell proliferation. Cells are transfected with empty vector con-
trol (EV) or IRF-1 WT or T311D/S317D and seeded at a low density in the presence
of geneticin to select for cells containing the expression plasmid. The expression plas-
mid contains a neomycin gene which confers resistance to geneticin. The concentration
of geneticin that will kill untransfected cells varies depending on cell line. Therefore,
before carrying out the colony formation assays, kill curves were constructed for A375
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and H1299 cells to determine the optimum geneticin concentration. Untransfected cells
were plated at low density and incubated in medium containing various concentrations of
geneticin. At a number of time points, the survival of the cells is estimated. The opti-
mum concentration of geneticin for colony formation assays is the lowest concentration
required to kill all untransfected within 5 days. For H1299 cells, this is 600-800µg/ml
whereas for A375 cells, 1200-1500µg/ml (Fig 5.1).
Once the optimum geneticin concentration had been established, cells were trans-
fected for 24 hours with pcDNA3 EV, IRF-1 WT or IRF-1 T311D/S317D, then seeded
at low density in the appropriate concentration of antibiotic. The medium was changed
after four days and the geneticin refreshed. After 10 days, colonies were fixed and stained
with Giemsa for counting. For both H1299 (Fig 5.2) and A375 (Fig 5.3) cells, IRF-1 is
an efficient suppressor of anchorage-dependent colony formation. In both cases, IRF-
1 T311D/S317D appears slightly more effective than IRF-1 WT, but this difference is
not significant. Transfection of A375 cells with IRF-1 WT resulted in a average 3.4
fold decrease in the number of colonies and transfection with IRF-1 T311D/S317D a 5.7
fold decrease (Fig 5.3A). For H1299 cells, IRF-1 T311D/S317D was even more effec-
tive as its transfection resulted in a 14 fold decrease compared to a 3.7 fold decrease
with IRF-1 WT(Fig 5.2A). However, when the sizes of the colonies are measured, in
H1299 cells, both IRF-1 WT and IRF-1-T311D/S317D transfected cells show a reduc-
tion in colony sizes, although only the reduction for IRF-1 T311D/S317D is significant
(Fig 5.2B), whereas in A375 cells, there is no significant difference in colony size (Fig
5.3B). Representative images of colonies obtained are shown in Fig 5.2C and 5.3C.
For H1299 cells, this implies that the ability of IRF-1 to suppress anchorage dependent-
colony formation is dependent on its ability to inhibit cell proliferation (because IRF-
1 treated cells produce smaller colonies). IRF-1 T311D/S317D is consistently, but not
significantly, more effective at colony formation suppression in both cell lines. Further
experiments using larger numbers of cells could be appropriate to clarify this since, in
some cases, no colonies were established on IRF-1 T311D/S317D-transfected plates, and
therefore, the difference in relative numbers of colonies may be underestimated. If the
difference between IRF-1 WT and T311D/S317D colony formation suppression was sig-






























































Figure 5.1: Kill curves to determine optimum geneticin concentration for H1299 and A375 cell
colony formation assays. (A) H1299 cells or (B) A375 cells were plated at low density and
incubated with a titration of geneticin. Cells surviving were estimated after 3, 5 and 7 days.




















































Figure 5.2: Effect of IRF-1 on anchorage dependent colony formation for H1299 cells. Cells
transfected with pcDNA3-EV, -IRF-1 WT or -IRF-1 T311D/SD317D were seeded in geneticin
(750µg/ml) and grown for 10 days before methanol fixation and staining with Giemsa stain. (A)
Cells were counted using Image J. (B) Average size of colonies was estimated using Image J. Sig-
nificant differences between colony numbers/sizes compared to EV by randomised block ANOVA
followed by Tukey’s test are indiciated. (* p=<0.05, *** p=<0.001). Results expressed as mean
+/- standard deviation for duplicates. (C) Representative images of colonies from EV, IRF-1 WT
and IRF-1 T311D/S317D-transfected cells. Data representative of three independent experiments.
















































Figure 5.3: Effect of IRF-1 on anchorage dependent colony formation for A375 cells. Cells
transfected with pcDNA3-EV, -IRF-1 WT or -IRF-1 T311D/SD317D were seeded in geneticin
(1500µg/ml) and grown for 10 days before methanol fixation and staining with Giemsa stain.
(A) Cells were counted using Image J. (B) Average size of colonies was estimated using Image
J. Significant differences between colony numbers/sizes compared to EV by randomised block
ANOVA followed by Tukey’s test are indiciated. (* p=<0.05, ** p=<0.01). Results expressed
as mean +/- standard deviation for duplicates. (C) Representative images of colonies from EV,
IRF-1 WT and IRF-1 T311D/S317D-transfected cells. Data representative of three independent
experiments.
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nificant, the enhanced activity of IRF-1 T311D/S317D could be due to either its effects on
cell growth (demonstrated by its effects on colony size), or due to an additional activity,
for example, affecting the initial stages of establishing a colony. For A375 cells, since the
colonies on IRF-1 WT and T311D/S317D-transfected plates have fewer colonies (with
IRF-1 T311D/S317D-transfected cells having the fewest), but similar-to-control sized
colonies, it seems that in these cells, IRF-1 affects the initial survival, and not the rate of
growth, of cells. Factors influencing the establishment of colonies could include apopto-
sis of cells, or reduced adhesion to substrate as a result of IRF-1 expression. To address
this, a time course looking at rates of apoptosis at various points after IRF-1 transfection
should be carried out.
As a tumour suppressor, IRF-1 should, if anything, enhance cell-substrate contacts,
but, as fewer colonies are established by IRF-1 expressing cells, an adhesion assays was
carried out to assess the effects of IRF-1 on cell-substrate adhesion. Preliminary results
indicated that neither IRF-1 WT nor IRF-1 T311D/S317D have any effect on cell adher-
ance to plastic (Fig 5.4), although a positive and negative control that enhance and reduce
cell adhesion need to be sourced. Sialomucin complex (SMC) which reduces A375 cell
adhesion to plastic could be used as a control. Its overexpression reduces adhesion and
inhibition restores adhesion[169].
5.2 Anchorage-independent Colony Formation Assays
Anchorage-independent colony formation assays measure the ability of cells to establish
and grow colonies in the absence of a substrate i.e. without attachment. This is a hallmark
of transformed cells. Again cells are seeded at a low density and maintained in geneticin
to select transformed cells. In these assays, however, the bottom of the well is covered
with a layer of agar to provide a solid support that cells cannot adhere to. Cells are
seeded in a methylcellulose mixture which is layered onto the agar. The viscosity of the
methylcellulose prevents the cells moving and clumping together, but cannot be used by
the cells as a substrate to attach to.




















Figure 5.4: Effect of IRF-1 on cell-substrate adhesion. A375 cells were transfected with pcDNA3-
EV, -IRF-1 WT or -T311D/S317D. After 24h, cells were harvested and allowed to readhere to
plastic for 1h then washed and stained. Cells were lysed and absorbance of solubilised stain was
measured to determine the level of adherance. Data from a single experiment. Results expressed
as mean +/- standard deviation for duplicates.
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HeLa and A375 cells were transfected for 24 hours with pcDNA3 EV, IRF-1 WT
or IRF-1 T311D/S317D, then seeded at low density in methylcellulose containing the
appropriate concentration of antibiotic. After 24 hours, to allow the cells to settle, im-
ages were taken to determine the average cell size. Minimum colony size was extrapo-
lated from these data as a colony is taken to be at least 3 cells in area. After around 6
days, the colonies were photographed and the number of colonies per number of events
(cells+colonies) was calculated. In A375 cells, IRF-1 reduces the frequency of single
cells growing into colonies (>3 cells) in methylcellulose, and C-terminal phosphoryla-
tion of IRF-1 (T311D/S317D) may enhance this effect (although after three repeats, the
difference between IRF-1 WT and IRF-1 T311D/S317D activity is not significant (Fig
5.6A). In HeLa cells, IRF-1 WT reproducibly but not significantly reduces the formation
of colonies whereas IRF-1 T311D/S317D significantly reduces the number of colonies
(Fig 5.5A). (HeLa cells were selected to compare to A375 as, unlike H1299 cells, these
produce good colonies, and they respond to IRF-1 T311D/S317D in the same way as
H1299 cells for luciferase reporter assays.) In both cell lines, IRF-1 reduces the prolifer-
ation of the cells, resulting in smaller colonies (Fig 5.5B, Fig 5.6B), but phosphorylation
seems to have no further effect on this activity. Representative images of colonies are
shown in Fig 5.5C and Fig 5.6C.
The reduction in the number of colonies in methylcellulose could be due to (1) the
mitigated proliferation rate reducing the number of cells that have divided sufficiently to
form colonies, (2) an initial barrier to colony formation imposed by IRF-1, (3) a rein-
statement of the anchorage-dependence exhibited by non-transformed cells, or indeed, a
combination of all three. Since the colony size of both IRF-1 WT- and T311D/S317D-
transfected cells is similar, yet IRF-1 T311D/S317D-transfected cells appear to produce
fewer colonies (although for A375 cells, further experiments need to be done to con-
firm a difference between IRF-1 WT and T311D/S317D as discussed for the anchorage-
dependent assays), it would seem that proliferation control is important but not the only
mechanism by which IRF-1 inhibits colony formation, and phosphorylation of IRF-1 en-
hances the unknown activity. Again, apoptosis and sensecence should be investigated.




















































Figure 5.5: Effect of IRF-1 on anchorage independent colony formation in HeLa cells. (A) An-
chorage independent colony formation assays were performed using pcDNA3-EV, -IRF-1 WT and
-IRF-1 T311D/S317D-transfected cells seeded in 1.4% methylcellulose containing 1500µg/ml ge-
neticin. Colonies were counted after 5-7 days using Image J. (B) Average size of colonies was
estimated using Image J. Significant differences between colony numbers/sizes compared to EV
by randomised block ANOVA followed by Tukey’s test are indiciated. (* p=<0.05, ** p=<0.01,
*** p=<0.001). Line indicates a significant difference between IRF-1 WT and DD-transfected
cell colony size. Results expressed as mean +/- standard deviation for duplicates. (C) Represen-
tative images of colonies from EV, IRF-1 WT and IRF-1 T311D/S317D-transfected cells. Data
representative of three independent experiments.






















































Figure 5.6: Effect of IRF-1 on anchorage independent colony formation in A375 cells. (A) An-
chorage independent colony formation assays were performed using pcDNA3-EV, -IRF-1 WT and
-IRF-1 T311D/S317D-transfected cells seeded in 1.4% methylcellulose containing 1500µg/ml ge-
neticin. Colonies were counted after 5-7 days using Image J. (B) Average size of colonies was
estimated using Image J. Significant differences between colony numbers/sizes compared to EV
by randomised block ANOVA followed by Tukey’s test are indiciated. (*** p=<0.001). Results
expressed as mean +/- standard deviation for duplicates. (C) Representative images of colonies
from EV, IRF-1 WT and IRF-1 T311D/S317D-transfected cells. Data representative of three in-
dependent experiments.
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5.3 Proliferation, Cell Cycle Arrest and Senescence
5.3.1 Proliferation
Inhibition of proliferation of cells by IRF-1 was also examined in a proliferation assay.
The colony size measured in the anchorage dependent colony formation assay suggested
that the proliferation of H1299 cells was inhibited by IRF-1 WT and further inhibited
by IRF-1 T311D/S317D, whereas, for A375 cells, proliferation might actually increase.
To address this more directly, cells were transfected for 24 hours, then seeded at low
density. After 1, 2 and 3 days growth, cells were stained, solubilised and the absorbance
of stain in the solution was used as a measure of cell numbers. The experiment was
only performed once once; in HeLa cells, IRF-1 may inhibit cell proliferation, but IRF-1
WT was more effective than IRF-1 T311D/S317D, suggesting that IRF-1 T311D/S317D
could have an additional mechanism by which it inhibits colony formation (Fig 5.7A). For
A375 cells, the proliferation of EV, IRF-1 WT and IRF-1 T311D/S317D cells was very
similar, although a slight increase in proliferation caused by IRF-1 WT and T311D/S317D
transfection is in agreement with the anchorage-dependent colony formation assay (Fig
5.7B). Selecting only IRF-1 expressing cells by geneticin treatment might give clearer
results.
5.3.2 Cell Cycle Arrest
The inhibition of proliferation seen above could be a result of IRF-1 induced cell cycle
arrest. Since IRF-1 upregulates the CDK inhibitors p21 [30] and p27[31], and down-
regulates cyclins D and E and CDKs 2 and 4 [68], this seemed very plausible. To ad-
dress this, HeLa and H1299 cells were transfected with pcDNA3 EV, IRF-1 WT or IRF-1
T311D/S317D. After 24 hours cells were fixed and cell cycle anaylsis by propidium io-
dide staining was carried out. However, only very subtle differences in profile between
EV, IRF-1 WT and IRF-1 T311D/S317D transfections were observed. In both cell lines,
IRF-1 WT causes a very modest arrest in G0/G1 phase and IRF-1 T311D/S317D a slightly
more pronounced effect (Fig 5.8). It is not clear whether this effect is significant, and





























































Figure 5.7: Effect of IRF-1 WT and T311D/S317D on cell proliferation. (A) HeLa cells (B) A375
cells. Proliferation of pcDNA3-EV, -IRF-1 WT and T311D/S317D-transfected cells was measured
by fixing and staining cells after 1, 2 and 3 days of growth, then lysing cells and measuring the
absorbance of the solubilised stain. Data representative of a single experiment.
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since the experiment was only carried out once, repeats are needed.
5.3.3 Senescence
A candidate for the alternative mechanism by which IRF-1 also inhibits colony formation
is senescence. Senescent cells have exited the cell cycle i.e. have undergone irreversible
G1 arrest and so do not proliferate, but remain as viable cells. In endothelial cells, IRF-1
has been shown to mediate IFN-α induced senescence [60]. In the anchorage-independent
colony formation assays, IRF-1 caused there to be fewer colonies per total cells without
affecting the total number of cells. Therefore, if IRF-1 T311D/S317D causes greater
initiation of senescence compared to IRF-1 WT, this would agree with the data from the
methylcellulose assay. It would not, however, be in keeping with the conflicting data
from the proliferation assay, which showed that IRF-1 WT reduced proliferation rates to
a greater extent than T311D/S317D (Fig 5.8A).
Senescence was measured in A375 cells using a senescence-associated β-galactosidase
staining kit. When the numbers of senescent cells were counted manually, the effect of
IRF-1 WT transfection was variable but IRF-1 T311D/S317D caused an increase in the
number of sensecent cells (Fig 5.9). This may mean that IRF-1 T311D/S317D enhances
senescence but the assay is not reliably quantatative and was not repeated. Manual count-
ing requires an arbitrary definition of a staining threshold above which a cell is considered
senescent. Greater confidence could be achieved using fluorometric senescence assay
where cleavage of a senescence-associated β-galactosidase substrate renders it fluores-
cent.
5.4 Inverse Invasion Assays
IRF-1 suppresses the MMP9 promoter [45], and inhibits metastasis in vivo [42], [23],
[46], but its effects on the invasive potential of cells in in vitro assays have not yet been in-
vestigated. Here, MDA-MB-231 cells were transfected with IRF-1 WT and T311D/S317D



































































Figure 5.8: Effect of IRF-1 WT and T311D/S317D on cell cycle arrest. (A) HeLa and (B) H1299
cells were transfected with pcDNA3-EV, -IRF-1 WT or T311D/S317D. After 24h, cells were fixed
and stained with propidium iodide then anaylsed by flow cytometry. Left panel displays cell cycle
profile data, right panel shows a comparison of the percentage of cells at each cycle cycle stage
for EV, IRF-1 WT and IRF-1 T311D/S317D. Data representative of a single experiment.






















Figure 5.9: Effect of IRF-1 WT and T311D/S317D on senescence. Senescence levels in pcDNA3-
EV, -IRF-1 WT and T311D/S317D-transfected A375 cells were estimated using a senescence-
associated β-galactosidase staining kit (NEB). Results expressed as mean +/- standard deviation
for duplicates. Data representative of a single experiment.
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and the extent of their invasion through matrigel-filled transwells was measured. MDA-
MB-231 cells are highly metastatic and so are very suitable for this assays. Lack of
IRF-1 expression has been linked to metastatic phenotype, and IRF-1 is expressed at very
low levels in MDA-MB-231 cells [23]. Therefore, transfection of IRF-1 into these cells
should give a measurable response in this assay.
In the inverse invasion assay (Fig 5.10A), a matrix (matrigel) is placed in a transwell
insert on top of a filter. The transwell is inverted and cells are seeded on the base of the
filter. Once the cells have attached, the transwell is placed right-way-up in a tissue culture
well containing medium without growth factors. Medium containing growth factors is
pipetted on top of the matrigel to create a gradient which encourages the cells to invade
upwards across the filter and into the matrix. After 3 days, the extent of invasion is
measured by staining the cells and visualising them using a confocal microscope, taking
images at 15µm intervals. Invasion of cells at each interval was expressed as a percent of
the staining at the confluent monolayer on the filter.
The preliminary results indicate that IRF-1 inhibits invasion of MDA-MB-231 cells,
and that IRF-1 T311D/S317D might be more effective than IRF-1 WT (Fig 5.10B&C).
While it is possible to be confident in the findings of each individual assay, this assay
will need repeated many times to have a statistically relevant data set. Before setting up
multiple repeats, however, the time of the assay needs to be reduced as IRF-1’s activity as
a growth suppressor makes normalisation difficult; after a few days, the number of cells
present on the monolayer is less for the IRF-1-transfected cells than the control. Since
the amount of invasion is expressed as a percentage of the monolayer, the results are still
relevant, however, it would be a more direct comparison to have confluent monolayers for
each condition.





































Figure 5.10: Effect of IRF-1 on invasion through matrigel. (A) Schematic representation of inverse
invasion assay. left panel An insert with a permeable membrane is inserted into a tissue culture
dish well. The well consitutes the lower chamber and the insert the upper chamber. /em centre
panel A matrix (in this case 50% matrigel) is placed in the insert to simulate the extracellular ma-
trix. Cells are seeded on the base of the membrane, then a gradient of growth factors is created by
filling the lower chamber with serum free medium, and the upper chamber with medium contain-
ing FBS. right panel The gradient encourages migration of the cells across the membrance and
invasion into the matrigel. (B) Inverse invasion of pcDNA3-EV, -IRF-1 WT and T311D/S317D-
transfected MDA-MB-231 cells. 24h after transfection, cells were seeded on matrigel-containing
transwell inserts and allowed to migrate for 3 days through a FBS gradient. Cells were stained
using calcein-AM and images were taken every 15µm from the base of the transwell. Staining at
each level was normalised to the staining at the base of the stack. Results expressed as mean +/-
standard error for four pictures from four different positions in each well.(C) Representative im-
ages of invasion of pcDNA3-EV, -IRF-1 WT and T311D/S317D-transfected MDA-MB-231 cells.
Data from a single experiment.
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5.5 Discussion
IFN-γ is known to elicit anti-tumoural effects by both directly affecting the tumour cell
and enhancing immune recognition of tumour cells [170]. IRF-1 is involved in mediat-
ing many of these activities. More recently, however, evidence has emerged that con-
stitutive activation of the STAT1 pathway (downstream of IFN-γ) may be oncogenic. It
has been suggested that radioresistance and chemoresistance are caused by the upregu-
lation of some Interferon Stimulated Genes (ISGs) (not including IRF-1) that promote
survival. This is speculated to be the result of activity by unphosphorylated STAT1 which
upregulates a different subset of promoters to phosphorylated STAT1, some of which
control prosurvival genes. Upregulation of STAT1 has been observed in radioresistant
and chemoresistant tumour cells [171]. Despite the anti-tumour activities of IFN-γ, its
upregulation of STAT1 may limit its theraputic value.
Consequently, IRF-1 artificially activated to mimic IFN-γ-mediated activation has
the potential be a useful tool. Although not all of the promoters targeted by IFN-γ are
activated by IRF-1, it is the downstream effector of many antitumour activities, and fur-
thermore, has been shown to demonstrate antioncogenic effects in vivo [41], [23], [61],
enhance the activity of chemotherapeutics [58], [59], [60] and mediate the apoptotic ac-
tivity of antiestrogens [57].
As summarised below, in this chapter the effects of mutations in IRF-1 mimicing
IFN-γ-induced phosphorylation have been examined in clonogenic and invasion assays.
IRF-1 has previously been shown to inhibit anchorage dependent [70] and indepen-
dent colony formation [5]. The data in this chapter build on those findings and shows that
C-terminal phosphorylation might enhance the activity of IRF-1 in such assays, altough
further experiments with more cells are required to confirm this as discussed above.
It has not been possible so far to fully elucidate the mechanism by which IRF-1 in-
hibits colony formation. The data presented here suggest that a dual mechanism is operat-
ing with proliferation being inhibited by IRF-1 in most cell lines for anchorage dependent
and independent growth, but a further, unknown mechanism might effect the greater inhi-
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bition seen with IRF-1 T311D/S317D. The effect of IRF-1 T311D/S317D on senescence
and apoptosis will be studied in more detail to determine if either of these could be re-
sponsible.
It would also be interesting to try and isolate cells from large and small colonies and
cells which did not produce colonies, and compare IRF-1 expression levels in each. It
is tempting to suspect that the size/presence of a colony is related to the level of IRF-
1 expression in each cell. Related to this, an attempt was made to create stable, IRF-
1 expressing, cell lines. Over time (a few weeks), the cells downregulated the forced
expression of IRF-1, even in the presence of a selection agent. Therefore the presence of
IRF-1 exerts a strong negative selection pressure and the extent of IRF-1 expression could
determine the rate of cell growth/colony initiation.
IRF-1 has here, for the first time, been shown to inhibit invasion in an in vitro metas-
tasis assay. IRF-1 has been shown to inhibit metastasis in vivo through its effects on
immune-mediated clearance of tumour cells [46], however, clearly in an in vitro assay,
another activity is responsible. Matrix Metalloproteases (MMPs) are involved in the in-
vasion and metastasis of tumour cells [172]. IRF-1 downregulates the MMP9 promoter
through competition with NF-κB [45]. Therefore, it would be useful to determine if the
effects of IRF-1 on invasion in the transwell invasion assays are linked to MMP9 inhibi-
tion. MMP9 activity of transfected cells could be measured using a gelatinase assay. Of
note, IRF-1 WT and T311D/S317D show similar efficiency of inhibition at the MMP9
promoter in reporter assays (Fig 4.2), but IRF-1 T311D/S317D might be more effective
in inhibiting invasion. Thus, inhibition of MMP9 at the promoter level may not be the
only mechanism operating. Perhaps other MMPs are regulated by IRF-1 or perhaps, as
discussed above, the optimisation of the in vitro assay will reveal that IRF-1 WT and
T311D/S317D have similar effects.
In conclusion, the results in this chapter demonstrate that in vitro IRF-1 T311D/S317D
might be a more effective tumour suppressor than IRF-1 WT. It follows that delivery of
IRF-1 T311D/S317D could be an effective cancer treatment, and a logical development of
this project would be to carry out in vivo experiments to determine the efficacy of IRF-1
T311D/S317D in inhibiting tumour growth, and augmenting the activity of pre-existing
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treatments such as antiestrogens.
An alternative to directly administering IRF-1 T311D/S317D through gene therapy
would be to activate the kinases responsible for phosphorylation of IRF-1 at these sites.
Small molecule activation of protein kinases is still in its infancy, but drugs employing
this mechanism are under investigation for diseases such as Alzheimers, (PKC activators)
[173], diabetes (GK activators) [174] and neurological diseases (Akt activators) [175].
Interestingly, both PKC and Akt are IFN-γ activated kinases and have been predicted to
phosphorylate IRF-1 Thr311 and Ser317 (see discussion). Kinase activators are commer-
cially available, and could be useful tools in identifying the kinases upstream of IRF-1
and further characterising the effects of phosphorylation at these sites on IRF-1 activity.
Chapter 6
Discussion and Future Directions
The aims of this thesis have been to identify regulatory phosphorylation events for IRF-
1 and to try to study the mechanisms by which these phosphorylations modulate IRF-1
activity. Using phosphospecific antibodies, phosphorylation at T311, and S317 sites was
observed in response to IFN-γ treatment, and at S317 in response to the DNA damage
mimetic etoposide. Phosphomimetic (S/T→D) mutants of each phosphorylation site, and
a dual phosphomimetic mutant where both sites were changed, were created. Since the
dual phosphomimetic mutant showed the highest activity in transcriptional reporter as-
says, this mutant was used to study the mechanism of the enhanced transcriptional ac-
tivity and to examine the effect of IFN-γ-induced phosphorylation on IRF-1 activity in
cell-based assays. Although the presence of dual phosphorylation at these sites in cells
could not be confirmed due to the deterioration of the phosphospecific antibodies, multi-
site phosphorylation is well-recognised and it is postulated that a requirement for multiple
phosphorylations imposes a threshold for activation [176].
Phosphorylation is well recognised as a crucial post-translatory modification of tran-
scription factors which can regulate transcription factor activity at a number of levels,
namely: localisation; stability; DNA binding and protein-protein interaction [177]. The
impact of phosphorylation on the regulation of IRF-1 through these mechanisms, and the
contributions of the findings reported in this thesis to the understanding of such regula-




Upon IFN-γ treatment, IRF-1 translocates to the nucleus [138]. Although prelimi-
nary studies suggest that neither 311T nor 317S phosphorylation affects nuclear transport,
(subcellular fractionation of cells transfected with IRF-1 containing phosphomimetic mu-
tations at the above sites indicates no difference in localisation compared to WT-IRF-1)
evidence from the literature implies that phosphorylation is important in this process, as
described below.
Inhibition of PKC by minocycline reduces IRF-1 nuclear translocation after IFN-γ
treatment without affecting total IRF-1 protein levels. PKC is upregulated by IFN-γ
treatment, therefore, it is plausible that phosphorylation of IRF-1 by PKC is required
for nuclear transport of IRF-1 [178].
After TLR9 stimulation by CpG DNA, IKKα is required for IRF-1 nuclear translo-
cation. Moreover, IKKα coimmunoprecipitates with IRF-1 and phosphorylates it in vitro
[179]. IRF-1 interacts with the TLR adaptor protein MyD88 after TLR9 stimulation,
resulting in its “licensing” (probably phosphorylation), and nuclear translocation [96].
Therefore, it is likely that, by analogy with IRF-7 [180], TLR9 engagement recruits
MyD88 which binds IRF-1. IRF-1 is then phosphorylated by IKKα which has been
activated by IRAK1 as a result of TLR9 engagement. Phosphorylated IRF-1 then translo-
cates to the nucleus where it can upregulate immune-related promoters. This is illustrated
in Fig 6.1.
IRF-1 contains a bipartite NLS. The NLS is contacted by importin-α1, which mediates
its nuclear translocation after IFNγ treatment [138]. Since there are phosphorylation sites
in and around the NLS, phosphorylation could regulate the interaction with importins. As
mentioned by Whitmarsh & Davies, phosphorylation could unmask a binding site for an
importin or block a binding site for another factor which occludes the importin binding
site [177]. In keeping with this, it has been shown that although the NLS is critical for
binding of the importin, the surrounding structure of the protein is also important for
















Figure 6.1: Predicted phosphorylation of IRF-1 in response to TLR9 activation (Adapted
from[180]). Unmethylated DNA activates TLR9. By analogy to IRF-7, the adaptor protein
MyD88 could contact IRF-1 and bring it into proximity with IRAK1-activated IKKα [180]. IKKα
phosphorylates IRF-1 [179]. Phosphorylation of IRF-1 after Myd88 interaction results in nuclear
translocation [96].
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Proteins with regulatory functions often have short half lives to allow rapid regulation
by changes in rates of synthesis [182]. The protein levels of IRF-1 are upregulated in
response to many stimuli. This involves enhanced mRNA production and, in the case
of genotoxic stress (but not viral mimetics), it has been shown that reduced degradation
of the protein also contributes to the increased steady state protein levels. ATM kinase
has been shown to be required for the induction of IRF-1 in response to genotoxic stress,
however, it is not known if direct or indirect kinase activity is involved [76].
IRF-1 is degraded by the 26S proteasome in response to its polyubiquitination. The
C-terminal portion of the protein was found to determine its stability but is not itself
ubiquitinated [123]. It is suggested that, as for IRF-3 [150], a phosphorylation-dependent
degradation signal could be located in the C-terminus of IRF-1 [122]. Pion et. al. have
defined the region 301-311 as comprising a degradation signal which most likely recruits
factors to deliver ubiquitinated IRF-1 to the proteasome [123]. Phosphorylation within
this region (most likely at Ser308 since Thr311 phosphorylation has been shown not to
affect stability) could regulate binding of the proteasome-delivery proteins. Interestingly,
work by Dr Sarah Meek indicated that a S → D mutation at the Ser308 site stabilises
IRF-1 protein (Dr Sarah Meek, unpublished observations).
Interestingly, in response to DNA damage (as a result of MNNG treatment), IRF-1 is
acetylated within the DNA binding domain by CBP (a protein closely related to p300).
Acetylation stabilises the IRF-1 protein, increasing its half-life without affecting mRNA
synthesis [44]. The mechanism of recruitment of CBP to IRF-1 upon DNA damage is
not known, however, since phosphorylation can modulate the recruitment of CBP/p300
to p53 [183], [184], and C-terminal phosphorylation of IRF-1 may enhance p300 binding
(Chapter 4), it is possible that phosphorylation directs p300 to IRF-1 in response to DNA
damage.
Although phosphorylation may be important for IRF-1 stability, the sites 311T and
317S do not appear to be involved in this regulation. Cycloheximide chase experiments
of IRF-1 phosphomimetic mutants show that in whole cell lysate, and in nuclear and cy-
toplasmic compartments, the half lives of WT, T311D, S317D and T311D/S317D IRF-1
are very similar. It would, however, be interesting to perform cycloheximide chase after
149
IFN-γ treatment, as activated transcription factors are often targeted for rapid degrada-
tion [185]. Phosphorylation at another site in response to IFN-γ treatment may enhance
degradation of IRF-1 in the nucleus. For example, phosphorylation of AML1c on specific
residues controls both transcriptional activity and degradation [186]. Similarly, activated
(non-RB bound) E2F-1 is phosphorylated by TFIIH (a component of the basal transcrip-
tion machinery) and is subsequently degraded [187]. IRF-1 and TFIIB physically interact
and cooperatively stimulate transcription in an in vitro transcription assay [188]. It would
be interesting to determine if the half life of IRF-1 is affected by this interaction, and if
IRF-1 can be targeted for degradation by TFIIH-mediated phosphorylation.
Protein-protein interaction
IRF-1 has previously been shown to interact with the co-activator p300 and enhance
its acetylation of p53 [67]. Evidence from this thesis, and from others in the Ball lab
indicates that phosphorylation of IRF-1 at 311T and 317S enhances its interaction with
the co-activator p300 (Chapter 4). This appears to enhance the transcriptional activity of
IRF-1 in response to IFN-γ treatment and correlates with the observations that a more
transcriptionally active form of IRF-3, IRF-3(5D), has a higher affinity for CBP/ p300
[165].
Several mechanisms have been suggested for the transcription-regulatory properties
of p300/CBP. One or a number of these may affect the activity of IRF-1. p300/CBP can
contact both sequence-specific transcription factors, and the basal transcription machin-
ery, thus, it can act as a bridge to couple recognition of a specific promoter to transcription
of the downstream gene. The varied substrates of p300/CBP allow it to act as a scaffold
for construction of a transcriptional regulatory complex. In addition, the HAT activity
of p300/CBP can alter chromatin structure through histone acetylation, or transcription
factor activity, for example, through altering DNA binding capacity, or modulating other
protein-protein interactions [167].
So far, p300-IRF-1 interaction has been shown in preliminary experiments to enhance
the DNA binding of IRF-1 (see below), however, further activities may be uncovered in
the future. IRF-1-p300 complex interaction with the transcription apparatus in vivo and
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with other cofactors should be investigated. A ChIP assay could be employed to discover
the effect of co-transfection with p300 on IRF-1 association with components of the tran-
scriptional machinery at promoters, and a ChIP assay coupled with mass-spectrometry
could identify binding partners recruited to IRF-1 through p300 activity. The acetylation
of IRF-1 after p300 binding should also be investigated.
The LXXLL motif within the IRF-1 Mf1 domain binds the Hsp70 chaperone protein,
which recruits Hsp90 to IRF-1. Hsp70 and Hsp90 cooperate to regulate the stability, lo-
calisation and activity of IRF-1 [121]. It has been shown recently in the Ball laboratory
that phosphorylation of an IRF-1 C-terminal peptide at Ser308 inhibits Hsp70 binding (Dr
Vikram Narayan, unpublished observations). To extend this, an ELISA was performed to
examine the effect of phosphorylation at Thr311 and Ser317 on Hsp70, Hsc70 and Hsp90
binding to full length IRF-1. It can be seen that endogenous Hsp70, Hsc70 and Hsp90
bind less well to immobilised IRF-1 T311D/S317D than IRF-1 WT (Fig 6.2A). Since
Hsp90 increases IRF-1 transcriptional activity, and enhances its nuclear accumulation
[121], and IRF-1 T311D/S317D is more transcriptionally active at IRF-1 transactivated
promoters (Chapter 4), it seems counterintuitive that IRF-1 T311D/S317D does not bind
as strongly to Hsp70/90. However, for IRF-3, it has been observed that Hsp90 forms
a complex with IRF-3 and the kinase TBK1, bringing them into close proximity to al-
low phosphorylation of IRF-3 by TBK1. After phosphorylation, IRF-3 dissociates from
Hsp90 and the IRF-3(5D) phosphomimetic mutant cannot bind Hsp90 [189]. Therefore, a
similar pathway could regulate IRF-1 where Hsp90 recruits an activatory kinase to IRF-1,
and after phosphorylation at 311T/317S sites the complex could dissociate, resulting in
a low affinity of IRF-1 T311D/S317D for Hsp70 and 90. The binding site for Hsp70 on
IRF-1 spans both 311T and 317S (Fig 6.2B from [121]). The residues on either side of
both phosphorylation sites are all critical for the interaction [121], therefore, it is possible
that phosphorylation directly blocks binding of Hsp70 and Hsp90.
A pull-down assay with Hsp90/control transfected cells (or Hsp90 inhibitor (17AAG)/control
treated cells) followed by a kinase assay using eluted IRF-1 binding proteins (as depicted
in Fig 6.3) would reveal if Hsp90 couples IRF-1 with a kinase. If an IRF-1 kinase is






































Figure 6.2: IRF-1 phosphorylation inhibits Hsp70, Hsc70 and Hsp90 binding. (A) 100ng purified
His-IRF-1 WT or T311D/S317D was immobilised on an ELISA plate and incubated with 300ng
A375 lysate for 1 hour. Binding of proteins from lysate was detected by anti-hsp70 (Stressgen),
anti-hsc70 (Stressgen) and anti-hsp90 (Stressgen) antibodies followed by HRP-swine anti-rabbit
antibody (Dako). Binding was normalised to IRF-1 WT-binding levels for each protein. Results
expressed as mean +/- standard deviation for triplicates. (B) Hsp70 binding motif [121] x is
any amino acid. Data representative of three independent experiments. Significant differences in
cofactor binding by paired t test are indiciated (* p=<0.05, ** p=<0.01).
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mass-spectrometry. Then, the effect of the kinase on IRF-1 activity, localisation and
DNA binding could be investigated. It is possible that a kinase is only recruited to the
complex after stimulation of cells, or that different kinases are recruited after different
signals, therefore, various cell stimuli should be incorporated into the experiment.
It is likely that there are other proteins differentially binding to IRF-1 WT and IRF-1
T311D/S317D, which could be identified using SILAC mass-spectrometry. An exam-
ple of how this technique was successfully used to identify phospho-dependent bind-
ing partners is given in reference [190]. Briefly, phosphorylated or non-phosphorylated
peptide is immobilised on a column, and incubated with cell lysate to pull out binding
partners. Phosphorylated peptide is incubated with lysate labelled by growing in me-
dia supplemented with, for example, heavy (13C lysine and arginine) amino acids, and
non-phosphorylated peptide is incubated with lysate labelled with, for example light (12C
lysine and arginine) amino acids. The binding partners can be eluted and separated by
SDS-PAGE, then identified using mass-spectrometry. The labelled amino acids allow
quantification of the relative amounts of each protein bound to the phosphorylated and
unphosphorylated peptides by comparing the 12C/13C isotope ratios [190].
It was interesting to note that IRF-1 T311D/S317D repressed the Cdk2 and MMP9
promoters to the same extent as IRF-1 WT. Therefore, phosphorylation at these sites
appears to have no effect on the interaction of IRF-1 with co-repressors.
DNA-binding
This thesis has demonstrated that phosphomimetic IRF-1 T311D/S317D shows en-
hanced DNA binding compared to IRF-1 WT in EMSAs. This is likely to be mediated by
enhanced binding of IRF-1 T311D/S317D to a cofactor, the histone acetylase p300, and
acetylation of IRF-1 appears to further stabilise the interaction with DNA (see Fig 4.10).
A model for this pathway has been suggested in Fig 6.4. This phenomenon has previously
been observed for p53, where phosphorylation of p53 increases its affinity for p300 and
PCAF, promoting acetylation elsewhere in p53 which, in turn, enhances DNA binding
[191] [192] and coactivator recruitment [168]. RelA also shows phosphorylation-induced







































Figure 6.3: Experimental design for determining if Hsp90 recruits a kinase to IRF-1. Lysate from
cells transfected with one-strep-IRF-1 +/- Hsp90 is passed over a streptactin column to isolate
one-strep-IRF-1 complexes. The complexes are gently washed and eluted using biotin. The eluted
complexes are used as a kinase source to phosphorylate purified, recombinant IRF-1. Phosphory-
lation could be visualised using a phosphorimager.
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transcription factors show enhanced DNA binding activity after p300-dependent acetyla-
tion including MEF2 [194], GATA4 [195], and Nrf2 [196]. IRF-1 has previously been
shown to interact with p300 and stimulate acetylation of promoter-bound p53 [67], but
this is the first time p300 has been shown to directly regulate IRF-1 activity.
Phosphorylation by Protein Kinase R (PKR) or a PKR-activated kinase modulates
IRF-1 DNA binding. PKR has been shown to be activated upon IFN-γ treatment [94].
In the absence of PKR, IRF-1 protein is expressed normally, but DNA binding activity in
response to various stresses is lost [197]. Further, inhibition of PKR by a hepatitis C virus
protein results in inhibition of DNA binding [198]. As yet, however, direct phosphoryla-
tion of IRF-1 by PKR has not been demonstrated, although, interestingly, 311T matches
the PKR consensus phosphorylation site [153].
Enhanced DNA binding of IRF-1 in response to IFN-γ treatment has been shown
indirectly by the large increase in the variety of promoters bound by IRF-1 after IFN-γ
treatment [43].
All of the mechanisms of regulation discussed above combine to dictate the transcrip-
tional activity of IRF-1. The reporter assays recorded in Chapter 4 show that for IRF-1-
activated promoters, phosphorylation in response to IFN-γ enhances transcriptional ac-
tivity, however, IRF-1-repressed promoters are not affected by phosphorylation at T311D
or S317D. Since IFN-γ triggers inhibition of both of the IRF-1-repressed promoters stud-
ied - the MMP9 [45] and Cdk2 [199] promoters, it is clear that other signals modulating
IRF-1 activity in response to IFN-γ treatment remain to be elucidated. Phosphorylation
at other sites, or other post-translational modifications could recruit co-repressors to co-
operate with IRF-1 at these promoters. It is clear that there is much work to be done to
fully characterise the regulation of IRF-1, even by a single signal.
One approach to better characterising the effect of, for example, IFN-γ treatment on
IRF-1 is to determine all the stimulus-specific phosphorylation sites using mass-spectrometry,
and then identify the kinases responsible. Since this is a large undertaking, a first step
could be the identification of kinases responsible for phosphorylation at the 311T and






























2. (a) acetylation further enhances,
or stabilises DNA binding conformation 
or (b) acetylation recruits another binding













3. Enhanced expression of
IRF-1 activated promoters
(a)(b)
Figure 6.4: Model for mechanism of enhanced transcriptional activity of IRF-1 after IFN-γ treat-
ment. IFN-γ causes upregulation of IRF-1 protein expression through STAT1. IFN-γ signalling
also activates/upregulates IRF-1 kinases. Phosphorylation of IRF-1 creates a binding site for p300.
p300 binding enhances the affinity of IRF-1 for DNA, and acetylation of IRF-1 by p300 further en-
hances DNA binding. This could be due either to (a) acetylation causing conformational change
of IRF-1 which further enhances or stabilises a favourable DNA binding conformation, or (b)
acetylation creating a binding site for another cofactor whose interaction stabilises or enhances a
favourable DNA binding conformation. As a result of the enhanced DNA binding, and potentially
the improved recruitment of other components of the transcriptional machinery by the cofactors,
there is enhanced expression of IRF-1 activated promoters.
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[151], KinasePhos2.0 [152] and PPSP [153], a list of kinases whose phosphorylation mo-
tifs matched 311T and 317S was generated. To narrow down the list, a literature search
was performed to identify kinases that were known to be activated upon IFN-γ treatment.
The resulting set of kinases is shown in Table 6.1. Inhibitors/siRNA studies could be used
to determine if these kinases can modulate IRF-1 activity, and 2D gels and in vitro kinase
assays could be used to assess if they can phosphorylate IRF-1. If S/T→ A mutation at
the appropriate site abrogates phosphorylation of IRF-1 by the kinase, it is likely that the
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Table 6.1: Kinases predicted to phosphorylate IRF-1 311T or 317S. Kinases reported to be acti-
vated by IFN-γ treatment are highlighted in bold.
An as yet unexplored aspect of IRF-1 regulation is role of dephosphorylation. No
phosphatases have been reported to act on IRF-1 and the impact of negative-regulatory
phosphorylations has not been studied. If a picture of the phosphorylated sites of “rest-
ing” IRF-1 was known, this could be compared to the phosphorylation of activated IRF-1,
and inhibitory phosphorylation sites identified. If such phosphorylation events were iden-
tified, inhibitors of the phosphatases responsible could also be useful drug targets.
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Acetylation of IRF-1 also deserves more attention. As well as the acetylation by p300
identified here, IRF-1 is known to bind PCAF and GCN5 at promoters and this interaction
enhances the activity of IRF-1 [127]. Thus, acetylation is likely to be a major player in
the regulation of IRF-1.
Cell based assays investigating the effect of phosphorylation on the tumour suppres-
sor activities of IRF-1 have shown that T311D/S317D IRF-1 may be more efficient at
suppressing anchorage dependent and independent colony formation, although this does
not appear to be due to effects on cell cycle progression, but could be triggering of senes-
cence. IRF-1 was also shown, for the first time, to be able to inhibit invasion in an in vitro
assay of invasion. Again phosphomimetic IRF-1 appears to enhance this activity.
On the basis of this enhanced tumour suppressor activity in vitro, it would be useful
to study the effects in vivo. What is the effect on tumour growth/metastasis of transfect-
ing cells with IRF-1 T311D/S317D before xenografting? Can administration of IRF-1
T311D/S317D slow/reverse the progression of tumours?
If the identitiy of the kinases catalysing the activatory phosphorylations was known,
it might be possible to manipulate these to enhance the effects of IRF-1 on tumours in
vivo. However, this might be a treatment doomed to rapid resistance, as many tumours
escape the control of IRF-1 by causing its downregulation [200], and the effects could
be non-specific. Therefore, administration of artificial IRF-1 seems like a better option.
Ectopic expression of IRF-1 by an adenoviral vector in mice has been shown to inhibit
tumour growth [41], [34], thus expression of activated IRF-1 (T311D/S317D) could be
even more effective.
As well as activating the transcriptional activity of IRF-1, ectopically expressed pro-
tein could be made more effective as a therapeutic by prolonging its half life. IRF-1 is
degraded through the ubiquitin-proteasome pathway [122], [123]. Perhaps mutation of
the lysine residues which accept the polyubiquitin could further enhance the activity of
IRF-1. It seems that this is a mechanism used in vivo to modulate IRF-1 activity since
acetylation of IRF-1 lysine residues (which protects them from ubiquitination) stabilises
the protein [44].
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It is important, however, to properly characterise the effects of the activatory muta-
tions. IRF-1 upregulation has been linked with autoimmune disease [87] [88] [89] in
vivo, therefore, the effect of T311D/S317D on inflammatory and immune-related pro-
moters should be studied (for example, by ChIP-seq). MHC I, iNOS and caspase 1 over-
expression have all been linked to MS [201] [88] [202] and since their promoters are all
regulated by IRF-1 [28] [35] [40], they could form an initial panel of genes to monitor.
In vivo studies should monitor for autoimmune side effects as well as considering tumour
suppression.
In conclusion, this thesis has firmly established phosphorylation as a post-translational
method of control of IRF-1. Two stimulus-specific phosphorylation sites have been identi-
fied and a model for the mechanism by which they selectively enhance the transcriptional
activity of IRF-1 has been suggested. Furthermore, the activity of a mutant mimicing
phosphorylation at the two sites (IRF-1 T311D/S317D) has been characterised in in vitro
assays and found to be an effective tumour suppressor and metastatic inhibitor.
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[86] Andrea Kröger, Dörte Ortmann, Tim U Krohne, Leonhardt Mohr, Hubert Blum,
Hansjörg Hauser, and Michael Geissler. Growth Suppression of the Hepatocellular
Carcinoma Cell Line Hepa1-6 by an Activatable Interferon Regulatory Factor-1 in
Mice. Cancer Research, 61:2609–2617, 2001.
[87] Ronald Feitosa, Konradin Metze, Maria Regina, Régis Silva, Maria De Lourdes,
and Lopes Ferrari. The ambiguous role of IRF-1 immunoexpression in myelodys-
plastic syndrome. Leukemia Research, 33:1308–12, 2009.
[88] By Yoshifumi Tada, Alexandra Ho, Toshifumi Matsuyama, and Tak W Mak. Re-
duced Incidence and Severity of Antigen-induced Autoimmune Diseases in Mice
Lacking Interferon Regulatory Factor-1. J Exp Med, 185(2):231–238, 1997.
[89] Zhihua Ren, Yan Wang, David Liebenson, Thomas Liggett, Rajendra Goswami,
Dusan Stefoski, and Roumen Balabanov. IRF-1 signaling in central nervous system
glial cells regulates inflammatory demyelination. Journal of Neuroimmunology,
233(1-2):147–159, 2011.
[90] George R Stark, Ian M Kerr, Bryan R G Williams, Robert H Silverman, and
Robert D Schreiber. How cells respond to interferons. Annual Review of Bio-
chemistry, 67:227–64, 1998.
[91] Naoko Kanda and Shinichi Watanabe. Prolactin Enhances Interferon-gamma-
Induced Production of CXC Ligand 9 (CXCL9), CXCL10, and CXCL11 in Human
Keratinocytes. Endocrinology, 148(5):2317–2325, 2007.
[92] Takashi Fujita, Luiz Reis, Nobumasa Watanabe, Yoko Kimura, Tadatsugu
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[104] Jérôme Galon, Chitra Sudarshan, Satochi Ito, David Finbloom, and John J O Shea.
IL-12 Induces IFN Regulating Factor-1 (IRF-1) Gene Expression in Human NK
and T Cells. The Journal of Immunology, 162:7256–7262, 1999.
[105] Suxing Liu, W Robert Bishop, and Ming Liu. Differential effects of cell cycle reg-
ulatory protein p21 WAF1 / Cip1 on apoptosis and sensitivity to cancer chemother-
apy. Drug Resistance Updates, 6:183–195, 2003.
[106] Sheila Harroch, Yael Gothelf, Nobumasa Watanabe, Michel Revel, and Judith
Chebath. Interleukin-6 Activates and Regulates Transcription Factors of the In-
terferon Regulatory Factor Family in M1 Cells. Journal of Biological Chemistry,
268(12):9092–9097, 1993.
[107] Peter C Heinrich, Iris Behrmann, Gerhard Muller-Newen, Fred Schaper, and Lutz
Graeve. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT path-
way. Biochem. J., 334:297–314, 1998.
[108] Hodaka Fujii, Yoko Nakagawa, Ulrike Schindleri, Atsuo Kawahara, Hisashi
Mori, Fabrice Gouilleux, Bernd Groner, James N Ihlei, Yasuhiro Minami, and
Tadaaki Miyazaki Ii. Activation of Stat5 by interleukin 2 requires a carboxyl-
terminal region of the interleukin 2 receptor 1B chain but is not essential for the
proliferative signal transmission. Cell, 92(June):5482–5486, 1995.
[109] Lee H Wong, Helena Sim, Moitreyee Chatterjee-kishore, Irene Hatzinisiriou, Rod-
ney J Devenish, George Stark, and Stephen J Ralph. Isolation and Characteriza-
tion of a Human STAT1 Gene. Journal of Biological Chemistry, 277(22):19408
–19417, 2002.
[110] Peter Andersen, Mikkel Wandahl Pedersen, Anders Woetmann, Mette Villingshø j,
Bibliography 173
Marie-Therese Stockhausen, Niels Odum, and Hans Skovgaard Poulsen. EGFR
induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth
arrest of human cancer cells. International Journal of Cancer, 122:342–349, 2008.
[111] Masaaki Miyamoto, Takashi Fujita, Yoko Kimura, Mitsuo Maruyama, Hisashi
Harada, Yoshiaki Sudo, Takashi Miyata, Tadatsugu Taniguchi, and Cellular Bi-
ology. Regulated Expression of a Gene Encoding a Nuclear Factor, IRF-1, That
Specifically Binds to IFN-b Gene Regulatory Elements. Cell, 54:903–913, 1988.
[112] Nobumasa Watanabe, Jun Sakakibara, Ara G Hovanessian, and Tadatsugu
Taniguchi. Activation of IFN-beta element by IRF-1 requires a post- translational
event in addition to IRF-1 synthesis. Nucleic Acids Research, 19(16):4421–4428,
1991.
[113] Richard Pine, Antony Canova, and Chris Schindler. Tyrosine phosphorylated p91
binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by
IFNcx and IFNy , and is likely to autoregulate the p91 gene. EMBO Journal,
13(1):158–167, 1994.
[114] Xiaoxia Li, Stewart Leung, Sajjad Qureshi, James E Darnell, and George R Stark.
Formation of STAT1-STAT2 Heterodimers and Their Role in the Activation of
IRF-1 Gene Transcription by Interferon- *. Journal of Biological Chemistry,
271(10):5790 –5794, 1996.
[115] Yu-fen Wang, Kevin D O Neal, and Li-yuan Yu-Lee. Multiple Prolactin ( PRL )
Receptor Cytoplasmic Residues and Stat1 Mediate PRL Signaling to the Interferon
Regulatory Factor-1 Promoter. Molecular Endocrinology, 11:1353–1364, 1997.
[116] Daisuke Imanishi, Kazuo Yamamoto, Hideki Tsushima, Yasushi Miyazaki, Kazu-
taka Kuriyama, Masao Tomonaga, and Toshifumi Matsuyama. Identification of a
Novel Cytokine Response Element in the Human IFN Regulatory Factor-1 Gene
Promoter. Journal of Immunology, 165:3907–3916, 2000.
[117] Istvan Arany, William E Whitehead, Kenneth J Grattendick, Istvan A Ember, and
Stephen K Tyring. Suppression of Growth by All-trans Retinoic Acid Requires
Prolonged Induction of Interferon Regulatory Factor 1 in Cervical Squamous Car-
cinoma (SiHa) Cells. Clinical and Diagnostic Laboratory Immunology, 9(5):1102–
1106, 2002.
Bibliography 174
[118] Richard Pine. Convergence of TNFα and IFNγ signalling pathways through syner-
gistic induction of IRF-1 / ISGF-2 is mediated by a composite GAS / κB promoter
element. Cell, 25(21), 1997.
[119] Rongtuan Lin and John Hiscott. A role for casein kinase II phosphorylation in the
regulation of IRF-1 transcriptional activity. Molecular and Cellular Biochemistry,
191:169–180, 1999.
[120] Melanie Giroux, Manuel Schmidt, and Albert Descoteaux. IFN-γ-Induced MHC
Class II Expression: Transactivation of Class II Transactivator Promoter IV by IFN
Regulatory Factor-1 is Regulated by Protein Kinase C-α. Journal of Immunology,
171:4187–4194, 2003.
[121] Vikram Narayan, Mirjam Eckert, Alicja Zylicz, Maciej Zylicz, and Kathryn L Ball.
Cooperative Regulation of the Interferon Regulatory Factor-1 Tumor Suppressor
Protein by Core Components of the Molecular Chaperone Machinery. Journal of
Biological Chemistry, 284(38):25889 –25899, 2009.
[122] Koji Nakagawa and Hideyoshi Yokosawa. Degradation of transcription factor IRF-
1 by the ubiquitin-proteasome pathway. Eur J Biochem, 267:1680–1686, 2000.
[123] Emmanuelle Pion, Vikram Narayan, Mirjam Eckert, and Kathryn L Ball. Role
of the IRF-1 enhancer domain in signalling polyubiquitination and degradation.
Cellular Signalling, 21(10):1479–87, 2009.
[124] Koji Nakagawa and Hideyoshi Yokosawa. PIAS3 induces SUMO-1 modification
and transcriptional repression of IRF-1. Cell, 530:204–208, 2002.
[125] Junsoo Park, Kwangsoo Kim, Eun-ju Lee, Yun-jee Seo, Si-nae Lim, Kyoung-
sook Park, Seung Bae Rho, Seung-hoon Lee, and Je-ho Lee. Elevated level
of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis.
PNAS, 104(43):17028–17033, 2007.
[126] Atsuko Masumi and Keiko Ozato. Coactivator p300 Acetylates the Interferon Reg-
ulatory Factor-2 in U937 Cells following Phorbol Ester Treatment. Journal of Bi-
ological Chemistry, 276(24):20973–20980, 2001.
[127] Atsuko Masumi, I-ming Wang, Bruno Lefebvre, Xing-jiao Yang, Yoshihiro
Nakatani, and Keiko Ozato. The Histone Acetylase PCAF Is a Phorbol-Ester-
Inducible Coactivator of the IRF Family That Confers Enhanced Interferon Re-
Bibliography 175
sponsiveness. Molecular and Cellular Biology, 19(3):1810–1820, 1999.
[128] Patrick A Grant. Review A tale of histone modifications. Science, pages 1–6, 2001.
[129] Giulia Marsili, Anna Lisa Remoli, Marco Sgarbanti, and Angela Battistini. Role
of Acetylases and Deacetylase Inhibitors in IRF-1-Mediated HIV-1 Long Termi-
nal Repeat Transcription. Annals New York Academy of Sciences, 1030:636–643,
2004.
[130] Menie Merika, Amy J Williams, Guoying Chen, Tucker Collins, and Dimitris
Thanos. Recruitment of CBP/p300 by the IFN-beta Enhanceosome Is Required
for Synergistic Activation of Transcription. Molecular Cell, 1:277–287, 1998.
[131] Wu-guo Deng and Kenneth K Wu. Regulation of Inducible Nitric Oxide Synthase
Expression by p300 and p50 Acetylation. The Journal of Immunology, 171:6581–
6588, 2003.
[132] Marta Saura, Carlos Zaragoza, Clare Bao, Audrey Mcmillan, and Charles J Lowen-
stein. Interaction of Interferon Regulatory Factor-1 and Nuclear Factor k B During
Activation of Inducible Nitric Oxide Synthase Transcription. Journal of Molecular
Biology, 289:459–471, 1999.
[133] Katrin Ramsauer, Matthias Farlik, Gordin Zupkovitz, Christian Seiser, Andrea
Kroger, Hansjörg Hauser, and Thomas Decker. Distinct modes of action applied by
transcription factors STAT1 and IRF1 to initiate transcription of the IFN-gamma-
inducible gbp2 gene. PNAS, 104(8):2849–2854, 2007.
[134] Moitreyee Chatterjee-kishore, Kenneth L Wright, Jenny P Ting, and George R
Stark. How Stat1 mediates constitutive gene expression : a complex of unphospho-
rylated Stat1 and IRF1 supports transcription of the LMP2 gene. EMBO Journal,
19(15):4111–4122, 2000.
[135] Atsushi Kumatori, Dan Yang, Shoichi Suzuki, and Michio Nakamura. Cooperation
of STAT-1 and IRF-1 in Interferon- -induced Transcription of the gp91 phox Gene
*. Biochemistry, 277(11):9103–9111, 2002.
[136] Yaxin Wang, Bo Gao, Wei Xu, and Sidong Xiong. BRG1 is indispensable for IFN-
gamma -induced TRIM22 expression , which is dependent on the recruitment of
IRF-1. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,
2011.
Bibliography 176
[137] Shinichi Matsuzaki, Tamotsu Ishizuka, Takeshi Hisada, Haruka Aoki, Mayumi
Komachi, Isao Ichimonji, Akihiro Ono, Yasuhiko Koga, Kunio Dobashi, Hitoshi
Kurose, Hideaki Tomura, Masatomo Mori, and Fumikazu Okajima. Lysophos-
phatidic Acid Inhibits CC Chemokine Ligand 5/RANTES Production by Blocking
IRF-1-Mediated Gene Transcription in Human Bronchial Epithelial Cells. Journal
of Immunology, 185:4863–4872, 2010.
[138] Noriko Umegaki, Katsuto Tamai, Hajime Nakano, Ryuta Moritsugu, Takehiko
Yamazaki, Ichiro Katayama, and Yasufumi Kaneda. Differential Regulation of
Karyopherin a 2 Expression by TGF-b 1 and IFN-c in Normal Human Epidermal
Keratinocytes : Evident Contribution of KPNA2 for Nuclear Translocation of IRF-
1. Journal of Investigative Dermatology, 127, 2007.
[139] Rongtuan Lin, Amir Mustafa, Hannah Nguyen, Dirk Gewert, and John Hiscott.
Mutational Analysis of Interferon (IFN) Regulatory Factors 1 and 2. Journal of
Biological Chemistry, 269(26):17542–17549, 1994.
[140] Carlos R Escalante, Junming Yie, Dimitris Thanos, and Aneel K Aggarwal. Struc-
ture of IRF-1 with bound DNA reveals determinants of interferon regulation. Na-
ture, 391:103–106, 1998.
[141] Sabine Kirchhoff, Andre Oumard, Mahtab Nourbakhsh, Ben-zion Levi, and
Hansjörg Hauser. Interplay between repressing and activating domains defines
the transcriptional activity of IRF-1. Eur J Biochem, 267:6753–6761, 2000.
[142] Fred Schaper, Sabine Kirchhoff, Guido Posern, Mario Ko, Andre Oumard, Rake-
fet Sharf, Ben-zion Levi, and Hansjörg Hauser. Functional domains of interferon
regulatory factor I (IRF-1). Biochem. J., 335:147–157, 1998.
[143] Sabine Kirchhoff, Fred Schaper, Andre Oumard, and Hansjörg Hauser. In vivo
formation of IRF-I homodimers. Biochimie, 80:659–664, 1998.
[144] Vikram Narayan, Petr Halada, Lenka Hernychova, Yuh Ping Chong, Jitka Z, Ted R
Hupp, Borivoj Vojtesek, and Kathryn L Ball. A Multiprotein Binding Interface
in an Intrinsically Disordered Region of the Tumor Suppressor Protein Interferon
Regulatory Factor-1 * . Journal of Biological Chemistry, 286(16):14291–14303,
2011.
[145] Vikram Narayan, Emmanuelle Pion, Vivien Landre, Petr Mu, and Kathryn L Ball.
Bibliography 177
Docking-dependent Ubiquitination of the Interferon Regulatory Factor-1 Tumor
Suppressor Protein by the Ubiquitin Ligase CHIP. Journal of Biological Chem-
istry, 286(1):607–619, 2011.
[146] A. Moeller, E Pion, V Narayan, and K Ball. intracellular activation of interferon
regulatory factor-1 by nanobodies to the multi-functional (Mf1) domain. Journal
of Biological Chemistry, 2010.
[147] Shigeru Oshima, Tetsuya Nakamura, Shin Namiki, Eriko Okada, Kiichiro
Tsuchiya, Ryuichi Okamoto, Motomi Yamazaki, Takanori Yokota, Masatoshi
Aida, Yuki Yamaguchi, Takanori Kanai, Hiroshi Handa, and Mamoru Watanabe.
Interferon Regulatory Factor 1 ( IRF-1 ) and IRF-2 Distinctively Up-Regulate Gene
Expression and Production of Interleukin-7 in Human Intestinal Epithelial Cells.
Society, 24(14):6298–6310, 2004.
[148] Hans Peter Sø rensen and Kim Kusk Mortensen. Soluble expression of recombi-
nant proteins in the cytoplasm of Escherichia coli. Microbial Cell Factories, 8:1–8,
2005.
[149] Brian K Kay, Jeremy Kasanov, and Montarop Yamabhai. Screening Phage-
Displayed Combinatorial Peptide Libraries. Methods, 24:240–246, 2001.
[150] Rongtuan Lin, Christophe Heylbroeck, Paula M Pitha, and John Hiscott. Virus-
Dependent Phosphorylation of the IRF-3 Transcription Factor Regulates Nuclear
Translocation, Transactivation Potential, and Proteasome-Mediated Degradation.
Molecular and Cellular Biology, 18(5):2986–2996, 1998.
[151] N Blom, T Sicheritz-Ponten, R Gupta, S Gammeltoft, and S Brunak. Prediction
of post-translational glycosylation and phosphorylation of proteins from the amino
acid sequence. Proteomics, 4(6):1633–1649, 2004.
[152] Y.H. Wong, T.Y. Lee, H.K. Liang, C.M Uang, Y.H. Yang, C.H. Chu, H.D. Huang,
M.T. Ko, and J.K. Hwang. KinasePhos 2.0: a web server for identifying protein
kinase-specific phosphorylation sites based on sequences and coupling patterns.
Nucleic Acids Research, 35:W588–594, 2007.
[153] Yu Xue, Jian Ren, Xinjiao Gao, Changjiang Jin, Longping Wen, and Xuebiao Yao.
GPS 2.0: Prediction of Kinase-Specific Phosphorylation Sites in Hierarchy. Mol
Cell Proteomics, 7:1598–1608, 2008.
Bibliography 178
[154] Hannah Nguyen, Chilakamarti V Ramana, Joshua Bayes, and George R Stark.
Roles of Phosphatidylinositol 3-Kinase in Interferon-gamma-dependent Phospho-
rylation of STAT1 on Serine 727 and Activation of Gene Expression. Biochemistry,
276(36):33361–33368, 2001.
[155] Dilip K Deb, Antonella Sassano, Fatima Lekmine, Beata Majchrzak, Amit Verma,
Suman Kambhampati, Shahab Uddin, Arshad Rahman, Eleanor N Fish, and
Leonidas C Platanias. Activation of Protein Kinase C δ by IFN- γ. The Journal of
Immunology, 171:267–273, 2003.
[156] Ursula M Halfter, Zachary E Derbyshire, and Richard R Vaillancourt. Interferon-γ
-dependent tyrosine phosphorylation of MEKK4 via Pyk2 is regulated by annexin
II and SHP2 in keratinocytes. Society, 28:17–28, 2005.
[157] Sanjit K Roy, Junbo Hu, Qingjun Meng, Ying Xia, Paul S Shapiro, Sekhar P M
Reddy, Leonidas C Platanias, Daniel J Lindner, Peter F Johnson, Catrin Pritchard,
Gilles Page, Jacques Pouyssegur, and Dhananjaya Kalakolanu. MEKK1 plays a
critical role in activating the transcription factor C /EBP-beta-dependent gene ex-
pression in response to IFN-gamma. PNAS, 99(12):7945–50, 2002.
[158] James Goding. Monocolonal Antibodies: Principles and Practice. Academic
Press, London, 3rd edition, 1996.
[159] W E I Wang, Satish Singh, David L Zeng, Kevin King, Sandeep Nema, and Wang
E T Al. Antibody Structure, Instability, and Formulation. Journal of Pharmaceu-
tical Sciences, 96(1):1–26, 2007.
[160] Tadatsugu Taniguchi, Kouetsu Ogasawara, Akinori Takaoka, and Nobuyuki
Tanaka. IRF FAMILY OF TRANSCRIPTION FACTORS AS REGULATORS OF
HOST DEFENSE. Annual Review of Immunology, 19:623–55, 2001.
[161] Donna D Eason, Alexander T Shepherd, and George Blanck. Interferon regulatory
factor 1 tryptophan 11 to arginine point mutation abolishes DNA binding. In Vitro,
1446:140–144, 1999.
[162] Takashi Fujita, Hiroshi Shibuya, and Haku Hotta. Interferon-beta Gene Regulation:
Tandemly Repeated Sequences of a Synthetic 6 bp Oligomer Function As a Virus-
Inducible Enhancer. Cell, 49(1983):357–367, 1987.
[163] Lorenza Bordoli, Marco Netsch, Urs Lüthi, Werner Lutz, and Richard Eck-
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